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Abstract
My work focused on understanding adipocyte function and regulation because of the
importance to diabetes. In addition to being a fat storage depot, adipose tissue is an endocrine
tissue. Adiponectin and leptin are two adipokines that control insulin sensitivity and energy
balance. In spite of their importance, there are still questions about their secretion. I hypothesized
that leptin and adiponectin follow different secretory routes. I found adiponectin localized in
Golgi and the trans Golgi Network, while leptin mostly localized in ER during basal
metabolisms. Common requirements for their secretion were the presence of class III Arf
proteins and an intact Golgi apparatus, since BFA treatment inhibited secretion of both
adiponectin and leptin. I found that trafficking of adiponectin is dependent on GGA1 coated
vesicles. Endosomal inactivation significantly reduced adiponectin, but not leptin, secretion in
both 3T3L1 and isolated rat adipocytes. Also, adiponectin, but not leptin, secretion was reduced
in cells expressing non- functional form of Rab11 and Rab5 proteins. However, secretion of
leptin, but not adiponectin was inhibited in cells expressing mutants of Protein Kinase D1. These
results suggest that leptin and adiponectin secretion involve distinct intracellular compartments
and pathways.
Insulin resistance is associated with macrophage infiltration into adipose tissue and
elevated levels of IL-6, TNF-and IL-1Therefore, the second part of my dissertation tested
the hypothesis that the interaction of macrophages and adipocytes causes insulin resistance. To
test this hypothesis, I co-cultured macrophages and adipocytes. I found that mouse elicited
peritoneal macrophages significantly decreased insulin-stimulated GLUT4 translocation to the
plasma membrane in a contact-independent manner. IL-6 was the most inhibitory cytokine in
reducing GLUT4 translocation, GLUT4 expression, Akt phsphorylation and reducing adipocyte
differentiation compared to TNF-and IL-1. These data suggest that IL-6 is the most effective
cytokine secreted by macrophages involved in insulin resistance. Lastly, I tested the impact of
adipocytes on macrophage differentiation in vitro and in vivo. I found that C2D macrophages
isolated from the peritoneal cavity had increased IL-6 transcript levels after co-culture with
3T3L1 adipocytes in vitro. After i.p. injection, C2D macrophages isolated from WAT increased
expression of mature macrophage surface markers and transcript levels of proinflammatory
cytokines compared to C2D cells in vitro. However, macrophages isolated from BAT expressed
low levels of cytokines and macrophage surface markers.
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1CHAPTER 1
INTRODUCTION
21. Diabetes
Diabetes is a serious health problem all over the word. More than 171 million people
have diabetes, and its prevalence is expected to reach 366 million by 2025 [1]. According to the
National Estimates on Diabetes for 2005, there are 20.8 million children and adults or 7% of the
population, who have diabetes. About 14.6 million have been diagnosed with diabetes; but 6.2
million people (or nearly one-third) are undiagnosed [2]. People with diabetes are at high risk of
heart failure [3, 4], stroke [5, 6], retinopathy [7], chronic kidney disease [3, 8] and other associated
disorders affecting the microvascular like diabetic foot [8-10].
1.1 Classification of diabetes mellitus
There are three major types of diabetes mellitus: Type 1 diabetes, Type 2 diabetes, and
gestational diabetes.
1.1.1 Type 1 diabetes mellitus:
Type 1 diabetes mellitus (juvenile onset, T1DM) results from the body's failure to
produce insulin. It results from combined genetic and environmental factors that affect the
immune system and destroys the patient’s insulin producing beta cels [11-13]. The lack of
insulin leads to hyperglycemia and its devastating complications, including cardiovascular
disease, blindness and kidney failure [12]. It is estimated that 5-10% of Americans who are
diagnosed with diabetes have T1DM [12]. T1DM accounts for the majority of childhood
diabetes. The American Diabetes Association (ADA) has proposed to classify diabetes with type
1A diabetes representing islet cell with the presence of autoantibodies mediating diabetes and
type 1B representing a non-autoimmune associated form of type 1 diabetes [12, 14]. The best
current marker for T1DM is the presence of three autoantibodies that are specific for glutamic
acid decarboxylase (GAD65), insulin and insulinoma antigen-2 [14, 15]. Type 1A diabetes is
3found most strongly associated with HLA DR and DQ loci in the class II region of the major
histocompatibility complex [13]. Since the MHC-II region controls antigen presentation, T1DM is
believed caused by antigen presentation to CD4+ cells, thymic selection and immune
responsiveness [11, 15].
1.1.2 Type 2 diabetes mellitus
Type 2 diabetes (T2DM) results from insulin resistance combined with insulin
deficiency. T2DM is found mostly in adults; however, the average age range of diabetics has
been decreasing because of earlier screening. This epidemic has been associated with obesity
and inactivity in children [16]. T2DM is now diagnosed in both adolescents and children. The
mechanisms underlying T2DM are not fully understood, but it is believed to be a multi-factorial
disorder. The more risk factors an individual has, the greater his/her likelihood of developing
T2DM. Obesity is one of the high risk factors. Over 90% of persons with T2DM are overweight
[16]. The Body Mass Index (BMI) is widely accepted as a prediction of T2DM. A BMI greater
than 27 indicates a risk for developing type 2 diabetes. An apple-shaped figure of individuals
who carry most of their weight in the trunk of their bodies is also considered a risk factor for
T2DM [17]. Age increases the risk of T2DM. Rate of diabetes in those aged 65 and over
(10.4%) is two times higher than the rate in those 35 to 64 (3.2%) [17]. A sedentary life style
also increased the risk; however, regular physical activity improved blood glucose control in
T2DM patients [17]. Other risk factors are family history of T2DM, history of gestational
diabetes, ethnic ancestry, high blood pressure and high cholesterol or fats in blood [17].
1.1.3 Gestational diabetes mellitus
Gestational diabetes (GDM) occurs during pregnancy and affects about 12% of all
pregnant women. There are approximately 135,000 cases in the United States each year, but the
4symptoms resolve after pregnancy in about 90% of those women [18]. Woman with a history of
GDM have a higher risk of type II diabetes and higher frequency of reoccurrences of GDM in
subsequent pregnancies [19]. The Australasian Carbohydrate Intolerance Study (ACHOIS)
revealed that a quarter of the babies whose mothers had GDM without proper treatment, died and
another 25% suffered with birth injury [20]. However, the hyperglycemia and hyperinsulinemia
were corrected, the incidence of death and birth defects decreased to almost none [20]. The
underlying mechanisms of GDM are not clear. However,a defect in pancreatic β cel function is 
consistently found in women with prior GDM [21].  Potential causes of inadequate β cel 
function are complex and are not fully understood. It may be related to the presence of
autoantibodies specific for islet cells [21, 22], mutations in genes coding for some key proteins
[23-25] like insulin promoter factor 1 [25-27] or hepatocyte nuclear factor 1α [25, 28].
1.1.4 Other specific types of diabetes
Other diabetes, not classified into the above three categories are diagnosed as “other 
specific types of diabetes”. These syndromes can be related to genetic defects of cell function
and insulin action, endocrinopathies, destruction of the pancreas by drugs or chemicals,
infections or rare forms of immune-linked diabetes (e.g. Stiff-Person-syndrome)[2].
1.2 Diabetic complications
The burden of diabetes relates more to the complications associated with the disease than
to its associated metabolic derangements. These include retinopathy, nephropathy, neuropathy
and, most commonly, cardiovascular complications. Two of the most important risk factors for
diabetic complications are hyperglycemia and elevated blood pressure caused by microvascular
abnormalities [29, 30].
1.3 Insulin
5Insulin is a key hormone in the body that regulates glucose and fatty acid metabolism. In
mammals, insulin is synthesized in the pancreas within the β-cells of the islets of Langerhans.
Insulin is composed of 51 amino acid residues and has a molecular weight of 5.8 kDa. The
structure of insulin is highly conserved in mammals. Bovine insulin differs by 3 residues
different from human insulin and by one residue different from porcine insulin [31]. Insulin is
composed of two polypeptide chains, A and B. The integrity of the three native disulfides of
insulin: CysA6-CysA11, CysA7-CysB7, CysA20-CysB19 are critical to insulin’s biological 
activity [32]. Breakage or disarrangement of any of the three disulfide bonds leads to the loss of
function of insulin.
Insulin binds to the insulin receptor to induce its biological function. The N-terminal -
helix of the insulin A-chain is a site with high affinity to the insulin receptor [33]. The second
binding site is ValB12 and TyrB16 of the B-chain -helix with the N-terminal of the subunit
of insulin receptor [34]. The binding of insulin to the insulin receptor triggers significant
biochemical activity inside of the cell. These include: increased glycogen synthesis, increased
fatty acid synthesis, decreased oxidation, decreased proteinolysis and lipolysis, decreased
gluconeogenesis and it can induce DNA replication, gene transcription and protein synthesis
[34].
In humans, skeletal muscle cells and adipocytes are the major cells involved in insulin-
dependent glucose uptake. Binding of insulin to the insulin receptor in the skeletal muscle and
adipocytes leads to activation of the AMP-activated protein kinase (AMPK) pathway that
stimulates fatty acid oxidation and more importantly the activation of Phosphoinositide-3
kinase (PI3K) pathway that mobilizes glucose transporter proteins, such as GLUT4, to the
plasma membrane [35-37].
61.4 Glucose transporter proteins
Glucose transporter proteins are integral proteins that transfer glucose across the plasma
membrane into cells. The transporters are categorized into two distinct groups according to their
structures and functions, the Na+-dependent glucose co-transporters (SGLT) [38] and the
facilitative Na+-independent sugar transporters (GLUT family) [39, 40].
1.4.1 Sodium-dependent glucose transporters (SGLT)
SGLT transport glucose via a secondary active transport mechanism. Glucose
transportation is coupled with the Na+ influx via a Na+-K+ ATPase pump that works against a
concentration gradient [40]. This process occurs on the lumen of the small intestine and in the
proximal tubules of kidneys [40]. There are three types of SGLT: SGLT1 and SGLT3 are found
expressed in the lumen of the small intestine and SGLT2 is expressed in the proximal tubules of
kidney [40].
1.4.2 Facilitative glucose transporters
The facilitative GLUT transporters transfer glucose by a diffusion gradient of glucose
(and other sugars) across the plasma membranes [41]. GLUT1 was the first GLUT molecule to
be isolated and this family now encompasses thirteen members [41]. All 13 members share a
representing three-dimensional structural similarity. Their predicted structure has twelve
transmembrane regions and both the N-terminal and the C-terminal are localized intracellularly
[41].
1.4.2.1 Classification
Based on the sequence alignment of all GLUT members, they have been classified into
three subclasses [41]. The class I facilitative transporters contain GLUT1–4. All four members
7have been comprehensively studied in terms of structure, function and tissue distribution [41].
The class II family of facilitative transporters is composed of the fructose transporter (GLUT5),
and also includes GLUT7, GLUT9, which has not yet been functionally characterized,
and GLUT11 [40]. The class III group has five members: GLUT6, GLUT8, GLUT10, GLUT12
and HMIT [40].
1.4.2.2 Glucose uptake transporter 4 (GLUT4)
GLUT4 belongs to the class I facilitative transporters family [40]. It is expressed in
heart, skeletal muscle and adipose tissue. During basal metabolism, GLUT4 cycles between the
intracellular storage compartment and the plasma membrane. It has been estimated that more
than 90% of the protein resides intracellularly [42-46]. Confocal microscopy demonstrated that
GLUT4 localized at tubulo-vesicular structures in the perinuclear region and in distinct foci
throughout the cytosol [43, 47]. GLUT4 has been partially localized in the Golgi compartment
[48], the trans-Golgi network [48] and in the recycling endosome compartment (ERC) [43]. The
non- ERC pool of GLUT4 is known as the GLUT4 storage vesicles (GSV). Details about
GLUT4 storage and trafficking will be discussed later. GSV are quickly mobilized to the cell
surface after insulin stimulation. The formation of GSV is dependent on the Golgi-localized -
ear-containing Arf-binding protein (GGA) and sortilin [49-51]. Mutations in GGA blocked the
formation of the GSV and inhibited insulin-stimulated glucose uptake in adipocytes [51].
GLUT4 mediates insulin induced glucose uptake into skeletal muscle, cardiac muscle and
adipose tissue. There is a general agreement that insulin largely promotes GLUT4 exocytosis,
and to a lesser extent, reduces GLUT4 endocytosis [44, 52]. It has been challenging to define the
biochemical nature of the “specialized compartment or GLUT4 storage vesicle” (SC/GSV) upon 
insulin stimulation. The insulin-responsive aminopeptidase (IRAP) co-localized with GLUT4
8and also moved to the cell surface with insulin stimulation [53]. Another protein associated with
GLUT4 is vesicle-associated membrane protein 2 (VAMP2). It is a vesicular soluble N-
ethylmaleimide-sensitive factor attachment protein receptor (v-SNARE) that is exclusively
required for GLUT4 fusion with the membrane after the insulin-stimulation [48].
Defects in GLUT4 are closely associated with insulin resistance. Animal and human
diabetic models exhibit reduced expression of GLUT4 in adipose tissue, but not in muscle [54];
however, in models where GLUT4 translocation is impaired upon insulin stimulation, it was
impaired in both adipose tissue and skeletal muscle [55]. Male mice heterozygous for a GLUT4
mutation (GLUT4 +/-) exhibited a decrease in GLUT4 expression in adipose tissue and skeletal
muscle. This reduction caused increased serum glucose and insulin, reduced muscle glucose
uptake, hypertension, and diabetic histopathologies in the heart and liver similar to humans with
non-insulin-dependent diabetes mellitus (NIDDM) in the absence of obesity [56-59].
Interestingly, adipose-specific GLUT4 is thought very important in regulating glucose
homeostasis and it affects insulin sensitivity in other tissues. Overexpression of GLUT4 in fat
not only normalized fasting hyperglycemia and glucose intolerance, but it also reversed the
enhanced clearance of an oral lipid load in muscle specific GLUT4 knockout mice [60].
1.4.2.Insulin signaling in GLUT4 translocation
1.4.2.1 PI3K dependent pathway
Engagement of insulin with its receptor triggers a cascade of tyrosine phosphorylation
events that ultimately promote the translocation of GLUT4-containing vesicles from the
intracellular storage pool to the cell surface [32, 61]. The insulin-receptor is composed of two
and twochains, which are linked by disulfide bonds. Thechains are entirely extracellular
and bind to insulin. The linkedchains span the membrane. Binding of insulin to the chains
9Figure 1. PI3K pathway involved in GLUT4 translocation. Insulin binding to insulin
receptor triggers tyrosine phsophorlylation of IRS. The SH2 domain of IRS binds to and
activates PI3K, which phosphorylates PI-4,5-P2 and forms PI-3,4,5-P3. PI-3,4,5-P3 phosporylates
Akt at serine 437 and parallels the phosphorylation of PDK1. Akt is subsequently phosphorlyate
Thr308 and is released. Akt then phosphorylates its substrate, AS160 and the inhibitory of
GLUT4 vesicles is released. GLUT4 is translocated to the plasma membrane and uptake glucose.
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leads to autophosphorylation of tyrosine 972, and activates the intrinsic tyrosine kinase activity
of thesubunits [32, 61].
GTP is dismissed. GLUT4 vesicles are thus able to translocate GLUT4 to the plasma
membrane and uptake glucose.
Phosphorylation of the insulin receptor activates substrate proteins from the insulin
receptor substrate family including IRS proteins (IRS-1,-2, 3,-4,-5 and –6), Gab-1, Shc, and
others [32]. Insulin-dependent tyrosine phosphorylation of IRS-1/2 creates docking sites for
downstream effector molecules including Class IA phosphatidylinositol 3-kinase (PI3K). This
protein is composed of a p85 regulatory subunit and a p110 catalytic subunit. The p85 subunit
binds to the Src homology 2 (SH2) domain of IRS, and activates the p110 catalytic domain.
Activated PI-3K then phosphorylates PI-4,5-P2 and forms PI-3,4,5-P3, which is important to the
translocation of GLUT4 [32]. Formation of PI-3,4,5-P3 provides a docking site to Akt (Protein
kinase B, PKB) via its pleckstrin homology (PH) domain and leads to the phosphorylation of
serine 437 (ser 473). This phosphorylation parallels the phosphorylation of phosphoinositide-
dependent-kinase-1 (PDK1), which promotes the interaction between Akt and PDK1. Thr308
subsequently is phosphorylated and Akt is then released [32].
There are three isoforms of Akt: Akt-1, -2 and -3 [62]. Bae et al. reported that Akt2/PKB
was the major isoform involved in insulin-stimulated GLUT4 translocation [62, 63]. Akt2 binds
with GLUT4-GSV during basal metabolism and the association increased with insulin
stimulation in response to Akt2 phosphorylation [63].
AS160 is a substrate of Akt. AS160 is expressed in cultured adipocytes and murine
skeletal muscle [48]. AS160 contains a GTPase activating domain (GAP) for Rab proteins,
which also binds with insulin-stimulated GLUT4-GSV. Thus, AS160 might mediate the signal
11
between Akt and GLUT4-GSV trafficking. AS160 is also an inhibitor of basal GLUT4-GSV
exocytosis [64, 65]. In the basal state, AS160 associates with GTPase Activating Protein (GAP),
which binds Rabs and maintains them in an inactivated form [65]. AS160 also contains two
phosphotyrosine-binding domains and multiple putative phosphorylation sites, including six
phospho-Akt substrate (PAS) motifs, which targeted by Akt, AMPK, or other upstream kinases
[66]. Upon insulin stimulation, AS160 is rapidly phosphorylated at PAS motifs [67] and
dissociates from GLUT4 vesicles [64], thus accelerate the translocation of GLUT4. Goodyear’s 
group studied the effects of wild type and mutant AS160 on basal and insulin- and contraction-
stimulated glucose uptake in mouse skeletal muscle in vivo. They demonstrated that AS160
phosphorylation at PAS motifs was required for full insulin- and contraction-stimulated glucose
uptake in mouse skeletal muscle and AS160 directly regulated insulin- and contraction-
stimulated uptake in mouse skeletal muscle [68].
1.4.2.2 PI3K-independent pathway
A second pathway important to insulin stimulation is the Cbl /CAP dependent pathway
[69, 70]. Mora’s group found Cbl pathway components present in murine heart, adipose tissue, 
skeletal muscle, cultured L6 myotubes and 3T3L1 adipocytes [71].
Cbl and the adaptor protein CAP are recruited to the plasma membrane after the
phosphorylation of APS (adaptor with pleckstrin homology (PH) and Src homology-2 (SH2)
domains) on a tyrosine residue [61, 72]. Once phosphorylated by the receptor, Cbl-associated
protein (CAP) binds to Cbl and targets Cbl to the lipid raft microdomains in the plasma
membrane. Cbl/CAP recruit CrkII and the guanyl nucleotide exchange factor C3G to the lipid
raft and provide a docking site to them. C3G then activates the small GTP binding protein TC10.
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Activation of TC10 leads to cytoskeletal rearrangement, which is essential for the insulin-
stimulated GLUT4 translocation [61, 72].
The importance of Cbl/CAP pathway in regulating GLUT4 translocation is controversial.
Knock down of CAP; Cbl and CrkII by RNAi suggested that this pathway was not required for
GLUT4 translocation [73]. Others, including the Mora lab, have indicated that Cbl pathway
plays an important role in whole body glucose homeostasis through insulin action. Mora’s group 
has reported that Cbl/CAP/TC10 pathway is activated in murine cardiac muscle and is impaired
during obesity and insulin deficiency [71].
2. Adipocytes as endocrine cells
2.1 White adipose tissue (WAT) versus brown adipose tissue (BAT)
There are two different types of adipose tissue, white and brown. WAT and BAT (white
and brown adipose tissue respectively) are normally localized in anatomically distinct areas in
rodents [74]. The morphology of WAT and BAT adipocytes are very different. White adipocyte
contains a scant ring of cytoplasm surrounding a single large lipid droplet, while brown
adipocyte contains multiple lipid droplets of varying size and has high numbers of mitochondria
packed with cristae [74].
WAT is an energy store organ as well as an endocrine organ [75, 76], which will be
discussed next. BAT is commonly caled ‘baby fat’ as it is present in babies and comprises up to
5% of body weight but diminishes with age and virtually disappears by adulthood [77]. Brown
fat is of particular importance in neonates, small mammals in cold environments, and animals
that hibernate, because it stores energy as heat [77]. Uncoupling protein 1 (UCP1) is the key
protein that regulates thermogenic capacity of BAT, which can uncouple oxidative
phosphorylation and utilize substrates to generate heat rather than ATP [78]. BAT is primarily
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localized around the organs. Brown adipocytes are electrically coupled via gap junctions and
highly vascularized with high blood flow rates for the requirement of the brain, spinal cord,
heart, lungs and kidneys during cold stress [79].
Despite the distinct function between BAT and WAT, there are linkages between them.
BAT is transformed into WAT during development, and WAT instead, can be turned into BAT
in certain situation. Adenovirus-mediated expression of human PGC-1 alpha increased the
expression of UCP1, respiratory chain proteins, and fatty acid oxidation enzymes in human
subcutaneous white adipocytes. Therefore, these adipocytes acquired typical features of brown
fat cells [80, 81]. In another study, after 14 days of hyperleptinemia induced by adenovirus,
adipocytes became shrunken, fatless, and encased in a thick basement-membrane-like matrix.
Gene expression of UCP-1 and -2 were increased and lipid-enzymes were down-regulated [82].
Long time treatment ofcarotene increased UCP-1 expression [83] and hypertrophy of WAT in
a dose-dependent manner [84]. Thus, conversation of BAT from WAT has been regarded as a
new stratagem for diabetes and obesity therapy.
There is evidence to show that BAT has an anti-obesity function. Hamann et al showed
increased body weight and increased expression of TNF-and decreased expression of GLUT4
in WAT of uncoupling protein-diphtheria toxin A chain (UCP-DTA) transgenic mice with
decreased BAT and fed with high fat diet [85]. Mice lacking UCP1 are cold-sensitive, yet are
neither obese nor prone to diet-induced obesity [86]. Moreover, dysfunction of BAT has been
found in ob/ob (leptin-deficient) and db/db (leptin receptor-deficient) [87, 88].
2.2 Adipocyte secreted hormones
Adipocytes have been traditionally viewed as energy storage cells. More than 95% of
cell body is composed of a storage form of triglycerides that can be released into the plasma
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when needed. Adipocyte size ranges from 25 to 200m in diameter depending on the amount of
lipid stored [89].   The major adipose tissue is caled “white adipose tissue (WAT)”, which is 
composed of mostly adipocytes, surrounded by loose connective tissue macrophages, fibroblasts,
adipocyte cell precursors, and various other cell types like endothelial cells, etc [76]. The
largest WAT is found subcutanously and around the viscera [74]. The rapid rise of insulin,
glucose and lipids in the postpandrial state stimulates the formation and storage of triglycerides
in the liver and adipocytes. Conversely, a decrease in insulin concentration triggers glycogen
breakdown and lipolysis via the action of glucagons, epinephrine, and glucocorticoids [90].
It is now clear that adipocytes serve not only as energy storage cells but also as endocrine
cells, releasing many endocrine and paracrine factors [76]. Adipocytokines are those bioactive
mediators secreted by adipose tissue composed of adipocytes and other cell types [89]. These
include several highly activated molecules like adiponectin, leptin, visfatin, resistin and some
cytokines like TNF-, IL-1, IL-6, and MCP-1.
2.2.1 Adiponectin
Adiponectin, also known as acrp30, adipoQ, GBP28 or ApM1, is a 247 amino acid
protein [91]. Adiponectin belongs to the C1q family, which is characterized by a distinctive
“globular domain” and a carboxyl terminus composed of colagen,  “the stalk” [92]. The
primary structure of adiponectin contains an N-terminal signal sequence, a variable domain, a
collagen-like domain, and C-terminal globular domain. F1 mice from globular domain
adiponectin (gAd) transgenic (Tg) mice crossed with leptin-deficient ob/ob mice showed
amelioration of insulin resistance [93] and suggests that the globular domain is the active domain
of adiponectin. Interestingly, the crystal structure of a homotrimeric fragment from adiponectin
reveals an unexpected homology to the tumor necrosis factor (TNF) family [92], and suggested
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shared impacts between TNF-and adiponectin on inflammation, adaptive immunity, apoptosis
and energy homeostasis.
Adiponectin circulates in the plasma in several different polymers, but not in monomeric
form [94]. The multimers are formed through disulfide bonds at Cys-39 that binds the
collagenous domains [94]. In human plasma and in culture medium, adiponectin can be found in
a low molecular weight form composed of trimer or hexamers, or with a high molecular weight
form made of a multimer larger than 300 kDa [95, 96]. Adiponectin concentration in human
blood ranges from 5-10 mg/ml [97]. Low levels of total and high molecular weight but not
trimeric or hexameric forms of adiponectin correlate with type 2 diabetes [98], metabolic
syndrome and liver injury [99] and coronary artery disease (CAD) [94]. Prospective studies have
shown that lower adiponectin levels are associated with a higher incidence and development of
type 2 diabetes [100-102].
The factors that regulate the adiponectin levels are not completely understood. Females
have higher concentrations of adiponectin and higher sensitivity to adiponectin than males,
which suggests that female hormones are involved in its regulation [103, 104]. However,
additional data are needed to test this hypothesis. Some dietary factors like soy protein and fish
oil increase adiponectin levels, which partially explains why they improve insulin sensitivity
[105, 106]. Restriction of methionine and carbohydrates also increases the level of adiponectin
[107], whereas conjugated linoleic acid inhibits glucose metabolism, and leptin and adiponectin
secretion in primary cultured rat adipocytes [108]. Therefore, there are many factors that can
change the production of adiponectin.
The absence of adiponectin is closely related to insulin resistance, particularly when
combined with a high-fat diet. Adiponectin KO mice exhibited severe diet-induced insulin
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resistance with reduced IRS-1-associated P13-kinase activity in muscle [109]. Adiponectin
administration to diabetic mice caused low blood glucose concentrations and ameliorated insulin
resistance [93, 110, 111]. Scherer’s group reported that a single injection of purified 
recombinant adiponectin into mice triggered a transient decrease in basal glucose levels by
inhibiting both the expression of hepatic gluconeogenic enzymes and the rate of endogenous
glucose production [111-113].  Lodish’s group reportedthat acute treatment of mice with
globular domain of Acrp30 increased fatty-acid oxidation in muscle and decreased plasma
glucose in mice [114]. Therefore, alteration in mitochondrial function can impact the
adiponectin-glucose balance. The thiazolidinedione class of antidiabetic drugs, which also have
positive effects on cardiovascular diseases, increases the active form of adiponectin, resulting in
increased insulin sensitivity [115]. These data are supported by data from adiponectin transgenic
mice [116]. Globular adiponectin transgenic ob/ob mice have partial amelioration of insulin
resistance, while adiponectin knockout mice showed mild insulin resistance [93].
Two adiponectin receptors (AdipoR1 and AdipoR2) have been reported. AdipoR1 was
ubiquitously expressed and most abundantly expressed in skeletal muscle, whereas AdipoR2 was
most abundantly expressed in mouse liver [117]. Suppression of AdipoR1/R2 expression by
small-interfering RNA reduced the increase in fatty-acid oxidation by adiponectin [117].
Interestingly, AdipoR1-/- mice showed increased adiposity associated with decreased glucose
tolerance, while AdipoR2-/- mice were lean, resistant to high-fat diet-induced obesity and had
improved glucose tolerance. Thus, AdipoR1 and AdipoR2 are believed to be involved in energy
metabolism but have opposing effects [118].
How adiponectin exerts its effect as an insulin sensitizer is still unclear. There are several
hypotheses. Adiponectin increases the level of peroxisome proliferator-activated receptor
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(PPAR)-which caused a decreased triglyceride (TG) content in the liver and skeletal muscle
[113, 119]PPAR-agonistrosiglitazone and TZD, both increased plasma levels of
adiponectin [113, 119]. Thus, the effects of these drugs as insulin sensitizers could be
attributable to the fact that they increase circulating adiponectin levels [113, 119]. Adiponectin
stimulated phosphorylation and activation of AMPK in skeletal muscle and liver [120].
Therefore, it may also stimulate-oxidation and glucose uptake. Adiponectin was also reported
to increase glucose uptake via stimulating AMPK pathway in rat adipocytes [121].
Recently, Kubota et al reported that adiponectin enhances AMPK activity in the arcuate
hypothalamus via its receptor AdipoR1 to stimulate food intake [122]. Huypens et al reported
adiponectin induced an activation of AMPK in beta cells, which inhibited their biosynthesis of
glucose-carbon to lipids [123].
Adiponectin may play a role in human innate immunity [76].  Matsuzawa’s group 
reported that adiponectin suppressed bone marrow cell colony formation by colony-forming
units (CFU)-granulocyte-macrophage, CFU-macrophage, and CFU-granulocyte precursor and
inhibited mature macrophages function [124]. Treatment of cultured macrophages with
adiponectin significantly inhibited their phagocytic activity and their lipopolysaccharide (LPS)-
induced production of TNF-[76].  Tilg’s group reported that adiponectin induced the 
production of the anti-inflammatory mediators IL-10 and IL-1RA by primary human monocytes,
monocyte-derived macrophages, and dendritic cells [125]. Adiponectin also inhibited LPS-
stimulated IL-6 and TNF-gene transcription [126, 127]. This is consistent with reports that
adiponectin knockout mice had a higher level of TNF-gene transcripts and a higher level of
serum TNF-[128]Obviously, adiponectin is not only an important mediator in the regulation
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of insulin resistance but also can suppress inflammation in vivo and cytokine release in cultured
cells [76].
2.2.2 Leptin
Leptin is a 16 kDa polypeptide product of the obese (ob) gene. Like adiponectin, leptin is
a major hormone secreted by adipocytes and it regulates a wide range of biological responses
including energy homeostasis, neuroendocrine function, innate immunity and reproduction [129].
Leptin has a conserved homology among species and has a structural similarity to other
proinflammatory cytokines such as IL-6 and IL-12 [129]. Leptin contains an intra-chain
disulfide bond that appears to be necessary for its biological activity [130]. Leptin is mostly
produced in adipose tissue although it has been detected in the gastric wall, vascular cells,
placenta, ovary, skeletal muscle and liver [131]. Leptin expression is influenced by energy
stores in fat [131]. Leptin levels increase within hours after a meal in rodents and after several
days of overfeeding in humans [132]. Insulin stimulates leptin expression and secretion in
primary adipocytes [133]. Other factors, such as dexamethasone [134], thyrotrophin (TSH)
[135], TNF-[136] and IL-6 [137] also regulate leptin release.
Leptin concentrations in the blood are in the range of several ng/ml, both as an active free
form and as an inactive bound form which occurs by its association with plasma proteins and the
leptin receptor isoform [131]. Leptin receptors (OB-R) are expressed in variety of tissues, which
suggested that it has a wide range of actions. However, leptin receptor mutations cause early
onset obesity in rodents [133]. This is consistent with measurements of high leptin concentration
and low leptin receptor expression in most diabetic patients [89]. Human studies have
discovered that leptin has pleiotropic effects in the human body. In children with protein-energy
malnutrition, selective deficiencies of nutrients and poor general intake of food is associated with
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low leptin levels [138, 139]. Children with leptin deficiency and massive obesity have a robust
skeleton [139]. Clinically, providing leptin to girls with anorexia nervosa with leptin deficiency
improves their immune system based on in vitro testing [139-141]. Low serum leptin and
adiponectin levels are associated with premature intrauterine growth retardation in infants [142].
The primary physiological role of leptin is to communicate (CNS) the abundance of
available energy stores to the central nervous system and brain and to restrain food intake [143].
The absence of leptin causes an increased appetite, increased food intake and extra energy
storage in the form of fat. Indeed, adiministration of leptin to rodents decreased food intake and
increased energy consumption, leading to weight loss [143]. However, leptin-induced weight
loss was restricted to the fat and not lean tissue [143]. Leptin activated lipid oxidation, at least
partially by inducing the expression of enzymes involved in lipid metabolism [143]. Leptin also
stimulated apoptosis of adipocytes through activation of caspase-8 [144].
The ability of leptin to decrease body fat content suggests leptin is an anti-obesity
hormone. However, high leptin levels have been found in obese and diabetic mice and humans
[145], which is defined as “leptin resistence”.  Sometimes it is combined with low-level
expression of leptin receptors. Another mechanism is that leptin receptors become saturated as
leptin levels rise, which leads to leptin resistance [139]. Therefore, disruption of leptin action is
thought to play a role in development of diabetes. This hypothesis is supported by data showing
that mutations of the ob gene cause early onset obesity and type II diabetes in mice and humans
[143]. A frameshift/premature stop mutation, c.398delG (Delta133G mutation) caused a
congenital leptin deficiency and led to severe early-onset obesity [146]. A homozygous
frameshift mutation (delta133) in the human leptin (ob) gene was associated with undetectable
serum leptin and extreme obesity [147].
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Leptin binding to the leptin receptor leads to the formation of a Ob-R/JAK2 (Janus-
activated kinase) complex that triggers phosphorylation [148]. JAK2 phosphorylation leads to
activation of the PI3K and MAPK pathways that regulate apoptosis, energy homeostasis and
gene transcription [149]. Leptin signaling occurs mainly through signal transducers and
activators of transcription (STAT3). Phosphorylation of STAT3 triggers dimerization and
translocation to the nucleus which leads to activation of gene transcription [148]. The targets
include: genes of suppressors of the cytokine signaling family (SOCS3) [150]. Therefore, leptin
regulates various signaling pathways and impacts gene transcription.
Leptin action also affects to the immune system. Leptin stimulates the proliferation of
stem cells and regulates hematopoiesis [151]. It participates in innate immunity by promoting
the maturation and survival of dendritic cells (DC) [152] and stimulates macrophage
proliferation, phagocytosis, and production of proinflammatory cytokines [129]. Moreover,
leptin plays a direct role in adaptive immunity by regulating the expression of Ob-R on both T
and B cells and promoted the suvival of T and B cells by suppressing Fas-mediated apoptosis
[153]. Also, leptin has been shown to increase the production of IL-2 and IFN-by T
lymphocytes [129].
Other roles of leptin include regulating fetal and brain development [129]. However,
although leptin plays a wide range of roles, the major function of leptin is to regulate energy
homeostatsis.
2.2.3 Resistin
Resistin (resistance to insulin) is a member of a family of cysteine-rich C-terminal
domain proteins called resistin-like molecules (RELM). Resistin is an approximately 12 kDa
polypeptide containing a carboxy-terminal, disulfide-rich, -sandwich domain and an amino-
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terminal -helical segment [89]. It is secreted as a disulfide-linked homodimer via disulfide
bonds at cysteine residue (Cys26) [154].
Resistin is an insulin antagonist and it counterbalances the effects of adiponectin in the
liver [155]. The physiological role of resistin in humans remains unclear. However in mice, its
expression has been correlated to obesity [155]. Human resistin shares only 64% homology with
murine resistin and lacks one of the isoforms found in mouse, which suggests a different
physiological role in the two species [155]. In humans, in contrast to what happens in mice,
resistin was produced at higher concentrations in cultured preadipocytes than in mature fat cells
[156]. Furthermore, there is no consistent link between adipocyte expressed resistin or
circulating resistin and adiposity or insulin resistance [156]. Thus, the function of resistin needs
to be better understood.
In vitro and in vivo studies both showed murine resistin specifically expressed in adipose
tissue were down regulated by thiazolidinedione [156]. However, the expression of resistin in
humans was very low, even undetectable under certain conditions [154]. Recombinant resistin
impaired insulin-stimulated glucose uptake in cultured adipocytes, whereas anti-resistin
antibodies prevented this effect [156]. L6 myocytes treated with recombinant mouse resistin
showed impaired glucose tolerance and insulin resistance [157]. These data suggest that resistin
induces insulin resistance and that hyperresistinemia at least partially contributes to impaired
insulin sensitivity in obese rodents. The role of resistin has also been studied in knockout mice.
Loss of resistin in ob/ob mice improved glucose tolerance and insulin sensitivity by enhancing
insulin-mediated glucose disposal in muscle and adipose tissue [158]. In contrast, in C57BL/6J
mice with diet-induced obesity, resistin deficiency reduced hepatic glucose production and
increased peripheral glucose uptake [158].
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Although resistin was first identified as an “insulin resistant hormone”, more and more 
evidence indicates it also plays a role in the immune system. Proinflammatory cytokines such as
TNF-IL-6 and LPS regulated resistin gene transcription in both 3T3L1 adipocytes and human
peripheral blood mononuclear cells (PBMC) [159]. Resistin also regulated the expression of
proinflammatory cytokines [154]. For example, resistin increased the expression of IL-6 and
TNF-by inducing translocation of NF-B [160]. Higher levels of resistin positively correlated
with many inflammatory factors in persons with severe inflammation. Moreover, resistin was
found to play a role in inflammation-related disease such as atherosclerosis, arthritis and Type 1
diabetes [154].
2.2.4 Visfatin
Visfatin, previously recognized as a pre-B cell colony-enhancing factor (PBEF), is
expressed in bone marrow, liver and skeletal muscle. However, it is highly expressed in human
visceral fat [161]. Both obese mice and people have higher concentrations of visfatin than lean
individuals [162]. Visfatin mRNA was markedly higher in mature adipocytes than in
preadipocytes, suggesting that lipid concentration affects its production [161] or it could be an
adipocytes-specific factor expressed only when adipocytes are differentiated. This hypothesis is
consistent with the observation that the amount of plasma visfatin strongly correlated with the
amount of visceral fat as assessed by computer tomography [163].
There is still some debate about how visfatin and body fat are related. Some reported
visfatin level was higher in obese people [164], while others failed to find differences between
lean and obese people [165, 166].  There is also controversy about visfatin’s role in glucose 
metabolism and insulin resistance [167]. Moreover, except for one report [162], there do not
appear to be differences in visfatin content between visceral and subcutaneous fat [167-169].
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One time injection of visfatin reduced blood glucose, but insulin levels were not affected
[161]. This suggests that visfatin plays a direct role in glucose uptake and glycolysis
independent of insulin. The same effect was observed in other mouse models including lean
mice, type II diabetic mice and obese mice [161]. Nishizawa’s lab reported that visfatin 
mimicked insulin action in 3T3L1 adipocytes and L6 myocytes by stimulating glucose uptake
[161]. They generated visfatin-deficient mice and found that plasma glucose was higher in
visfatin-/+ heterozygote mice compared to knockout mice [161]. In addition, the knockout mice
exhibited impaired glucose tolerance and insulin sensitivity [163]. Visfatin has been shown to
inducd adipogenesis [161]. Visfatin stimulated the differentiation of preadipocytes to mature fat
cells, induced triglyceride accumulation, and accelerated triglyceride synthesis [161]. Visfatin
binds to the same receptor of insulin, using a different epitope [161], which explains why it can
parallel the action of insulin. It stimulated the phosphorylation of IRS-1/2, and activate both
PI3K and Ras/MAPK [170, 171].
3. Role of macrophages and their interaction with adipocytes.
The growing understanding of adipose tissue macrophages in obese animals and
individuals has revealed a strong interaction crosstalk between adipocytes and macrophages.
Chapter 4 and 5 of this dissertation will address this interaction. Therefore, I will address the
current understanding of this issue.
3.1 Insulin resistance: an inflammatory disease
Systemic chronic inflammation may have an important role in the pathogenesis of
obesity-related diabetes [131]. In patients who are insulin resistant, there are high
circulatinglevels of adiponectin, leptin, IL-6, CRP and TNF-[172]w these cytokines
contribute to insulin resistance will be discussed later. The adipose tissue of patients with insulin
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resistance has a large number of infiltrated macrophages [173]. These macrophages induce or
exacerbate the amount of cytokine produced by the adipocytes [173]. Interestingly, adipocytes
are a major source of TNF-IL6 and IL-1. One third of the IL-6 found in obese people with
insulin resistance came from adipocytes [76].
3.2 Characteristics of Adipose tissue macrophages
Insulin resistance has been associated with chronic inflammation [131] and obesity is
related to an elevated level of proinflammatory cytokines [149]. In particular, obesity is
associated with significantly enhanced infiltration of macrophages into the adipose tissue [174].
The precise mechanisms causing inflammation into adipose tissue remains to be
elucidated. Monocyte chemoattractant proteins such as (MCP-1, CCL-2) and its receptor and
macrophage migration inhibitory factor (MIF) may play a role [174, 175]. The mRNA level of
Monocyte chemotactic protein-1 (MCP-1) was higher in visceral adipose tissue in obese and
diabetic patients compared to normal people [176]. Adipose tissue MCP-1 mRNA and the
plasma MCP-1 concentrations were increased in genetically obese diabetic (db/db) mice and in
WT mice with obesity induced by a high-fat diet compared to normal control mice [176].
Overexpression of MCP-1 in visceral adipose tissue resulted in insulin resistance, macrophage
infiltration into adipose tissue, and increased hepatic triglyceride content [176].
Adipose tissue macrophages are the major source of TNF-and MCP-1 in adipose tissue
and they also expressed a very high level of IL-6 [177]. Clearly, adipocytes and macrophages
share many characteristics. There is even some suggestion that adipocytes can be converted into
expressing macrophage-like properties after in vivo adaptive transfer [178]. Both adipocytes and
macrophages produce proinflammatory cytokines like TNF-IL-1and IL-6, whereas leptin
and adiponectin released by adipocytes may have antiinflamatory effects as mentioned above.
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Therefore, there must be cross-talk between the two cell types that result in the onset of type II
diabetes.
There is a correlation between macrophage content in adipose tissue and insulin resistance
[177]. However, resident macrophages in adipose tissue display a different phenotype compared
to inflammatory macrophages. macrophages are classified as either classically (M1) or
alternatively (M2) activated macrophages [179, 180]. M1 macrophages are generated by IFN-
alone or in combination of LPS, as well as by IL-12 or IL-18 [180] and are generally
characterized by interleukin (IL)–12high, IL-23high, IL-10low phenotype [181]. The M2
macrophages are generated through interaction with IL-4 and IL-13 and generally share an IL-
12low, IL-23low, IL-10high phenotype [179, 181]. M1 macrophages secrete proinflammatory
cytokines, such as TNF-IL-6 and IL-1. M2 cells are characterized as anti-inflammatory
macrophages during type I inflammatory responses and promote angiogenesis and wound healing
[181]. Whereas inflammatory macrophages expressed high levels of proinflammatory cytokines,
resident macrophages expressed high levels of Arginase-1, Ym-1 and Found in inflammatory
zone 1 (Fizz-1) [182], which are recognized as markers of “alternative macrophage” (M2
macrophages) [182, 183]. Resident macrophages in WAT have been found to display a M2
phenotype [182]. When M2 macrophages were inactivated in a macrophage-specific PPAR
knockout mouse, the mice showed impaired glucose tolerance and insulin sensitivity when fed a
high fat diet [182]. They also had significantly lower levels of oxidative phosphorylation gene
expression in liver and muscle [182]. This affects in energy metabolism and is one factor that
leads to decreased insulin sensitivity. Odegaard et al suggested that M2 macrophages protect
against the metabolic consequences of obesity; however, this hypothesis has yet to be tested.
3.3 Important cytokines involved in insulin resistance
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3.3.1 TNF-
TNF- is a cytokine initially described as an endotoxin-induced factor that caused
necrosis of tumors and was subsequently shown to be identical to cachexin, a factor secreted by
macrophages in vitro [184]. TNF-isnow recognized as a multi-functional regulatory cytokine,
involved in inflammation, apoptosis, cell survival, cytotoxicity, and insulin resistance.
TNF-is a 26-kDa plasma membrane-bound protein that is cleaved into a 17-kDa
biologically active protein [184]. There are two receptors for TNF-, type I and type II that
regulate different functions [184].A death domain (DD) is important for TNF-. This domain
binds the TNF receptor 1-associated protein (TRADD), and at least three additional proteins,
TRAF2, FADD, and RIP, are recruited [185] to activate downstream signaling. These signals
regulate cell apoptosis or cell survival.
The association between TNF-and insulin resistance was first discovered by
Spiegelman’s group [186]. Both mRNA and TNF-protein were elevated in the adipose tissue
of obese animals and humans [187]. Within adipose tissue, TNF-was expressed mostly by
adipocytes and stromovascular cells, although adipose tissue was composed of variety of cells
types including immune cells [188]. Adipose tissue also expressed both types of TNF-
receptors [189].
Long term exposure of cultured cells or animals to TNF-induced insulin resistance,
characterized by hyperinsulinemia and an increased prevalence of obesity, hypertension,
dyslipidemia and type 2 diabetes [184]. Furthermore it has been demonstrated that this is a
direct effect of TNF-because neutralization of TNF-in 3T3L1 adipocytes increased insulin-
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stimulated glucose uptake in these cells [190]. Moreover, the adoptive transfer of bone marrow
cells from TNF+/+ into TNF-KO mice reduced insulin resistance of the recipients [191].
Several hypotheses have been proposed to explain how TNF-induces insulin resistance
in adipocytes. For example, TNF-inhibited insulin-stimulated IRS-1 phosphorylation. Thus, it
might inhibit PI3K and inhibit a pathway that regulates glucose uptake [192]. In addition, TNF-
up regulates transcription of many preadipocyte genes and proinflammatory cytokines, such as
IL-6 and MCP-1 [192]. These proteins were elevated in the plasma or adipose tissue of diabetic
patients. TNF-also inhibited adiponectin expression, which may impaire insulin action [97].
Furthermore, TNF-directly stimulated lipolysis, which caused in increased plasma free fatty
acids [97]. This also caused hepatic insulin resistance by inhibiting insulin suppression of
glycogenolysis [193, 194].
3.3.2 IL-
IL-6 is another cytokine that has long been recognized for its effects on the immune
system [195]. It is associated with obesity and insulin resistance, too [196]. IL-6 belongs to the
IL-6 family of cytokines, including IL-11, oncostatin M, leukemia inhibitory factor and other
proteins, which commonly use gp130 (also known as IL-6Ror CD130) as part of their
receptors [197]. IL-6 circulates in multiple glycosylated forms ranging from 22 to 27-kDa in size
[75]. Several cell types, including most cells of the immune system, endothelial cells, skeletal
and smooth muscle cells, adipocytes, islet -cells, hepatocytes, microglial cells, and astrocytes,
produce IL-6 [198]. Like TNF-adipose tissue is a major source of plasma IL-6 [199].
Adipocytes secretes 2 to 3 times more IL-6 than stromovascular cells [75].
IL-6 binds to a type I cytokine receptor complex containing a ligand-binding IL-
6Rgpand a signal-transducing component gp130 [197]. Upon formation of the IL-6/IL-
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6R/gp130 hexameric signaling complex, signals are passed either through Janus kinase
(JAK)/signal transducers and activator of transcription (STAT) or the Src homology 2–
containing tyrosine phosphatase (SHP-2)/extracellular signal–regulated kinase (ERK)/mitogen-
activated protein kinase (MAPK) pathways or both [198]. IL-6 induces fever and the acute phase
response, which is defined as the complex series of inflammatory reactions initiated in response
to infection, physical trauma, or malignancy [200]. Therefore, enlarged adipose tissue has the
potential to exacerate both responses. IL-6 is made in responses to specific microbial molecules
as pathogen associated molecular patterns (PAMPs). These PAMPs bind to Toll-like receptors,
whose activation induces intracellular signaling cascades that give rise to inflammatory cytokine
production [201, 202].
IL-6 is a strong inducer of the acute-phase response and is associated with a higher level
of C-reactive protein (CRP) [203]. In proinflammatory insulin-resistant states, like obesity and
type II diabetes, plasma IL-6 is found moderately increased [204]. The in vivo release of IL-6
from fat contributes more than one third of the basal circulating IL-6 and explains the positive
correlation between serum levels of IL-6 and obesity [205]. Enhanced macrophages infiltration
also accounts for the elevated IL-6 [204]. IL-6 decreases IRS-1 protein expression and insulin-
stimulated tyrosine phosphorylation which reduces insulin-stimulated glucose transport in 3T3L1
adipocytes [206]. IL-6 suppresses insulin-induced lipogenesis and reduces expression of GLUT4
via repressed PKB/ERK pathway [207]. Furthermore, IL-6 decreased adiponectin gene
expression and secretion in a dose- and time-dependent manner in 3T3L1 adipocytes [208]. All
of these changes contribute to a glucose intolerant state.
In skeletal muscle, IL-6 is synthesized and released from skeletal muscle in large
amounts during exercise [209]. Thus, it serves as an exercise signal involved in glucose
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homeostasis by activation of AMP-activated protein kinase [199]. This regulation is exemplified
by observations in the human hepatocarcinoma HepG2 cell line. In this cell line, IL-6 decreased
SOCS3 transcription by inhibiting JAK/STAT activation, which caused inhibition of insulin
receptor (IR) phosphorylation and insulin receptor substrate (IRS) phosphorylation [210]. Thus,
increased glyconeogenesis and decreased gluconeogenesis decrease glycogen storage, a
consequence of insulin resistance [211].
3.3.3 IL-
IL-1β is one of the major pro-inflammatory cytokines that is produced by monocytes,
dendritic cells and macrophages [212]. The original member of the IL-1 family, includes IL-1,
IL-1IL-1 receptor antagonist (IL-1Ra) and six additional members including IL-18 and IL-
1F7b [212, 213]. IL-1is 17 kDa but starts as a 31-kDa precursor protein. Mature IL-1is
released from Pro-IL-1β folowing cleavage by the interleukin-1 converting enzyme (ICE,
caspase-1) [212]. The three- dimensional structure of IL-1is primarily barrel-shaped and
composed of 12-14-strands [214].
There are three members of the IL-1 receptor gene family: IL-1RI, IL-1RII and IL-1sIIR
[215]. IL-1 has a higher affinity to IL-1RII than IL-1RI. IL-1RII contains a single
transmembrane domain and the extracellular domain is found in the circulation as a soluble
receptor (sR). Because IL-1sRII can bind to IL-1, it serves as a natural antagonist of IL-1
[215].
IL-1 has wide ranging impacts gene transcription [212]. For example, IL-1affects
molecules involved in inflammation, like IL-6, TNF-TNF-receptor, IL-1R, and many
chemokine proteins [212]. Signal transduction involves several pathways: 1) G-protein
hydrolysis leads to the release of ceramide, which phosphorylates a p97 kinase and activates p38
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MAPK [216]; 2) activation of phospholipase C (PLC) causes a hydrolysis of phosphatidylcholine
(PC), phosphatidylethanoloamine (PE) or phosphatidylserine (PS). These induce the release of
diacylglycerol (DAG), the physiological substrate of protein kinase C (PKC). Phospholipid
cleavage also phosphorylates protein kinase A, to activate the p38 MAPK pathway [217]. IL-1
levels in the circulation of animals or humans correlate with the severity of some diseases; for
example, tumor angiogenesis [218], age-related cognitive dysfunction [219] and arthritis [220].
The contribution of TNF-α and IL-6 to insulin resistance are better documented than
those of IL-1β. IL-1concentrations are higher in overweight and obese people [221].
Moreover, individuals with a higher combined levels of IL-1and IL-6 levels are at greater risk
of developing type 2 diabetes than individuals with increased IL-6 alone [222]. Therefore, these
are some suggestions that IL-1plays some role in obesity.
IL-1 and IL-1R regulate lipid metabolism in vivo. IL-1Ra-/- mice gained less weight and
accumulate less fat when they were fed a high-fat diet [223]. In vitro, recombinant murine
interleukin 1 (rIL-1) inhibited lipoprotein lipase (LPL) activity in 3T3-L1 cells [224]. IL-1also
inhibited adipocyte differentiation in long-term human bone marrow cultures [225]. Moreover,
continous treatment with IL-1decreased insulin receptor substrate (IRS-1) but not IRS-2
expression in both 3T3-L1 and human adipocytes [226].
3.4 Macrophage and adipocyte differentiation
t is now recognized that the stromal-vascular compartment of adipose tissue contains
various precursors and stems cells, which give rise to multiple cell types [227]. Among the
stromal cells, there are preadipocytes that differentiate into adipocytes [227]. Macrophage
infiltration into the stroma of adipose tissue might inhibit adipogenesis [228]. Weisberg et al.
[174] and Xu et al. [229] reported that inflammatory macrophages accumulated around small
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adipocytes, and induced apoptosis. Little is known about the roles of macrophages in
adipogenesis and obesity. Moreover, the reports on this topic are inconsistent. Nishimura et al.,
found two types of cell clusters that showed a macrophages phenotype [228]. CD34+ CD68+
cells were associated with the small differentiating adipocytes and CD34–CD68+ macrophages
were scattered in the stroma [228]. While the role of CD34–CD68+ macrophages not clear, the
CD34+ CD68+ cells appeared to accelerate angiogenesis and promote the differentiation of the
preadipocytes [228].
Macrophages play a role in adipocyte differentiation by secreting proinflammatory
cytokines. This hypothesis is supported by several observations that have been reviewed in
detail above. However, two additional observations reinforce this key point. Somm et al
reported decreased fat mass in IL-1Ra-/- mice. This was a defect in adipogenesis and increased
energy expenditure in those mice [230]. Hongan et al., found that leukemia inhibitory factor
(LIF) treatment had minimal effects on adipocyte differentiation, but did inhibit triacylglyceride
(TAG) accumulation during adipogenesis [231]. Chapter 4 of this dissertation will address the
importance of macrophages and cytokines on adipocytes.
4 Intracellular trafficking
Secreted proteins need to be transported outside of the cells after they are synthesized and
processed in the endoplasmic reticulum (ER). The cellular biosynthetic-machinery allows cells
to modify molecules it produces, to pass them through the Golgi complex, and to pack them into
granules for exocytosis at the plasma membrane [232]. Vesicles continually bud from one
membrane and fuse with another, the process by which cells acquire and secret. These processes
are highly regulated and organized with specific proteins. Given the importance of the adipose
tissue as a secretory organ, one of the main challenges is to discern the specific molecular
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mechanisms that regulate and control protein trafficking. This has been one of the main areas of
my doctoral work in chapter 2 and 3. Therefore I will provide some background information on
this topic.
4.1 Transport from the ER through the Golgi apparatus
Newly synthesized proteins enter the ER by crossing the ER membrane from the cytosol.
Some proteins carry a N-terminal signal sequence that is cleaved. Proteins are transported to the
Golgi apparatus and from the Golgi apparatus to the cell surface or elsewhere. The golgi
apparatus is a major site of carbohydrate synthesis, as well as a sorting organelle for the products
of the ER [233]. Proteins that are sent to the Golgi apparatus are attached to the carbohydrates
made in Golgi apparatus as oligosaccharide side chains [233]. These oligosaccharide chains are
served as ‘tickets” that direct specific proteins into vesicles going to the destination.  A large 
number of plasma proteins are attached to a glycosylphosphatidyl-inositol (GPI) anchor to the C
terminus. [233] Since these proteins are attached to the exterior of the plasma membrane only by
GPI anchors, they can release soluble proteins in response to signals [233]. GPI anchors are also
used to direct proteins into lipid rafts [233].
Proteins are first packaged into small COPII-coated transport vesicles. Some cargo
proteins are actively recruited into such vesicles, where they become concentrated. Membrane
proteins carrys exit signals that recognize the COPII coat by complementary receptors that are
packaged into budding COPII (coatomer protein II) -coat transport vesicles [234]. Recruitment
of coat proteins from the cytosol to organelle membranes is mediated by ARF/Sal1 family of
small GTPase in a GTP-dependent manner [235]. The vesicular tubular cluster, which is
generated continually, mediates the transportation from ER to the Golgi apparatus and move
along microtubules to carry proteins from the ER to the Golgi apparatus. The retrieval (or
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retrograde) transport continues as the vesicular tubular clusters move to the Golgi apparatus
[233]. Thus, those proteins participating in the ER budding reaction and the escaped proteins
that are not properly folded and assembled are controlled and are returned to the ER to be reused.
COPI is involved in the retrograde traffic from the Golgi to the ER and also functions in the
endosomal compartment. COPII is involved in the anterograde traffic from the ER to the Golgi
[233].
4.1.1 Arf proteins
Recently, the human Arf (ADP-ribosylation factor) family has been expanded to 21
members, with six Arf proteins and fifteen Arl (Arf-like protein) proteins [236]. Arf1, Arf 3-6
are found in human, while Arf2 has been lost in human [236]. These six molecules can be
divided into three classes on the basis of their primary structure. Class I includes Arf1, Arf2 and
Arf3; class II includes Arf4 and Arf5; class III includes Arf6 [236]. Arfs regulate the budding of
vesicles in the endocytic and exocytic pathway by recruiting other adaptor proteins or coat Golgi
membranes when bound to GTP or GTP S but not GDP [236]. Target proteins recruited by Arfs
proteins include: COPI and II, AP-1, AP-3 and AP-4, GGA1-3 (Golgi-associated -adaptin ear
homology domain Arf-interacting protein1-3) and MINT1-3 (Munc18 interacting protein 1-3)
[234].
Arf proteins cycle between their active-GTP-bound and inactive-GDP-bound forms.
Hydrolysis of bound GTP is mediated by GTPase-activating proteins (GAPs), whereas guanine
nucleotide-exchange factors (GEFs) exchange GDP to GTP [236]. The specific roles of different
Arf are still poorly understood. However, Arf proteins 1, 3, 4, and 5 are predominantly cytosolic
but could be recruited to a variety of intracellular, but not plasma membranes. Arf6 is uniquely
localized to the plasma membranes, which suggested that Arf6 has unique functions [237] during
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cell adhesion, migration, and cancer cell invasion [238] as well as during membrane trafficking
[239]. The Arf6 GTPase cycle has been shown to regulate endosome membrane trafficking,
regulated exocytosis, and actin remodeling at the cell surface [240]. Arf6 affects cell migration
in epithelial cells by facilitating junction disassembling through its effect on endocytosis [241].
Therefore, the role of ARF6 at the cell surface parallels the role of ARF1 at the Golgi [242].
Two-hybrid assays of Arf-coat protein interaction showed little specificity and knocking down of
a single Arf by RNAi has no effect on secretory traffic and endosome recycling [243, 244].
These data suggest that the function of Arf proteins is redundant. However, double knock down
experiments show some specificity between Arfs. Arf1 and Arf3 are involved in the trafficking
from ER to cis-Golgi [243, 244].
Arf1 regulates COPI, adaptor protein (AP)-1, AP-3, AP-4 and GGAs [245], and plays a
role in the secretory pathway by budding transport vesicles. Arf-1-GTP and the COPI coatomer
complex comprises the basic components of budded COPI-coated vesicles in vitro [246].
4.2 Transport from the Trans Golgi Network (TGN) to the cell exterior
When transport vesicles destined for the plasma membrane leave the TGN, the membrane
proteins and the lipids in these vesicles provide new components for the plasma membrane,
while the soluble proteins are secreted to the extracellular space. All cells use the constitutive
secretory pathway to transport mature proteins to the outside of the cells. However, some
specialized secretory cells have a regulated secretory pathway, in which soluble proteins are
stored for later release [233].
Clathrin coats are the third well-characterized class of coated vesicles, which are
involved in endocytosis and exocytosis, regulating traffic between TGN and endosomes.
Clathrin coats contain clathrin and heterotrimeric adaptor protein (AP) complexes ([247]. There
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are four types of APs in mammalian cells and only AP-1 and AP-2 have been widely studied.
However, the unique intracellular localization of the four isotypes suggests their specialized
function in different trafficking steps between TGN and plasma membrane [248]. At steady
state, most AP-1 is localized to tubular, clathrin-coated structures on the TGN [249].
Recruitment of AP-1 to membranes is dependent on Arf. AP-1 mediates antegrade transport
from the TGN to endosome and GGAs regulates the retograde transport [248]. The AP-2
associates with the plasma membrane and mediates endocytosis [248]. The AP-3 is involved in
protein trafficking to lysosomes, while little is known about AP-4 [250].
4.2.1 GGA proteins
GGAs was first identified by Boman et al in 2000 using a yeast two-hybrid screening of a
human cDNA library with a Arf3-GTP as bait [251]. Until now, three isoforms of GGAs have
been found in human: GGA1, GGA2 and GGA3; and two isoforms in yeast: Gga1p and Gga2p
[250]. The molecular size of GGAs varies from 60-80 kDa. The GGAs have four functional
domains: the N-terminal ~140-AA VHS domain, the GGA and Tom1 (GAT) domain, the hinge
and the C-terminal ~160-AA-adaptin ear homology (GAE) domain [252].
The VHS domain recognizes the cytoplasmic domain of transmembrane proteins found in
TGN[250]. It was shown that the acidic amino acid cluster-dileucine (ACLL) within the
cytoplasmic domain of transmembrane protein is the site recognized by VHS of GGAs [250]. It
has been found that the GGA binding proteins, CI-MPR, CD-MPR, sortilin and LRP3 all
contained the ACLL similar site [250]. It is also interesting that the hinge of GGA1 and GGA3,
but not GGA2 both contain a potential ACLL sequence and the phosphorylation of a serine in
such sequence autoinhibits the interaction between VHS domain of GGA with the ACLL
sequence of cargo proteins [253]. GGAs are recruited to the TGN via binding to activated (GTP-
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bound) Arf proteins [252]. Treatment of brefeldin A (BFA), an inhibitor of guanine nucleotide
exchange factors for Arfs, caused redistribution of GGAs from TGN to cytosol [254]. All
human GGAs can interact with all forms of Arf [254]. However, it is unknown if specific
isoforms of Arfs are involved in different isoforms of GGA. All of the GGAs contain a clathrin
box, potential clathrin-binding sequence (consensus sequence, L (L/I)(D/E/N)(L/F)(D/E)) [255],
through which GGAs on the TGN membrane recruit clathrin. The GAE domain shares several
similar binding partners with the ear domain of adaptin and functions on binding with
accessory proteins [250].
Although it is well-established that GGA proteins regulate coat assembly and are
involved in the trafficking between TGN and endosome, there are questions remaining about
specialized proteins whose intracellular trafficking is regulated by GGA proteins.
4.2.2 Rab proteins
Rabs are a ubiquitously expressed family of small Ras-like GTPases [240]. There are
more than 60 members in mammalian cells and 11 members in yeast [256]. Most of Rab
proteins contain a C-terminal prenylation motif, a hypervariable domain and two switch regions
[257]. The C-terminal prenylation motif is important for membrane insertion [258]. Pfeffer et
al. found that modification of the two cysteines to a single cysteines on Rab5a and Rab27a led to
improper insertion of those into the ER and Golgi instead of into early endosomes and
melanosomes, respectively [259]. The hypervariable domain is a flexible domain that changes
conformation upon the exchange of GDP and GTP bound forms [257]. The hypervariable
domain is thought to contain the targeting signal for Rab protein [260]. However, a recent study
found that replacing the hypervariable domain of Rab5a with that of Rab1a, Rab2a, Rab7 and
Rab27a had no effect on its function and localization on early endosome [261].
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Rab GTPase cycles between their GTP-bound and GDP-bound states. Like Arf proteins,
this switch is regulated by GEF and GAPs [262]. Rab proteins also recycle between membrane
bound and cytosolic forms, which is coupled to their nucleotide load. Membrane insertion
requires the modification of two carboxyl-terminal cysteines with isoprenyl lipid moieties [258].
Ras-GDP binds to the GDP dissociation inhibitor (GDI), masking the isoprenyl anchor and thus
maintains the Ras-GDP localization in the cytosol [258]. Once dissociation from the GDI by
GDI displacement factor (GDF) [263], Rab proteins can exchange GDP to GTP form under the
control of GEF [258]. The active Rab-GTP is able to insert into the target membrane.
Rab effectors are important to help establishment of the membrane domain marked by
specific Rab proteins. For example, mannose 6-phosphate receptors (MPRs) are involved in
sorting during vesicle formation and Rab9 on the late endosome is required for the recycling of
MPRs [264]. Early endosome antigen 1 (EEA1) and Rabaptin5 bind to Rab5 in endosome-
endosome fusion [265].
Rabs are versatile catalysts. They participate in receptor cargo collection; enabling motor
proteins to interact with membranes and interact with effectors to mediate the accurate docking
and fusion of transport vesicles with their targets [266]. Rab proteins are involved in the
endocytic and exocytic pathway by recruiting sets of effectors to distinct regions [257]. These
effectors mediate endosomal functions including endosome membrane fusion, packaging of
cargo into vesicles [266]. Rab proteins localize to specific intracellular compartments consistent
with their function in distinct vesicular transport process. Rab1 localizes in the intermediate
compartment of the cis-Glogi network and regulate ER to Golgi transport [267]. Rab4 and Rab5
are involved in the early endosome and regulate clathrin-coated-vesicle-mediated transport
[268]. Rab11 is in the recycling endosome and mediates the recycling of membrane proteins to
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the plasma membrane [268]. Rab 9 and Rab7 are segregated in late endosomes [266, 269].
Distinct intracellular localization and functions in intracellular trafficking have been established
for other Rab members.
4.3 Constitutively vs regulated secretory pathway in adipocytes
It is known that adipocytes secrete over 300 proteins that affect numerous cell biological
and metabolic pathways. However, little is known about which pathways are used to transport
these proteins outside of the cell. Adipocytes have two transport pathways: constitutively and
regulated secretory pathways [270]. To compare these two pathways, I will summarize the
intracellular trafficking of GLUT4 as an example of the regulated secretory pathway and the
intracellular trafficking of leptin as an example of the constitutive secretory pathway.
4.3.1 Regulated secretory pathway in adipocytes: intracellular trafficking of GLUT4
GLUT4 continuously recycles between the plasma membrane and intracellularstorage
compartment [48]. GLUT4 is found in many organelles, including the plasma membrane,
sorting endosomes, recycling endosomes, the TGN and small vesicles that mediate the transport
of GLUT4 between these compartments [48]. At basal state, almost no GLUT4 stays on the
plasma membrane. However, within 15 minutes after insulin stimulation, about 95% of GLUT4
is transported to the plasma membrane [69, 271, 272]. How insulin affects GLUT4 exocytosis is
still not clear.
Colocalization study by confocal micrscopy showed 40% to 50% of GLUT4 was
colocalized with a transferrin receptor (TfnR)-positive endosomal compartment, while 50 to 60%
is in a second, TfnR-negative compartment [273]. Endosomal ablation showed that only 30-40
% of the GLUT4 was in the endosomes under basal conditions [274]. It is GLUT4 in the TfnR-
negative compartment that is rapidly mobilized after insulin stimulation [43]. The insulin-
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responsive aminopeptidase (IRAP), identified as a receptor for angiotension IV [275], was
shown to be colocalized with GLUT4 and transported to the plasma membrane upon insulin
stimulation in parallel with GLUT4 [276]. In fibroblasts, most GLUT4 and IRAP are
colocalized with TfR in endosomes [277] away from the insulin-regulatable storage
compartment, which explains why the insulin-mediated redistribution of Glut4 effect is
relatively small in these cells.
Other GLUT4 pools responsive to insulin stimulation are TGN-originating small vesicles.
Recent evidence indicates that GLUT4 recycles between the TGN and endosomes [278].
GLUT4 localized to adaptor-protein-1 (AP-1) positive, clathrin-coated, vesicles around the TGN
in adipocytes [279]. These vesicles also contained syntaxin 6 and syntaxin 16 [48], which
confirms that they bud off from the TGN.
A more insulin responsive GLUT4 storage compartment, GLUT4 storage vesicles
(GSVs), has been identified, as the TGN pool and the endosomal pool of GLUT4 is less insulin-
sensitive. These vesicles are relatively small (around 50 nm) and do not contain TfR [48],
however, they contain IRAP [53] and the v-SNARE, vesicle-associated membrane protein
(VAMP2), which forms a complex with t-SNAREs on the plasma membranes in muscle and
adipocytes [280]. GGAs, found in the GSVs, plays a role in the sorting of GLUT4 from the
TGN to the GSVs [127]. It is also suggested that GGAs binds to the ubiquitinated cargos and
regulate the degradation of IRAP and GLUT4 [281].
A comprehensive model of GLUT4 transportation can be divided into six steps. The
biogenesis of GSVs [282], transport of GSVs along microtubules and corticle actin [141],
tethering [283], docking [280] and fusion with the plasma membrane [284], and endocytosis.
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The insulin signaling pathways that lead to the translocation of GLUT4 has been
identified as the PI3K pathway [285]. Activation of PI3K occurs through PI3K-dependent
kinase and its downstream target Akt/PKB, which has been reviewed earlier. Recently, a Rab
GTPase activating protein (RabGAP), Akt-substrate of 160 kDa (AS160) has been identified to
function during insulin-stimulated GLUT4 translocation. AS160, as a RabGAP, may regulate the
Rab activity that occurs in the GLUT4 transport [286]. The unstimulated AS160 maintains a
RabGDP form that prevents GLUT4 translocation [286]. Akt phosphorylates AS160 at four
separate sites. Activated As160 catalyses 14-3-3 binding and facilitates the activation of Rab
proteins [287]. Recently, Rab 2A, Rab 11, Rab 14 and Rab 10 have been identified in the
insulin-stimulated GSVs mobilization [288]. Despite the intense study of GLUT4 intracellular
transport, our understanding of the regulation of this pathway, especially by macrophages,
remains incomplete.
4.3.2 The continuous secretory pathway in adipocytes: intracellular trafficking of leptin
Insulin stimulates leptin secretion. A two-hour incubation of rat adipocytes with insulin
did not affect the transcription of leptin, but the secretion of leptin increased two fold [134].
Dexamethasone, however, stimulated both ob gene transcription and leptin secretion by 2-4 fold
in the same cells within 2-hour after insulin stimulation [134]. Treatment of adipocytes with the
PI3K inhibitor LY294002 and MAPK kinase inhibitor PD98059 for two hours showed no effect
on ob gene transcription or the basal secretion of leptin. However, leptin secretion stimulated by
both insulin and dexamethathone was significantly decreased [134]. These data suggested that
insulin stimulated leptin secretion is regulated through both PI3K and MAPK pathways.
To analyse the leptin pool, Bradley et al did subcellular fractionation on rat adipocytes.
They identified two internal membrane factions, the low density microsomes (LDM) and the
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high density microsomes (HDM). ER-specific proteins, translocon-associated protein-(TRAP-
and calnexin localized in the HDM and leptin primarily associated with the HDM [289].
Consistent with these data, Roh et al., identified the major leptin-containing membrane
compartment as an ER- rich compartment in rat adipocytes using sucrose gradient centrifugation
and confocal microscopy techniques [290].
Barr et al. reported insulin stimulated leptin exocytosis from an ER-rich compartment
without any observable accumulation in secretory vesicles [289]. As leptin is not glycosylated, it
is rapidly transport to the Golgi once synthesized in the ER [289]. The absence of leptin in the
Golgi-rich LDM also confirmed this point. However, an intact Golgi is also required for the
secretion of leptin. Bradley et al. showed that brefeldin A treatment inhibited secretion of leptin
in both basal and insulin-stimulated conditions [289]. A temperature of 20 oC is able to recruit
proteins that exit from ER into the Golgi compartment. Incubation of rat adipocytes at 20 oC for
1.5 hours induced a redistribution of leptin from the ER-rich HDM to Golgi-rich LDM [134].
These data suggest that leptin is transported through the Golgi apparatus and trans-Golgi
network.
The hypothesis that leptin secretion is primarily through a constitutive secretory pathway
is widely accepted by most of the researchers. However, the specific mechanisms regulating the
insulin-stimulated leptin secretion are poorly understood. Chapter 3 of my dissertation sheds
light into the mechanism regulating adiponectin and leptin trafficking in adipocytes.
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CHAPTER 2
INTRACELLULAR TRAFFICKING AND SECRETION OF
ADIPONECTIN IS DEPENDENT ON GGA-COATED VESICLES
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ABSTRACT
Adiponectin (Acrp30) is an insulin-sensitizing hormone produced and secreted
exclusively by adipose tissue. Confocal fluorescent microscopy demonstrated the colocalization
of adiponectin with the Golgi membrane markers p115, -COP, and the trans-Golgi network
marker, syntaxin 6. Treatment of cells with brefeldin A redistributed adiponectin to the
endoplasmic reticulum where it colocalized with the chaperone protein BIP and inhibited
secretion of adiponectin demonstrating a requirement for a functional Golgi apparatus for
adiponectin release. Confocal fluorescent microscopy also demonstrated a colocalization of
endogenous adiponectin with that of expressed GGA1myc (Golgi-localizing -adaptin ear
homology ARF-binding protein) but with no significant overlap between adiponectin and the
GGA2myc or GGA3myc isoforms. Consistent with confocal fluorescent microscopy,
transmission electron microscopy demonstrated the colocalization of GGA1 with adiponectin.
Although GGA1 did not directly interact with the adiponectin protein, the adiponectin enriched
membrane compartments of adipocyte were precipitated by aGST-GGA1cargo binding domain
(VHS) fusion protein but not with a GST-GGA2 VHS or GST-GGA3 VHS fusion proteins.
Moreover, co-expression of adiponectin with a GGA1 dominant-interfering mutant (GGA1-VHS
GAT domain) resulted in a marked inhibition of adiponectin secretion in both 3T3L1 adipocytes
and HEK293 cells, whereas no inhibition was detected with the truncated mutants GGA2-
VHSGAT or GGA3-VHSGAT. Moreover, co-expression of wild type GGA1 with adiponectin
enhanced secretion of adiponectin. Interestingly, leptin secretion was unaffected by neither the
wild type form or GGA1 mutant. Taken together these data demonstrate that the trafficking of
adiponectin through its secretory pathway is dependent on GGAcoated vesicles.
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INTRODUCTION
Over the past several years many studies have documented that in addition to being a fat
storage depot, adipocytes are a bona fide endocrine tissue that secrete several hormones that
control insulin sensitivity and energy balance [90, 270, 291]. In particular, adiponectin, also
called adipocyte complement-related protein of 30 kDa (Acrp30), adipoQ, GBP28, and apM1,
was originally isolated as a highly induced gene following adipocyte differentiation [292]. This
hormone is secreted exclusively by adipocytes [292-295] and functions in vivo as an insulin
sensitizer [111, 114, 296], reducing glucose production by the liver [112] and enhancing fatty
acid oxidation in skeletal muscle [114] through the activation of two distinct receptor isoforms
[117]. These receptors mediate increased AMP-dependent kinase activation [121, 297, 298] and
peroxisome proliferating activated receptor-ligand activity [93].
Adiponectin serum levels inversely correlate with insulin resistance in both in animals
and humans [299-303] in contrast to that observed for other adipokines such as tumor necrosis
factor-and resistin [222, 304-306]. Type 2 diabetic patients also display reduced levels of
adiponectin [307-310]. Moreover, injection of purified adiponectin decreases glucose levels in
ob/ob, non-obese diabetic, or streptozotocin-induced diabetic mice [91].
Adiponectin is initially synthesized as pre-hormone with a classical signal sequence that
is cotranslationally removed as the protein translocates into the lumen of the endoplasmic
reticulum [311]. The secreted protein consists of an amino-terminal collagen domain that shares
significant homology to collagen VIII and X [4, 6], a carboxylterminal globular domain that is
homologous to the complement factor C1q [92], and the hibernation-regulated serum proteins,
hib20, hib25, and hib27 [293]. The three-dimensional structure determined by x-ray analysis also
revealed that adiponectin shares significant homology to tumor necrosis factor-, another
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adipocyte-secreted hormone that is implicated in the induction of insulin resistance [92].
However, in serum adiponectin circulates as two forms, a lower molecular weight trimer-dimer
and a higher oligomeric molecular weight complex. Recent studies have demonstrated that
disulfide bond formation through Cys-39 is essential for the assembly of the higher oligomeric
complexes [95].
The GGA2 proteins (for Golgi localizing _ adaptin ear homology domain ARF-binding
protein) are a family of ubiquitously expressed monomeric clathrin adaptors that mediate sorting
at the trans-Golgi network (TGN) of specific cargo in an Arf-dependent manner. There are three
different isoforms ofGGAproteins termed GGA1, GGA2, and GGA3. These proteins have a
modular structure consisting of an NH2-terminal VHS (Vps27, Hrs, STAM) domain, and Arf-
binding GAT (GGA and TOM1) domain, a clathrin binding hinge region, and a COOH-terminal
-adaptin “ear”(GAE) domain. The VHS domain binds acidic cluster-dileucine sorting signals
present in the cytosolic domain of transmembrane vesicle proteins [312, 313]such as the
mannose 6-phosphate receptor [254], sortilin [314], and -secretase [315]. The GAT domain
binds to activated ADP-ribosylating factors [316-319], whereasthe hinge region recruits clathrin
[316]. The GAE region has been shown to interact with accessory proteins including rabaptin-5
[320, 321], enthoprotin [322],-synergin [323], and with ubiquitin [324].
In the present study, we demonstrate that adiponectin in the steady state is predominantly
localized in a peri-nuclear compartment indistinguishable from the Golgi apparatus/TGN.
Consistent with the morphological observations, secretion of adiponectin is severely inhibited by
treatment of cells with brefeldin A (BFA). Furthermore a dominantinterfering mutant of the
GGA1protein (GGA1VHSGATdomain) was able to block both traffic of the GLUT4 glucose
transporter to its insulin-sensitive intracellular compartment and secretion of adiponectin but did
46
not affect leptin secretion. In addition, confocal and transmission electron microscopy studies
showed colocalization of adiponectin with the GGA1 isoform. These data suggest that
adiponectin (but not leptin) secretion is dependent on GGA proteins and suggest that GGA
adaptors participate in the regulation of selective adipokine trafficking in adipocytes.
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EXPERIMENTAL PROCEDURES
Materials
Brefeldin A and cycloheximide were obtained from Sigma. Brefeldin A was prepared as
a 5 mg/ml stock in methanol and used at a final concentration of g/ml. Cycloheximide was
prepared as a 10 mg/ml stock and used at a final concentration of 10 g/ml. Adiponectin
antibody was obtained as described previously (5). Antibodies for syntaxin 6, p115, and BIP
were from BD Biosciences. Antibody for vesicular stomatitis virus-G (VSV-G) protein was
obtained from Acurate Biochemicals. Anti-myc and anti-GGA1 antibodies were from Santa Cruz
Biotechnology. Biotin-conjugated anti-myc antibody was from Sigma. Antibody anti-GFP was
from Roche Applied Science, Dulbecco’s modified Eagle’ s medium (DMEM), Opti-MEM I,
fetal bovine serum, calf serum, and trypsin were from Invitrogen. Lipofectamine 2000 was
obtained from invitrogen. Radioimmunoassay kit for adiponectin was obtained from Linco
Research (St. Charles, MO). ELISA kits for adiponectin and leptin were purchased from R&D
Systems. The GGA1, GGA2, and GGA3 wild type constructs and eGFP-VHS-GAT domain
were obtained from Dr. J. Bonifacino (National Institutes of Health). A plasmid encoding for the
VSV-G protein wild type protein was a gift from Dr. M. McNiven (Mayo Clinic and Graduate
School, Rochester, MN).
Generation of DNA Constructs
The GST-GGA1 VHS-GAT, GSTGGA2 VHS-GAT, and GST-GGA3 VHS-GAT
constructs were generated by PCR amplification of the VHS-GAT domains of the wild type
forms of GGA1–3, followed by ligation into the GST-expressing vector pGEX4T (Amersham
Biosciences).
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Cell Culture and Transient Transfection
3T3L1 cells were obtained from the American Type Tissue Culture repository. Cells
were cultured in DMEM supplemented with 25 mM glucose, 10% calf serum at 37 oC with 8%
CO2. The cells were differentiated into adipocytes with 1 g/ml insulin, 1 M dexamethasone,
and 0.5 mM isobutyl-1-methylxanthine as described previously [325]. Differentiated adipocytes
were electroporated at 950 microfarads and 0.15 V, using a Gene Pulse II electroporator from
Bio-Rad. Following electroporation cells were plated on collagen IV-treated coverslips and
allowed to recover in DMEM supplemented with 10% Serum. HEK293 cells were cultured in
minimal essentialmedium containing 10% of FBS and penicillin/streptomycin at 37 oC with 5%
CO2. Cells were plated in 24-well plates and transfected using Lipofectamine 2000 (Invitrogen)
folowing the manufacturer’s instructions.
Immunofluorescence and Image Analysis
Transfected and intact adipocytes were washed in phosphate buffered saline (PBS) and
treated for 15 min with a solution containing 4% paraformaldehyde, 0.2% Triton X-100, and
0.4% bovine serum albumin (BSA). Cells were then incubated in blocking buffer containing 5%
donkey serum (Sigma) and 1% BSA for 1 h at room temperature. Primary and secondary
antibodies, as indicated in the figure legends to Figs. 1, 2, 4, and 7, were used at 1:100 dilutions
in blocking buffer. The cells were washed three times with PBS and mounted on glass slides
with Vectashield (Vector Laboratories) and were imaged using a Zeiss LSM 510 META
confocal microscope. Images were then imported to Adobe Photoshop (Adobe Systems, Inc.) for
processing.
Temperature Block
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After electroporation 3T3L1 adipocytes were placed overnight inDMEM containing 10%
fetal bovine serum at either 16 or 19oC. Following an overnight incubation cells were fixed and
permeabilized as indicated above and processed for immunofluorescence.
Pull-down Assay and Western Blot Analysis
For the pull-down assay, whole cell extracts were prepared in HES buffer: 30 mM Hepes,
pH 7.4, 1 mM EDTA, 250 mM sucrose) supplemented with 1 mM phenylmethylsulfonyl
fluoride, 10 g/ml aprotinin, 1 g/ml leupeptin, and 1 g/ml pepstatin. Cells were then
homogenized in a Dounce homogenizer (five times) and lysates centrifuged to 37,000 rpm for 10
min at 4 °C. Equal volumes of the supernatant were taken (1 mg of protein) and incubated with
glutathione beads (GST or GST-GGA1VHS GAT) for 2 h at 4oC. Samples were centrifuged
briefly (13,000 rpm for 1 min), and the beads were washed three times with PBS. Pelleted
samples were eluted in 2 X loading sample buffer. Samples were boiled for 5 min and loaded
onto a SDS-PAGE. Samples transferred to a nitrocellulose membrane and immunobloted with an
antibody specific for adiponectin.
Radioimmunoassays and ELISA
Fully differentiated cells were trypsinized for 10 min and replated at equal densities into
12 well multidishes and were allowed to recover overnight in DMEM containing 10% FBS.
Following an overnight incubation the medium was changed to DMEM without serum
supplementation, and at different time intervals an aliquot of medium was collected for
radioimmunoassay following the manufacturer ’ s instructions (Linco Research). Similarly,
ELISA assays were performed on aliquots of medium taken 24-30 h following transfection. Prior
to radioimmunoassay/ELISA floating cells were removed by centrifugation at 500 g for 5 min
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and the supernatant used for the radioimmunoassay/ELISA quantification. In parallel an aliquot
of the whole cell lysate was also quantified.
Transmission Electron Microscopy
HEK293 cells were collected by trypsinization (5 min) followed by inactivation of
trypsin with 10% FBS medium. Cells were then centrifuged and washed twice with PBS.
Pelleted cells were fixed in 2% parafolmaldehyde, 0.2% glutaraldehyde for 24 h at 4oC. Cells
were dehydrated in ascending alcohol series (50-100%) 15 min each and infiltrated in LR White
resin overnight. Samples were then cured at 50oC for 48 h, sectioned, and mounted on nickel
grids. Following aldehyde quenching with 50 mM glycine, for 30 min, samples were incubated
in a blocking solution containing 5% donkey serum and 1% BSA for 1 h at room temperature.
Immunolabeling with specific primary antibodies at 1:100 was done overnight at 4oC. Samples
were washed three times with PBS and secondary antibodies (goat anti-rabbit IgG 25-nm gold
and goat anti-mouse IgG 10-nm gold) were added at 1:50 for 2 h at room temperature. Samples
were washed in PBS and water and visualized in a FEI CM100 microscope.
Statistical Analysis
One-way ANOVA was performed using SAS statistical software.
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RESULTS
Intracellular Localization of Adiponectin in 3T3L1 Adipocytes
To characterize the intracellular localization of adiponectin, we examined the distribution
of adiponectin with several intracellular markers. The endogenous adiponectin protein (Figure 2,
a, d, and g) was primarily localized in the peri-nuclear compartment as well as some scattered
vesicle staining throughout the cytoplasm. The peri-nuclear distribution overlapped with Golgi
markers p115 (Figure 2, a-c), syntaxin 5 (Figure 2, d-f), and -COP (data not shown) and the
TGN marker syntaxin 6 (Figure 2, g-i).
We further confirmed the Golgi localization of adiponectin by using reduced temperature
to block secretory protein trafficking. VSV-G protein is a membrane protein in the constitutive
secretory pathway that accumulates in the endoplasmic reticulum at 16oC and in the Golgi
complex at 19oC [326]. Incubation of cells at 16oC immediately following transfection resulted
in a diffuse intracellular labeling of VSV-G protein, consistent with the endoplasmic reticulum
distribution in these cells (Figure 3A, panel a). At 19oC, VSV-G protein displayed a predominant
peri-nuclear distribution consistent with Golgi localization (Figure 3, panel b). To ensure that the
temperature block did not damage the cells and thereby resulted in an aberrant accumulation in
the Golgi, following incubation at 19oC the cells were shifted to 37oC for 1 h (Figure 3A, panel
c). Under these conditions, the VSV-G protein was fully capable of exiting the Golgi and traffic
to the plasma membrane. In parallel, at 19oC, VSV-G protein colocalized with endogenous
adiponectin (Figure 3B, panels d-f).
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FIGURE 2. Localization of endogenous adiponectin in the Golgi/TGN. Fully
differentiated adipocytes were fixed, permeabilized, and immunostained with a specific
polyclonal antibody specific for adiponectin (panels a, d, and g) or with the cis-Golgi markers
p115 (panel b) and syntaxin 5 (panel e), or with the trans-Golgi network marker syntaxin 6
(panel h). The merged images are shown in the right panels. The yellow color in the merged
images (panels c, f, and i) indicates colocalization. Images were obtained using a Zeiss 510
META confocal microscope.
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FIGURE 3. Adiponectin colocalizes with the vesicular stomatitis virus G protein. A,
temperature block of the VSV-G protein. Fully differentiated adipocytes were lectroporated with a
construct coding for the vesicular stomatitis virus protein. After electroporation cells were incubated
overnight at 16°C (panel a), overnight at 19°C (panel b), or incubated overnight at 19°C and then placed
at 37°C for 1 h prior to analysis (panel c). Following these incubations cells were fixed permeabilized,
and immunostained with an antibody specific for VSV-G protein obtained from Acurate Biochemicals,
Inc., as described under “Experimental Procedures.” Images were obtained using a Zeiss 510 META 
confocal microscope. B, colocalization of endogenous adiponectin and VSV-G protein. Fully
differentiated adipocytes were electroporated with a construct coding for the vesicular stomatitis virus G
protein. After electroporation cells were incubated overnight at 19°C. The next day, cells were fixed,
permeabilized, and immunostained with an antibody specific for VSV-G protein (panel d) or with an
antibody specific for adiponectin (panel e) as described under “Experimental Procedures.” Panel d shows
GFP VSV-G protein. The yellow color in the merged image (panel f) indicates colocalization. Images
were obtained using a Zeiss 510 META confocal microscope. IF, immunofluorescence.
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BFA is a fungal metabolite that inhibits guanylnucleotide exchange factors that act on
class I Arf GTP-binding proteins [327]. This inhibition results in a block of anterograde Golgi
trafficking and thereby causes the collapse of the Golgi stacks back into the endoplasmic
reticulum [328, 329]. We next determined the effect of BFA on adiponectin secretion by
radioimmunoassay (Figure 3A). In control cells, there was a constitutive secretion of adiponectin
into the medium that was relatively linear over the time course examined (Figure 4A). Treatment
with BFA completely blocked the release of adiponectin, whereas the protein synthesis inhibitor,
cycloheximide, had no effect (Figure 4A). Identical results were obtained when the incubation
medium was assayed by immunoblotting (Data not shown). Furthermore, cycloheximide
treatment for 2 h did not alter the distribution of intracellular endogenous adiponectin in 3T3L1
adipocytes, which remained associated with the Golgi markers (Figure 4B). As a control for
cycloheximide action, HEK293 cells were transfected with a vector coding for a green
fluorescent protein. Immediately following transfection a subset of cells were treated with
cycloheximide. Imaging of these cells revealed no reporter gene expression in the cells treated
with the drug (Figure 4C).
Adiponectin Colocalizalizes with GGA Isoforms
Since adiponectin was localized in the Golgi/TGN region at steady state in 3T3L1
adipocytes we postulated that adaptor proteins at the TGN could regulate adiponectin secretion
in adipocytes. GGA proteins are molecular adaptors that mediate sorting at the TGN of specific
cargo vesicles and recruit clathrin in an Arf-dependent manner. Recent reports have documented
that GGA adaptors facilitate transport of the glucose transporter GLUT4 to the insulin-sensitive
compartment in adipocytes (53, 54). To investigate whether GGA coat adaptors are involved in
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FIGURE 4. Secretion of adiponectin is inhibited by brefeldin A but not by cycloheximide. A,
time course of adiponectin secretion. Fully differentiated adipocytes were replated in 12-well dishes with
the same cell density and allowed to recover in DMEM with 10% FBS. 24 h later, medium was changed
to DMEM without serum, in the absence of drug (No treatment), in the presence of 5 _g/ml brefeldin A,
(+Brefeldin A), or in the presence of 10 g/ml cycloheximide (+Cycloheximide). A small aliquot of
medium was taken at the indicated times, spun for 5 min at 3000 rpm, and the supernatant collected to
determine the amount of adiponectin by radioimmunoassay (RIA). B, Golgi preparation of 3T3L1
adipocytes. Differentiated adipocytes were left untreated or treated with 10g/ml cycloheximide (CHX)
for 2h at 37 °C. Following this time, cells were fractionated and the Golgi membranes purified as
described under “Experimental Procedures.” Equal amounts ofthe total lysate or the purified Golgi
fraction were loaded onto a SDS-PAGE and immunobloted with the indicated specific antibodies. A
representative blot of three independent experiments is shown. H, homogenate. C, cycloheximide inhibits
the expression of the green fluorescent reporter gene ARF-1 GFP. HEK293 cells were transfected with a
construct coding for a GFP-tagged ARF-1 protein. Immediately after transfection cycloheximide (+CHX)
was added to group of cells, whereas a group of cells were left untreated (+CHX). Following the treatment
with the drug, images of cells were taken on a NIKON TE2000 microscope on a fluorescein
isothiocyanate (FITC) or brightfield setting.
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adiponectin secretion, we first examined the colocalization of the GGA isoforms with
endogenous adiponectin by confocal microscopy imaging. This was performed in adipocytes that
expressed the wild type forms of GGA1myc, GGA2myc, or GGA3myc. Double staining was
performed as indicated under“Experimental Procedures”using a myc antibody and an antibody
specific for adiponectin (Figure 5, A-C). As shown in Figure 5A, panel b, expressed GGA1myc
displayed a perinuclear localization that substantially overlapped with that of endogenous
adiponectin (Figure 5A, panel c). Similar distributions were observed for GGA2myc (Figure 5B,
panel b) and GGA3myc (Figure 5C, panel c) isoforms. Interestingly, insulin treatment of the
cells for 30 min had no significant effect on the distribution of neither adiponectin nor the
expressed GGA isoforms (Figure 5A, panel f and Figure5B, panel f). Overall, these results
demonstrate that GGA proteins broadly colocalized with endogenous adiponectin and suggest
that GGA adaptors may be involved in the trafficking of adiponectin from Golgi/TGN
compartments.
To further confirm these studies, we next examined the localization of endogenous
adiponectin and endogenous GGA1 in isolated mouse adipocytes and the localization of
expressed adiponectin and GGA1-VHS-eGFP in HEK293 cells by transmission electron
microscopy (Figure6). In isolated fat tissue, immunogold labeling of adiponectin (10-nm gold)
and GGA1 (25-nm gold) indicated that these proteins were in close proximity (Figure 6, A and
B). Similar results were obtained in HEK293 cells expressing adiponectin (25-nm gold particles)
and GGA1-VHS (10-nm gold particles), where both proteins were primarily confined to the
perinuclear region (Figure 6, C and D). Although we were unable to preserve a high degree of
membrane morphology, higher magnification clearly demonstrated that the GGA1 positive gold
particles were colocalized with the adiponectin-positive gold particles (Figure 6, B and D).
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FIGURE 5. Colocalization of GGA proteins and endogenous adiponectin
inadipocytes. Fully differentiated adipocytes were electroporated with a construct coding for the
wild type form of GGA1 myc (A), GGA2myc (B), or GGA3myc (C). Following an overnight
incubation to allow for protein expression, cells were fixed, permeabilized, and stained as
indicated under “Experimental Procedures” with an antibody specific for adiponectin (panels a
and d) and an antibody for myc (panels b and c). When indicated a subset of cells was treated
with 100 nM insulin for 30 min prior to fixation. Confocal imaging was performed in a Zeiss 510
META confocal microscope. The yellow color in the merged images (panels c and f) indicates
colocalization. Shown are representative cells of three independent experiments.
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FIGURE 6. Colocalization of GGA proteins and adiponectin. A and B, isolated mice
adipocytes were fixed and processed for electron microscopy as indicated under “Experimental 
Procedures.” Immunolabeling was performed with an antibody against adiponectin and antibody against 
GGA1 (Santa Cruz Biotechnology). Secondary antibodies were: goat anti rabbit IgG 10-nm gold for
adiponectin and donkey anti-goat IgG 25-nm gold for GGA1. Samples were visualized in a FEI CM100
transmission electron microscope. The arrows indicate colocalization of the two proteins. C and D,
HEK293 cells were cultured and cotransfected with a vector expressing adiponectin-myc and either the
GGA1 VHS-GFP. 24 h following transfection cells were processed for transmission electron microscopy
as described under “Experimental Procedures.” Immunolabeling was performed with an antibody against
adiponectin and antibody against GFP (Roche Applied Science). Secondary antibodies were: goat anti
rabbit IgG 25-nm gold for adiponectin and goat anti-mouse IgG 10-nm gold for GFP. Samples were
visualized in a FEI CM100 transmission electron microscope. The arrows indicate colocalization of the
two proteins.
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Unfortunately, the lack of suitable GGA2- and GGA3-specific antibodies prevented us
from examining the colocalization of these proteins with endogenous adiponectin in electron
microscopy studies. To further characterize the interaction between adiponectin-containing
vesicles and the different GGA isoforms, we designed biochemical and functional assays, which
are detailed below.
To investigate whether recombinant GGA proteins could bind to adiponectin-containing
vesicles in vitro, we next generated constructs expressing the cargo binding domain (VHS) and
Arf binding domain (GAT) of either GGA1, GGA2, orGGA3proteins fused in frame to GST
(GST-GGA1VHSGAT, GST-GGA2VHSGAT, or GST-GGA3VHSGAT) and performed in vitro
pull down assays. Adiponectin vesicles from adipocyte lysates could be effectively precipitated
with recombinant GST GGA1-VHSGAT immobilized to glutathione-Sepharose beads (Figure
6A, lane 2, but not with GST alone (Figure 7A, lane 1). This was specific for the GGA1 VHS-
GAT domain as neither the GGA2 nor GGA3 VHS-GAT domains were capable of precipitating
adiponectincontaining compartments (Figure 7A, lanes 3 and 4). Precipitation of adiponectin by
recombinant GST-GGA1VHSGAT occurred in the absence of detergent (Figure 7B, lane 2), but
there was no precipitation of adiponectin in the presence of detergent (Figure 7B, lane 4).
Although the amount of adiponectin precipitated by GST GGA1-VHS was relatively small
compared with the total amount of adiponectin present (Figure 7, A and B, lane 2), these data
demonstrated that GGA1 could interact with adiponectin-containing compartments but not
directly with adiponectin itself.
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FIGURE 7. Recombinant GGA1, but not GGA2 or GGA3, binds to adiponectin-
containing vesicles. A, a GST alone or a GST fusion protein with the VHS-GAT domain of
either GGA1, GGA2, or GGA3 was produced in bacteria, purified, and bound to glutathione
beads as indicated under “Experimental Procedures.” Whole cel lysates obtained from fully
differentiated 3T3L1 adipocytes were incubated with either the GST or GSTGGA1/2/3-VHS-
GAT fusion proteins for 2 h at 4°C. Following this incubation the bound material (pellets) and
the non-bound material (SN) were separated by brief centrifugation, the pellets washed, and the
samples loaded onto an SDS-PAGE for immunoblotting with a specific antibody against
adiponectin. A representative blot of five independent experiments is shown. B, whole cell
lysates obtained from fully differentiated 3T3L1 adipocytes were incubated with either GST or
GST-GGA1VHS-GAT fusion protein for 2 h at 4°C in the absence of detergent (lanes 1 and 2)
or in the presence of 1% Triton X-100 (lanes 3 and 4). Following this incubation the bound
material (pellets) and the non-bound material (SN) were separated by brief centrifugation, the
pellets washed, and the samples loaded onto an SDS-PAGE for immunoblotting with a specific
antibody against adiponectin. A representative blot of three independent experiments is shown.
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FIGURE 8. A, the VHS domain of GGA1 act as a dominant negative inhibiting Glut4
translocation in response to insulin. Fully differentiated adipocytes were co-electroporated with a
construct coding for the myc tag Glut4 glucose transporter and the empty vector pcDNA3.1
(panels a and f) or the vector coding for the glucose transporter Glut4myc and a construct
expressing the VHS and GAT domains of GGA1 fused to eGFP (panels b, c, g, and h) or the
vector encoding for the glucose transporter glut4 fused to eGFP (Glut4eGFP) and a construct
coding for the wild type form of GGA1 (GGA1myc) (panels d, e, i, and j). Following
electroporation cells were allowed to recover for 24 h and incubated in DMEM without serum or
for 2 h at 37 °C. A subset of cells was then stimulated with 100 nM insulin for 30 min at 37 °C.
Following these incubations cells were fixed, permeabilized, and immunostained with an
antibody specific against the myc epitope (panels a, b, e, f, g, and j). Images were obtained using
a Zeiss 510 confocal microscope. B, the VHS domain of GGA1 inhibits adiponectin secretion in
3T3L1 adipocytes. Differentiated 3T3L1 adipocytes were cultured and co-electroporated with a
vector expressing adiponectin-myc, a vector expressing adiponectin-myc and the wild
typeGGA1construct, or the adiponectin-myc vector and a construct coding for the corresponding
dominant-interfering mutant (VHS-GATdomains) of eachGGAprotein (GGA1-VHS, GGA2-
VHS, GGA3-VHS). 24–36 h following transfection medium and whole cell lysates were
obtained, and an aliquot was quantified by ELISA as described under “Experimental 
Procedures.” C, the VHS domain of GGA1 inhibits adiponectin secretion but not leptin secretion
in 293 cells. 293 cells were cotransfected with a vector expressing adiponectin-myc and either an
empty vector, a irrelevant protein (the glucose transporter GLUT1), a construct coding for GGA1
wild type (GGA1 WT), or a vector coding vector for the corresponding dominant-interfering
mutant (VHS-GAT domains) of each GGA protein (GGA1-VHS, GGA2-VHS, GGA3-VHS).
An independent set of cells was transfected with a construct expressing full-length of leptin and
either an empty vector or a construct coding for GGA1 wild type or the dominant-interfering
mutant of GGA1 mutant, which contains only the VHS-GAT domain. 24–36 h following
transfection medium and whole cell lysates were obtained and an aliquot quantified by ELISA as
described under “ExperimentalProcedures.” Secreted adiponectin (expressed as percent of total 
adiponectin expressed) ± S.E. is represented from three independent experiments. Expression of
GGA proteins was confirmed by Western blot analysis (data not shown). A one-way ANOVA
was utilized to determine significance. The adipokine_empty vector control was utilized as a
reference. Significance (asterisk) was considered if p<0.01. D, adiponectin-myc localizes to a
perinuclear compartment in 3T3L1 adipocytes. Adipocytes were transfected with a construct
coding for myc-tagged adiponectin (adiponectin-myc) and a construct coding for the GFP-
labeled ADP-ribosylating factor-1 protein (ARF-1 GFP). Cells were allowed to recover and the
next day were fixed, permeabilized, and immunostained with an antibody for anti-myc (panel a)
and a secondary antibody conjugated to Texas Red. Panel b shows ARF-1 GFP. Images were
obtained using a Zeiss 510 META confocal microscope.Panel c shows the merged image.
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A Dominant-interfering Mutant of GGA1 Blocks Adiponectin Secretion
We next investigated whether GGA proteins are involved in the cargo selection of
adiponectin-containing vesicles in 3T3L1 adipocytes. Expression of GLUT4 in adipocytes
resulted in the typical perinuclear localization of this protein and insulin-stimulated the
translocation of GLUT4 to the plasma membrane (Figure 8A, panels a and f). Co-expression of
the dominant-interfering GGA1 mutants (VHS domain) had no apparent effect on GLUT4
localization but markedly inhibited the insulin-stimulated translocation of the newly synthesized
GLUT4 protein (Figure 8A, panels b, c, g, and h). As a control, co-expression of the full-length
GGA1 protein had no significant effect on the basal or insulin-stimulated translocation of
GLUT4 (Figure 8A, panels d, e, i, and j). These data are consistent with previous data
demonstrating that the expression of a dominant-interferingGGA1mutant inhibits the insulin-
stimulated translocation of the newly synthesized GLUT4 protein [50].
To assess the functional effect of the GGA1 VHS domain on adiponectin secretion,
3T3L1 adipocytes (Figure 8B) or HEK293 cells (Figure 8C, open bars) were cotransfected with
a construct expressing a myc-tagged adiponectin protein and various control and GGA mutants.
The expressed adiponectin-myc protein displayed perinuclear localization (Figure 8D, panel a)
that overlapped with that of the Golgi localized GFPtagged ADP-ribosylating factor (ARF-1
GFP) (Figure 8D, panels b and c). Expression of the full-length GGA1 protein had no significant
effect on adiponectin-myc secretion in 3T3L1 adipocytes (Figure 8B), whereas a small
reproducible enhancement of adiponectin secretion was observed in HEK293 cells compared
with cells transfected with adiponectin alone or cells transfected with adiponectin and an
irrelevant protein, GLUT1 (Figure 8C). In contrast, expression of the GGA1VHSGAT domain
inhibited adiponectin secretion in both cell types. The inhibitory action of GGA1VHSGAT was
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specific, as the VHSGAT domains of GGA2 and GGA3 were without affect (Figure 8, B and C).
Moreover, the GGA1VHSGAT domain had no significant effect on the secretion of leptin
(Figure 8C, filled bars). Taken together, these data support a model in which adiponectin
secretion is specifically dependent upon GGA1 function.
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DISCUSSION
Adiponectin increases energy expenditure and decreases circulating glucose and fatty
acid levels without a reduction in food uptake [91, 111, 114, 297]. Based upon the central role
that adiponectin plays in the control of metabolism, energy homeostasis, and insulin sensitivity,
we elected to study the secretory membrane trafficking pathways that are responsible for the
release of this adipokine from adipocytes. Confocal microscopy studies in 3T3L1 adipocytes
showed that adiponectin was mostly distributed to the perinuclear region; with some punctuate
staining throughout the cytoplasm. The adiponectin perinuclear distribution stained positive for
markers of the Golgi/TGN, such as p115 and syntaxin 6, whereas no colocalization was detected
with endosomal markers or endoplasmic reticulum markers (data not shown). In addition,
temperature blocks at 19 oC showed colocalization of endogenous adiponectin with the VSV-G
protein, which at this temperature is trapped specifically in the TGN. Thus, our data support the
hypothesis that a substantial amount of adiponectin in the steady state is located in the
Golgi/TGN. Another study had previously reported that adiponectin containing transport vesicles
partially overlap with the endoplasmic reticulum marker GRP94 [330]. Although we do not
know the basis for these differences, consistent with adiponectin transport through the Golgi
complex, brefeldin A completely blocked adiponectin secretion, indicating that a functional
Golgi apparatus is required for adiponectin secretion.
It is well established that traffic through the Golgi requires the recruitment of coat
proteins on Golgi membranes, through a process regulated by members of the ADP-ribosylation
factors (Arf) family of small GTP-binding proteins (39, 42, 58). These factors recruit adaptor
molecules that in turn recruit clathrin to the nascent vesicles. To examine what other elements
are required for the trafficking of adiponectin containing vesicles, we examined the role of the
67
coat adaptor GGA proteins. Recently it has been reported that these proteins mediate the sorting
of GLUT4-containing vesicles into the insulin-responsive storage compartment in 3T3L1
adipocytes (53, 54).
To examine whether this interaction between GGA and adiponectin occurs in vivo, we
transfected fully differentiated adipocytes with GGA1myc, GGA2myc, or GGA3myc constructs
and analyzed by confocal microscopy whether endogenous adiponectin colocalized with these
GGA proteins. Our results showed that expressed GGA proteins exhibited a substantial degree of
colocalization with that of endogenous adiponectin in differentiated 3T3L1 cells. Transmission
electron microscopy studies also confirmed localization of GGA1 adaptor proteins with
adiponectin in mouse adipocytes.
Structural analysis of GGA proteins has showed differences in the VHS domains of
GGA1 and GGA2, with GGA2 having a more flexible and unwound6 helix end [331], and this
can contribute to the recognition of distinct cargo vesicles. While evidence exists that insulin
enhances secretion of adiponectin (5, 56), we did not observe any change in the degree of
colocalization between GGA and adiponectin following the treatment of cells with insulin. This
would suggest that the pool of adiponectin under investigation here is constitutively secreted.
Alternatively, insulin may act through a distal (post-TGN) target compartment. Further studies
are needed to determine the site of insulin action that results in enhanced adiponectin secretion in
adipocytes.
Nevertheless, using GGA precipitation assays, we observed an interaction of the GGA1
VHSGAT domain with adiponectin-containing transport compartments. This binding was
specific, since no separation was achieved using the GST portion only or GST fusions with the
other GGA isoforms. Importantly, GGA1 did not directly interact with the GGA1 protein but
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indirectly associated with the adiponectin-containing transport compartments. This is consistent
with the known topology of the GGA proteins (cytosolic) and adiponectin (intraluminal) and
further indicates that the adiponectin transport vesicles also contain a specific GGA1 target
protein necessary for appropriate cargo selection. At present, the identity of this protein is
unknown, and further work is needed to determine which additional proteins participate in the
GGAcoating of adiponectin vesicles.
In addition to the ability of GGA1 to associate with adiponectincontaining compartments,
expression of the dominant-interfering GGA1 mutant that contains the vesicle-binding domain
VHS-GAT inhibited adiponectin secretion. This again was specific for GGA1, as the same
domains in GGA2 and GGA3 were without affect. GGA1 function was also specific for
adiponectin secretion as another adipokine, leptin, was not affected by expression of the
dominant-interfering GGA1 mutant. Interestingly, we also found that expression of fulllength
wild type GGA1 protein enhanced adiponectin release in HEK293 cells but not in differentiated
3T3L1 adipocytes, which suggests that the amount of GGA1 protein in HEK293 cells may be
ratelimiting for adiponectin secretion in these cells.
In summary, our microscopy biochemical and functional data strongly suggest that
GGAcoat adaptors regulate selective cargo formation at the TGN of adipocytes. While
intracellular traffic and secretion of adiponectin are mediated by GGA1-coated vesicles, leptin
secretion is independent of GGA adaptors. Further studies will now be needed to determine
whether GGA-mediated adiponectin secretion is a direct plasma membrane secretory pathway,
independent of the recycling endosome system, and to identify other protein components that
participate in the generation of adiponectin-containing vesicles.
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CHAPTER 3
ADIPONECTIN AND LEPTIN ARE SECRETED THROUGH
DISTINCT TRAFFICKING PATHWAYS IN ADIPOCYTES.
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ABSTRACT
Adiponectin and leptin are two adipokines secreted by white adipose tissue that regulate
insulin sensitivity. Previously we reported that adiponectin but not leptin release depends on
GGA-coated vesicle formation, suggesting that leptin and adiponectin may follow different
secretory routes. Here we have examined the intracellular trafficking pathways that lead to the
secretion of these two hormones. While adiponectin and leptin displayed distinct localization in
the steady-state, treatment of adipocytes with brefeldin A inhibited both adiponectin and leptin
secretion to a similar level, indicating a common requirement for class III ADP-ribosylating
factors and an intact Golgi apparatus. Adiponectin secretion was significantly reduced by
endosomal inactivation in both 3T3L1 and rat isolated adipocytes, whereas this treatment had no
effect on leptin secretion. Importantly, endosomal inactivation completely abolished the insulin
stimulatory effect on adiponectin release in rat adipocytes. Confocal microscopy studies revealed
colocalization of adiponectin with endogenous rab11 a marker for the recycling endosome, and
with expressed rab5-GFP mutant (rab5Q75L) a marker for the early endosome compartment.
Colocalization of adiponectin and rab5Q75L was increased in endosome inactivated cells.
Consistent with these findings adiponectin secretion was reduced in cells expressing mutants of
Rab11 and Rab5 proteins. In contrast, expression of an inactive (kinase dead) mutant of Protein
Kinase D1 moderately, but significantly inhibited leptin secretion without altering adiponectin
secretion. Taken together, these results suggest that leptin and adiponectin secretion involve
distinct intracellular compartments and that endosomal compartments are required for
adiponectin but not for leptin secretion.
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INTRODUCTION
Adiponectin and leptin are two hormones secreted by white adipose tissue that regulate
insulin sensitivity and energy balance [270, 332, 333]. Adiponectin, functions in vivo as an
insulin sensitizer [111, 114, 296, 303], reducing glucose production by the liver [112] and
enhancing fatty acid oxidation in skeletal muscle [114]. Leptin acts in the hypothalamus to
regulate food intake and energy expenditure (reviewed in [334-336]) and also activates fatty acid
oxidation in skeletal muscle through the stimulation of the enzyme AMP-dependent kinase
(AMPK) [337].
Serum levels of leptin correlate with adipose cell mass and BMI [338-341]. Leptin
levels are also increased by feeding and decreased by fasting. Leptin synthesis and secretion is
stimulated by insulin [133, 134, 289, 342], glucocorticoids [134, 343-345], glycolytic substrates
and amino acids [346, 347] and inhibited by ß-adrenergic agonists [348-350]. Insulin is thought
to increase both transcription of the leptin gene and secretion [134]. Like leptin, adiponectin
secretion is stimulated by insulin [351, 352] and reduced in the fasting state. However, in
contrast to leptin, adiponectin serum levels are negatively correlated with obesity and fat cell size
[340], and peroxisome proliferative activated receptor (PPAR) gamma agonists increase
adiponectin production and secretion [113, 353, 354]. Adiponectin is known to be secreted in
different oligomeric forms [95, 355], with the highest oligomeric form being the most
biologically active [95, 355].
While substantial information exists on the physiological effects of leptin and
adiponectin, the precise intracellular compartmentalization and trafficking pathways leading to
the secretion of these two hormones and the molecular components that mediate the traffic of
these adipokines are still poorly understood. Our previous observations [356] and the work by
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others [293] support the hypothesis that adiponectin is secreted following synthesis at the
endoplasmic reticulum, and processing in the Golgi/trans-Golgi network. We have recently
reported that at the trans-Golgi network, formation and exit of adiponectin-containing vesicles is
dependent on the formation of Golgi localizing γ-ear adaptor 1 (GGA1) coated vesicles, while
the secretion of leptin is independent of GGA1 coat formation [347]. These results suggested that
these two hormones may be located in distinct intracellular compartments and may follow
distinct trafficking pathways. Indeed, the intracellular compartmentalization of leptin in
adipocytes has remained controversial. While several studies [289, 347] have reported that in rat
adipocytes a substantial amount of leptin is localized in the endoplasmic reticulum in the steady
state, other studies suggest that the majority of leptin is accumulated in distinct small
intracellular vesicle compartments [357]. Recent fluorescence microscopy studies provided
evidence that a portion of leptin is localized in the endoplasmic reticulum, Golgi apparatus and
also in small intracellular vesicular vesicles [347].
In the present study, we aimed to elucidate the intracellular compartmentalization and
trafficking pathways of these two hormones in 3T3L1 and isolated rat adipocytes. We report here
that adiponectin and leptin have distinct intracellular localization in their steady state and
adiponectin but not leptin release occurs via endosomal compartments in both 3T3L1 and
isolated rat adipocytes. Moreover, insulin-mediated stimulation of adiponectin release is
completely blocked by endosomal inactivation in isolated rat adipocytes suggesting that insulin
acts at the level of endosomes to enhance adiponectin release. Further, we found that expression
of a kinase dead mutant of the enzyme protein kinase D1 selectively inhibits leptin but not
adiponectin release. Taken together, these data support the hypothesis that these two proteins
take divergent trafficking pathways at the trans-Golgi network, and thus, while adiponectin
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release is dependent on intact recycling and early endosome compartments, leptin secretion is
independent of the endosomal system.
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MATERIALS AND METHODS
Materials and antibodies.
Brefeldin A, DAB, BSA and were obtained from Sigma (St. Louis, MO). Anti-myc
antibody (Clone 9E11) was obtained from Santa Cruz Biotechnology, anti-HA antibody was
obtained from Sigma, anti-rab5 and anti-rab 11 were acquired from BD Biosciences, anti-
adiponectin antibody was a gift from Dr. P. Scherer (Albert Einstein, NY), and anti-transferrin
receptor was obtained from Zymed. Transferrin-HRP was acquired from Accurate Chemical &
Scientific Corp. Dulbecco’s Modified Eagle Media, Opti-Minimum Essential Media, Fetal
Bovine Serum, Calf Serum and Trypsin were purchased from Invitrogen. Collagenase type I was
obtained from Worthington pharmaceuticals.
Generation of DNA constructs.
The construct encoding for human adiponectin was generated by RT-PCR and subcloned
in the pcDNA3 vector (Invitrogen) incorporating a myc tag at the C-terminus. The clone coding
for the mouse leptin was subcloned into the pcDNA 3 vector (Invitrogen) and an HA
(Haemagglutinin tag) was added in frame in the C-terminus. Identity and positioning of the clone
was confirmed by sequencing. The plasmid encoding for GFP tagged syntaxin 6 protein was a
gift from Dr. J. Pessin (SUNY, Stonybrook). Plasmids encoding the GFP tagged wild type or
K618N mutant of the protein kinase D1 were provided by Dr. V. Malhotra (UCSD). Plasmids
encoding the GFP-rab5 wild type, Q79L and S34N mutants were provided by Dr. B. Ceresa
(University of Oklahoma). Plasmids encoding the GFP-rab11 Q70L and S25N mutants were
provided by Dr. M.McCaffrey (University College Cork).
Animals and adipocyte isolation.
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Sprague-Dawley rats (160-200g) were obtained from Charles River. Animals were
housed in a 12 hr light/dark cycle and fed ad libitum. Animals were euthanized by carbon
dioxide asphyxiation and the epidydimal adipose pads were quickly removed. Isolation of
adipocytes was performed as previously described [358]. The experimental protocol was
examined and approved by the Kansas State University Institutional Committee for the Use of
animals.
Cell culture and transient transfection.
3T3L1 adipocytes was transfected as previously reported [356].
Pull-down Assay and Western Blot Analysis.
Pull-down Assay and Western Blot Analysis was performed as described [356].
Immunofluorescence and image analysis.
Cells were washed in phosphate buffered saline (PBS) and were fixed, permeabilized and
immunostained as described [356].
Inactivation of the endosomal compartments.
Endosomal ablation of 3T3-L1 cells was performed as described previously [359].
Endosomal ablation of isolated rat adipocytes was performed with a minor modification. Briefly,
after isolation adipocytes were incubated in Krebs-ringer solution for 1.5 h at 37°C. Cells were
then incubated in Krebs-ringer solution containing Tfn-HRP (20 μg/ml) for 1.5 h at 37oC. Cells
were then washed three times with isotonic citrate buffer (150 mM NaCl, 200 mM Sodium
Citrate, pH= 5.0) for 10 minutes each time and once with Krebs-ringer solution. Krebs-ringer
solution containing 200μg/ml DAB and 0.04% H2O2, pH=7.2, was then added to the cells.
Following a 60 min. incubation at 37oC in the dark, the reaction was stopped by washing with
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warm Krebs-Ringer containing 0.5% BSA. Cells were then incubated in Krebs-Ringer for 2
hours. When indicated insulin was added at a final concentration of 20 nM.
Sucrose gradient centrifugation of adipocytes.
Cells were lysed in ice-cold HES buffer (0.25M glucose, 20 mM HEPES, pH 7.4, 1 mM
EDTA and 150 mM NaCl) containing protease inhibitors: 1 mM phenylmethylsulfonyl fluoride,
10 g/ml aprotinin, 1 g/ml leupeptin, and 1 g/ml pepstatin. Cells were homogenized with 5
strokes on a glass Dounce homogenizer. Homogenates were centrifuged at 2,095 x g for 15 min.
and the supernatants were collected and loaded onto a discontinuous sucrose gradient containing:
1.5M, 1.3M, 1.1M, 1.0M, 0.9M, 0.8M, 0.7M, 0.6M and 0.5M sucrose in HES. Samples were
then centrifuged at 75,000 x g for 24h at 4oC and 0.5 ml fractions recovered from the top of the
tube. Equal volumes of each fraction were separated by SDS-PAGE and transferred to
nitrocellulose filters for immunoblotting.
Determination of adipokine secretion by ELISA.
ELISA kits specific for adiponectin or leptin were obtained from R&D Systems
(Minnesota). Prior to the ELISA, floating cells were removed by a brief centrifugation at 500 x g
for 5 min and an aliquot of the supernatant was used for the quantification. In parallel, an aliquot
of the whole cell lysate was also quantified. Adipokine secretion was calculated as a percentage
of total adipokine content as follows: adipokine in the media/ total adipokine (= media + lysate)
x 100. To detect adiponectin-myc a modified sandwich ELISA protocol was used with an anti-
human adiponectin antibody (DY1065 from R&D Systems at a final concentration of 2μg/ml) 
and an antibody anti-myc conjugated to biotin (Sigma, Cat. nº: B7554) as a capture antibody.
Statistical Analysis.
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A one way ANOVA was performed using SAS statistical software. Statistical
significance was considered if p<0.05.
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RESULTS
Adiponectin and leptin secretion require an intact Golgi apparatus.
Our previous findings demonstrated the requirement of the formation of GGA1-coated
vesicles at the trans-Golgi network for adiponectin release but not for leptin release [356]. This
suggested that the intracellular trafficking pathways for the secretion of these hormones may be
different. To test this hypothesis we determined by confocal fluorescence microscopy the steady-
state intracellular compartmentalization of these two hormones in adipocytes. Differentiated
3T3L1 cells were electroporated with either a myc-tagged adiponectin or HA-tagged leptin
constructs to allow for the detection of these proteins using the tag specific antibodies. This was
especially important for leptin, since in our hands, the endogenous expression in 3T3L1 cells is
very low. After expression of these proteins, cells were fixed permeabilized and immunostained
with anti-tag and antibodies against well known intracellular markers. We found that while
adiponectin-myc was localized in the perinuclear region [356] and significantly colocalized with
syntaxin 6 (Fig9A panels a-c), leptin displayed no colocalization with syntaxin 6 (Figure 9B
panels a-c). Leptin distribution overlapped with the endoplasmic reticulum marker BIP (Fig 9B,
panels d-f) whereas the majority of adiponectin-myc was not colocalized with this marker
(Figure 9A. panels d-f).
Despite having substantially different steady-state localization, it is possible that both
hormones traffic through the same secretory pathway. To examine whether a functional Golgi
apparatus is required for leptin secretion, fully differentiated 3T3L1 adipocytes expressing
leptin-HA were either left untreated or treated with the fungal metabolite brefeldin A (BFA) for
2 hrs. Since BFA inhibits guanidyl nucleotide exchange factors that act on ARF-GTP binding
proteins in the Golgi [327], this inhibition causes a block in the anterograde
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Figure 9. Localization of adiponectin and leptin in 3T3L1 adipocytes. Fully differentiated
adipocytes were electroporated with a construct coding for either adiponectin-myc (panel A) or
leptin-HA (panel B). Cells were then fixed, permeabilized, and immunostained with a specific
antibody anti-myc and a secondary antibody conjugated to Texas red (A, panels a and d) , or a
primary anti-HA antibody and a secondary Texas red-conjugated antibody (B, panels a and d) or
with an antibody specific for the trans-Golgi network marker syntaxin 6 (A and B, panel b), the
ER marker BIP (A and B, panel e). The merged images are shown in the right panels. The
yellow color in the merged images (A and B, panels c and f) indicate colocalization. Images
were obtained with a Zeiss 510 META confocal microscope.
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Golgi trafficking and thereby causes the collapse of the Golgi stacks back into the endoplasmic
reticulum [328, 360]. Following treatment, the amount of secreted leptin-HA (or adiponectin as
control) in the conditioned media was measured by ELISA. As shown in Figure10A. Brefeldin A
significantly inhibited the secretion of both adiponectin and leptin-HA to 53.0 ± 6.4% and 65.0 ±
6.6%, respectively, in 3T3L1 adipocytes. Similar results were obtained in isolated rat adipocytes
treated in vitro with BFA (Fig 10.B), where an inhibition of 61.0 ±3.5 % and 64.0 ± 8.4% was
seen for endogenous adiponectin and leptin respectively. These findings demonstrate that
blockage of class I ADP-ribosylating factors (ARFs) in the secretory pathway significantly
inhibits secretion of both hormones and suggest that both leptin and adiponectin traffic through
the Golgi and trans-Golgi network.
Adiponectin but not leptin secretion requires intact endosomes.
We have previously reported that adiponectin release requires the function of GGA1
adaptor proteins [356]. Since GGA proteins have been reported to direct traffic of selective cargo
from the trans-Golgi network to the endosomes [361], we hypothesized that adiponectin
secretion may occur via the endosomal system. To test this hypothesis, fully differentiated
3T3L1 adipocytes and rat isolated adipocytes were subjected to the endosomal inactivation
procedure described by Livingstone et al. [359]. As a control, a subset of cells were incubated in
the presence of HRP-conjugated transferrin (Tfn-HRP) but without the substrate DAB.
Following the endosome inactivation procedure, both the control and endosome inactivated cells
were lysed and fractionated to equilibrium in a sucrose gradient ultracentrifugation as described
in the methods section. The fractions were separated by SDS-PAGE transferred to a
nitrocellulose membrane and immunoblotted with the endosomal markers: transferrin receptor,
rab5 (an early endosome marker) and rab 11 (a recycling endosome). As
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Figure 10. Adiponectin and leptin secretion are inhibited by BFA. A) Secretion in 3T3L1
adipocytes. Adiponectin secretion (white bars): Fully differentiated 3T3L1 adipocytes were trypsinized
and replated in 12-well dishes to distribute the same number of cells per dish. Two hours later the
medium was changed to DMEM without serum in the absence (control) or presence of 5 µg/ml BFA.
Cells were incubated for additional 4hrs, and an aliquot of media and cell lysate were then taken for
adiponectin content quantification by ELISA as indicated in the methods section. Leptin secretion (black
bars): Fully differentiated adipocytes were electroporated with a construct coding for leptin-HA and
replated in 12-well dishes. 18 h following the electroporation the media was changed to DMEM without
BFA, or to DMEM supplemented with 5 µg/ml BFA. Four hours later, media and whole cell lysates were
obtained and an aliquot quantified by ELISA as described in the methods section. B) Secretion in isolated
rat adipocytes: Isolated rat adipocytes were obtained as described in the methods section. Equal volumes
of packed cells were distributed in separate tubes and incubated in Krebs-Ringer buffer in the absence or
presence of 5 µg/ml BFA for 2 hours. A small aliquot of medium was taken to independently determine
the amount of adiponectin and leptin by ELISA. Cell lysates were prepared and an aliquot quantitated for
the amount of each adipokine by ELISA. The amount of secreted adipokine (expressed as % of total
adipokine content) was calculated as described in the methods section and compared to the value obtained
for control adipocytes (no BFA treated). The graphs represent the percentage of adiponectin or leptin
secreted vs. control adipocytes (-BFA) ± S.E. obtained from three independent experiments, each
performed in triplicate. Differences were considered significantly different when p < 0.001 and is
indicated by an asterisk.
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shown in Figure 11A, in control cells where the DAB was omitted, transferrin receptor, rab 5
and rab 11, were revealed in light to medium sucrose density fractions. Under conditions where
cells were incubated in the presence of the HRP substrates DAB and H2O2, endosomal
inactivation was made evident by the presence of these proteins in the heaviest fractions (pelleted
material). For 3T3L1 cells (Fig 11A, top panel) a nearly complete endosomal inactivation was
observed. To confirm that the endosome inactivation procedure did not affect other non-
endosome compartments, samples were immunoblotted with an antibody for the trans-Golgi
network marker syntaxin 6. The localization of syntaxin 6 was unchanged after the endosomal
inactivation In addition, the endosomal inactivation procedure did not alter the overall cell
morphology or affect the intracellular steady-state localization of adiponectin-myc and leptin-HA
in these cells (data not shown).These results were reproduced in rat isolated adipocytes (Figure
11A lower panel).
We next determined whether adiponectin and leptin secretion are affected by endosome
inactivation in 3T3L1 adipocytes. As shown in Figure 11B (top panel) endosomal ablation
significantly reduced the amount of adiponectin secreted. This effect was DAB dose dependent
(Figure 11B, top panel). In contrast, leptin HA secretion in was not affected (Figure11B, lower
panel). To determine whether endosomes are important for adiponectin or leptin secretion in rat-
isolated adipocytes and to investigate whether insulin-stimulated release of these hormones is
dependent on the endosomal system, the same experiments were performed in isolated rat
adipocytes. Cells were incubated with transferrin-HRP and either vehicle or DAB. Following
the ablation, a subset of cells were either left untreated or were treated with 20 nM of insulin and
were incubated for 2 hrs. Aliquots of media were then taken and quantitated by ELISA for
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Figure 11. Secretion of adiponectin but not leptin is inhibited by endosomal inactivation. A)
Distribution of membranes containing transferrin receptor, rab5, rab11 and syntaxin 6 (syn6) in control
cells (-) or cells subjected to endosomal inactivation (+). Fully differentiated 3T3L1 cells (top panel) or
rat isolated adipocytes (bottom panel) were subjected to the endosomal inactivation procedure as
described in the methods section. As a control, a subset of cells was subjected to the same procedure
without the substrates DAB and H2O2. Total internal membranes were prepared and separated on a
discontinuous sucrose gradient as described in the methods section. Fractions of 0.5 ml were collected
from the top of the tube. For each fraction, an aliquot of 50 μl was separated by SDS/PAGE, transferred 
to a nitrocellulose filter and immunoblotted with specific antibodies to detect transferrin receptor, rab5,
rab11 and syntaxin 6 as indicated. Fraction 13 was the pellet at the bottom of the gradient. B) Secretion of
adiponectin (top) and leptin (bottom) in 3T3L1cells is inhibited by endosomal inactivation. Cells were
subjected to the endosome inactivation technique as described in the methods section using different
dosages of DAB as indicated. As a control, a subset of cells were either left untreated or treated with
H2O2 only, DAB only, or transferrin-HRP only. After endosomal inactivation, cells were incubated in
serum free DMEM for 4 hours at 37oC. At that time an aliquot of media was harvested and whole cell
lysates prepared and an aliquot of each was quantitated by ELISA for the presence of adiponectin. The
graphs display the amount of secreted adiponectin ± S.E. obtained from three independent experiments,
each experiment was performed in triplicate. Differences were considered significantly different when p<
0.05 and is indicated with an asterisk. C) Secretion of adiponectin but not leptin in isolated rat adipocytes
is inhibited by endosomal inactivation. Isolated epidydimal rat adipocyte cells were obtained by
collagenase digestion as described in the methods section. An equal volume of packed cells were
incubated in Krebs-Ringer buffer containing transferrin-HRP. A subset of cells were then treated with
DAB and H2O2 as described in the methods section to inactivate the endosomal compartments. A
subgroup of adipocytes was further incubated in the absence or presence of 20 nM insulin at 37°C for 1,
2 hrs. After this time, the conditioned media and a cell lysate were obtained and quantitated with
adiponectin or leptin specific ELISA kits. The results shown are the secretion percentage values
respective to the secretion measured in control cells (no endosomal inactivation) without insulin and are
the mean ± S.E., representing data from three independent experiments and each experiment was
performed in triplicate. Differences were considered significantly different when p < 0.05 and is indicated
with an asterisk.
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adiponectin or leptin. As shown in Figure 11C, insulin stimulated adiponectin release by 1.5 fold
(+INS group) whereas endosomal inactivation (+DAB) significantly inhibited adiponectin
secretion. Interestingly, insulin-mediated activation of adiponectin release was completely
abolished by endosomal inactivation (Fig 11C, +DAB+INS group). These results suggest that
insulin stimulates adiponectin release by increasing membrane traffic through the endosomal
system. Insulin caused a small but significant increase of leptin secretion (Fig 11C, +INS group)
but in contrast to adiponectin, leptin secretion was not affected by endosomal inactivation
(Figure 11C, +DAB group). Further, insulin-mediated increase in leptin secretion was not
affected by endosomal ablation (Figure11C, +DAB+INS group).
Recycling and early endosomes are involved in adiponectin secretion
We next identified which endosomal compartments participate in adiponectin trafficking.
We analyzed by confocal fluorescence microscopy the localization of adiponectin-myc and of
endogenous rab11 and rab 5 proteins or expressed GFP-tagged wild type and constitutively
active/inactive mutants of rab5. We found that adiponectin-myc partially colocalized with the
endogenous rab 5 (data not shown) or with expressed wild type GFP-rab5 (Fig 12A, panels a-c).
Adiponectin-myc could be detected in enlarged early endosomes generated by the expression of
the constitutively active form of rab5 (rab5Q79L) (Figure12A. panels d-f). Increased
colocalization of adiponectin-myc with GFP-Rab Q79L was observed in cells subjected to the
endosomal inactivation (Fig 12B, panels d-f) compared to cells with functional endosomes
(Figure12B, panels a-c). We also found significant colocalization between adiponectin-myc and
endogenous rab11 (Fig 12A, panels g-i).
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Figure 12. Adiponectin colocalizes with endosomal markers. A) Fully differentiated
adipocytes were coelectroporated with a construct coding for adiponectin-myc and either a construct
coding for a GFP- tagged wild type rab5 (panels a-c), or constitutive active mutant of rab5 (Rab5Q79L)
(panel d-f). Cells were then fixed, permeabilized, and immunostained with a specific antibody for myc
and a secondary antibody conjugated to Texas red (panels a, d and g), or for endogenous Rab11 and a
secondary antibody conjugated to Alexa-488 (panel h). The merged images are shown in the right panels
(c-i). Images were obtained using a Zeiss 510 META confocal microscope. B) A fraction of adiponectin-
myc is retained in the early endosome compartment after endosomal inactivation. Fully differentiated
adipocytes expressing adiponectin-myc and the GFP-tagged rab5 Q75L protein were subjected to the
endosomal inactivation. Upper panels (a to c) show the control group without DAB, lower panels (d-f)
show the endosome inactivated cells. Cells were then fixed, permeabilized, and immunostained with a
specific antibody for myc and a secondary antibody conjugated to Texas red (panels a, and d). The
merged images are shown in the right panels (c-f). Images were obtained using a Zeiss 510 META
confocal microscope. C) Recombinant GST- GGA1 protein precipitates vesicles containing adiponectin
and rab 11. Pull down assays were performed with recombinant GST or GST-GGA1VHS recombinant
protein as described in the methods section. The pelleted samples and supernatants (SN) were separated
by SDS-PAGE transferred to a nitrocellulose membrane and immunoblotted with an antibody specific for
adiponectin, rab5 or rab11. A representative blot of five independent experiments is shown.
88
These results suggested that the recycling and early endosome compartments may form
part of the secretory pathway for adiponectin in adipocytes. To confirm these results, we
conducted biochemical and functional studies in 3T3L1 adipocytes. We have previously reported
that a fraction of intracellular vesicles containing adiponectin can be precipitated with
recombinant GGA1 protein fused to GST [356]. We conducted pull down assays of 3T3L1
intracellular membranes using either GST or GST-GGA1 recombinant proteins immobilized to
glutathione-sepharose beads as we have described [356]. The pelleted samples were washed in
PBS, separated by SDS-PAGE, transferred to a nitrocellulose membrane and immunoblotted
with specific antibodies to detect endogenous adiponectin, rab5 and rab 11. The results displayed
in Figure 12C, show that a substantial amount of rab11 was readily detected selectively in the
precipitates containing adiponectin and the GST-GGA1 but not in the pellets of samples
incubated with control GST recombinant protein. This result is consistent with the amount of
colocalization between adiponectin-myc and rab11 detected in the immunofluorescence studies.
However, we were unable to detect endogenous rab 5 in the GGA1 precipitates of the pull down
assay (Figure 12B). The absence of rab5 in the precipitates could also originate from low
sensitivity of the assay, since only a fraction of adiponectin-containing vesicles precipitated with
GGA1. To complement these results, we performed functional studies to determine whether the
expression of mutant rab 5 or rab11 proteins could affect the amount of secreted adiponectin in
3T3L1 adipocytes. As a control, we measured the secretion of leptin in the conditioned medium
of these cells. The results expressed as a percentage of adiponectin or leptin secreted vs. total
adipokine present in the cell was compared to that obtained in cells expressing either adipokine
or an empty vector. As shown in Fig 13A the over expression of either rab11 mutant moderately
(~25%) but significantly inhibited the secretion of adiponectin without affecting leptin release.
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Figure 13. Expression of rab5 and rab11 mutants inhibit adiponectin secretion in
3T3L1 cells. Fully differentiated 3T3L1 cells were electroporated with a construct expressing
adiponectin-myc (white bars) or leptin-HA (black bars) and either an empty vector, wild type or
constitutive active and inactive mutants of rab 11 (Panel A) or rab5 (Panel B). Following
expression of the proteins, media and whole cell lysates were harvested and an aliquot of each
were quantified by ELISA as described in the methods section. The amount of secretion is shown
as the ratio to the secretion obtained in control adipocytes expressing each adipokine and the
empty vector ± S.E. The graph represents data from three independent experiments and 18
independent observations. Differences were considered significantly different when p < 0.05 and
is indicated with an asterisk. Expression of adiponectin-myc, leptin-HA and rab proteins were
confirmed by western blot analysis (data not shown). For this ELISA we utilized an adiponectin
capture and detection antibodies, respectively, as described before [356].
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A greater inhibition of adiponectin (~30% with rab5Q75L, ~64% with rab5S34N) was observed
in cells expressing mutants of rab5. As expected, no change in leptin secretion was observed
with either rab11 or rab5 mutants (Figure 13). Taken together, these results support the
hypothesis that both the recycling and early endosome compartments participate in the secretion
of adiponectin.
Leptin but not adiponectin traffic uses protein kinase D1.
Our results are consistent with the hypothesis that adiponectin and leptin take divergent
trafficking pathways en route to the plasma membrane. Recent evidence in the literature suggests
that the serine/threonine Protein Kinase D1, regulates fission at the trans-Golgi network of
transport vesicles that deliver cargo to the plasma membrane [362, 363]. We hypothesized that if
leptin secretion occurs directly from the TGN to the plasma membrane, its secretion would be
inhibited by mechanisms that block activation of this enzyme. To test this hypothesis, we
expressed a wild-type form of a GFP-tagged PKD1 or a GFP-kinase-dead mutant incorporating
the substitution K618N in 3T3L1 adipocytes. This mutation renders the protein catalytically
inactive but allows it to function as a dominant interfering mutant blocking the activation of the
endogenous PKD1 [362, 364]. The localization of PKD1 proteins in the Golgi/TGN
compartment was confirmed by confocal fluorescent microscopy and compared to the
localization of adiponectin-myc. The results shown in Figure 14A demonstrate that GFP-PKD1
and GFP-PKD1-K618N localize in a perinuclear compartment (Figure 14A, panels b and e) and
in close proximity to adiponectin-myc (Figure 14A, panels c and f). These results are consistent
with the TGN localization of the expressed GFP-PKD1 proteins. We then determined whether
expression of these PDK1 constructs would alter the secretion of co-expressed adiponectin-myc
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Figure 14. Secretion of leptin, but not adiponectin is inhibited by a mutant of PKD1. A)
Colocalization of adiponectin and PKD1. Fully differentiated adipocytes were co-electroporated with a
construct coding for adiponectin-myc and either a construct coding for a GFP-tagged wild type PKD
(panels a-c), or a construct coding for the PKD1 dominant interfering mutant PKD1-K618N (panel d-f).
Cells were then fixed, permeabilized and immunostained with a specific antibody anti-myc and a
secondary antibody conjugated to Texas red (panels a and d). The merged images are shown in the right
panels. Images were obtained using a Zeiss 510 META confocal microscope. B) A PKD1 mutant
inhibits leptin but not adiponectin secretion in 3T3L1 cells. Cells were co-electroporated with a vector
expressing adiponectin-myc or leptin-HA and either an empty vector, a construct coding for PKD1 wild
type or a construct coding for the mutant PKD1-K618N. Following expression of the proteins, the
conditioned media and whole cell lysates were obtained and an aliquot was taken for the adipokine
quantification by ELISA as described in the methods section. The secreted adipokine was calculated in
each group as a percentage of total adipokine content and compared to the secretion obtained in the
control group expressing adipokine plus the empty vector. The graph shows adipokine secretion vs.
control ± S.E, representing data from three independent experiments, each experiment performed in
triplicate. Differences were considered significantly different when p<0.05 and is indicated with an
asterisk. Adiponectin: White bars. Leptin: black bars.
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or leptin-HA. While we did not detect any change in the secretion of adiponectin-myc by
expressing either in the amount of secreted leptin-HA in cells selectively expressing the PKD1
mutant (Figure14B, black bars).
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DISCUSSION
In addition to its important role as a lipid storage depot, adipocytes play a key role in the
control of energy balance and insulin sensitivity through the secretion of various hormones.
Several studies have documented that secretion of these proteins occurs by both constitutive and
regulated mechanisms. For example, it is well documented that insulin stimulates the secretion of
leptin [289], adiponectin [330], and adipsin [365, 366]. The specific intracellular
compartmentalization and trafficking of these hormones is poorly understood. In this report, we
examined and compared the intracellular secretory pathways of two critical adipocyte hormones,
adiponectin and leptin.
Biochemical and fluorescence microscopy studies have previously demonstrated that
neither leptin [290] nor adiponectin [330] localize intracellularly with the well-studied
intracellular compartment containing the insulin-responsive glucose transporter Glut4.
Furthermore, the precise intracellular steady-state distribution of leptin in adipocytes has
remained somewhat controversial. While initial studies [289] had reported that a substantial
amount of leptin is found in the cortical endoplasmic reticulum of rat isolated adipocytes, other
biochemical studies [357] had found that the distribution of leptin-containing vesicles separated
by equilibrium sucrose density centrifugation was not consistent with that of the localization of
endoplasmic reticulum markers. To reconcile these differences and to investigate the intracellular
trafficking pathways required for leptin secretion in adipocytes, we first compared the
intracellular steady-state distribution of expressed leptin-HA with that of another adipokine,
adiponectin-myc in 3T3L1 adipocytes. Here we report that these hormones have distinct steady
state localizations, whereas adiponectin is localized within the TGN overlapping with the marker
syntaxin6, leptin is predominantly localized in close proximity of the endoplasmic reticulum
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marker BIP. Thus our results support those found by Barr et.al. [289] in rat adipocytes, and
confirm that in the steady-state the majority of adiponectin and leptin are located in distinct
intracellular compartments.
Despite displaying a distinct intracellular localization, treatment with brefeldin A,
inhibited the secretion of both adipokines in either cultured adipocytes or rat isolated adipose
cells (by 58% and 35% in 3T3L1 and 39% and 36% in rat adipocytes for adiponectin and leptin
secretion respectively). This finding suggests that both adiponectin and leptin traffic via
Golgi/TGN. Interestingly however, in both cell types, BFA did not completely inhibit the
secretion of these adipokines, indicating that the short term release of these hormones occurs
partially through a BFA insensitive mechanism, and most probably, a post-TGN compartment
which we hypothesize could represent the site for regulated secretion.
GGA adaptor proteins are important for the formation of adiponectin-containing vesicles
at the TGN of adipocytes [356]. Since GGA proteins participate in the TGN to endosome traffic,
we hypothesized that adiponectin secretion but not leptin secretion would involve the endosomal
compartment(s). To test this hypothesis, we conducted biochemical experiments to selectively
inactivate the endosomes of 3T3L1 adipocytes following the procedure first described by
Livingstone et al., 1996 [359]. We also adapted this technique to isolated rat adipocytes. To our
knowledge this is the first time that this technique has been applied to these cells. With this
technique we achieved a complete inactivation of the endosomal compartments in 3T3L1 cells
and a substantial (60%) inactivation of the endosomes in isolated rat adipocytes. Several reasons
could account for this difference. First, transferrin-HRP internalization may be slower or less
efficient than in 3T3L1 cells or alternatively, rat adipocytes may contain a larger endosomal
compartment than 3T3L1 adipocytes which may require higher amounts of Tfn-HRP and DAB
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to achieve a complete inactivation. Attempts to increase the time of capture of transferrin-HRP
or DAB and H2O2 substrate concentrations did not result in an increase in endosome inactivation
in these cells. Furthermore, higher concentrations of H2O2 resulted in decreased viability of
adipocytes (not shown). Nevertheless, our findings in rat isolated adipocytes corroborated the
results obtained in the cell line 3T3L1. Endosomal inactivation profoundly reduced the amount
of adiponectin secreted while leptin release remained unaffected, indicating that adiponectin but
not leptin secretion requires functional endosomes.
To identify the endosomal compartments involved in adiponectin secretion we used
confocal immunofluorescence and secretion studies in 3T3L1 adipocytes expressing adiponectin-
myc and GFP-tagged wild type and/or constitutively active/inactive mutants of the endosomal
markers rab11and rab5. Immunofluorescence studies revealed adiponectin-myc distributed in
close proximity to the endogenous rab 11 and rab5 proteins. In addition, rab11 was detected in
precipitated adiponectin- containing vesicles. Furthermore, over expression of a constitutively
active or inactive forms of either rab11 or the rab5 proteins, modestly but significantly, inhibited
adiponectin-myc release in 3T3L1 cells without affecting leptin release. Taken together, these
findings strongly suggest that intact endosomal compartments are required for adiponectin but
not leptin secretion. In agreement with these results, Gould’s group recently reported that a 
mutant of rab11 (rab11S25N) inhibited both basal and insulin-stimulated adiponectin secretion in
3T3L1 cells [367]. In line with this, our results in rat adipocytes strongly support the idea that
insulin-stimulation of adiponectin release may be mediated via insulin-mediated activation of the
endosomal membrane recycling. Similarly to adiponectin, adipsin, a serine protease released by
adipocytes is also released via TGN to endosome traffic [366]. While the acute effects of insulin
on leptin secretion have been reported to act at the level of secretion [134], our data support a
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model where insulin may increase secretion of adiponectin and leptin in different ways. It
remains to be established whether a similar or distinct insulin intracellular signaling cascades are
utilized to control secretion of each adipokine.
To further identify molecular regulators for leptin secretion we tested whether leptin
secretion is dependent on Protein Kinase D1 activity, and enzyme that regulates the formation of
TGN-derived vesicles en route to the plasma membrane [363, 368]. Over expression of a
dominant interfering mutant PKD1 K618N exhibited a moderate but significant decrease in
leptin release. This suggests the possibility that PKD1 may be involved in regulating at least
partially, the trafficking of leptin-containing vesicles. Further experiments are required to test
whether the PKD1 activity is required for the insulin-stimulated effect on leptin secretion.
Taken together, our results demonstrate that adiponectin and leptin are secreted through
distinct intracellular trafficking pathways and suggest that adipocytes rely on different avenues
for the constitutive and regulated secretion of these adipokines.
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FOOTNOTES
Abbreviations: ARF: ADP-ribosylating factor; BFA: Brefeldin A; BSA: Bovine Serum
Albumin; DAB: 3,3′-Diaminobenzidine; GGA1: Golgi localizing γ-adaptin ear homology domain
ARF binding protein; GST: Glutathione-S-transferase; HRP: Horse-Radish Peroxidase; PDK1:
protein kinase D1; PPAR: Peroxisome Proliferator-Activated receptor-γ agonist; Tfn: Transferin; 
HRP: Horse radish peroxidase: TGN: Trans-Golgi network.
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CHAPTER 4
MACROPHAGE-DERIVED IL-6 ALTERS GLUT4 IN
ADIPOCYTES
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ABSTRACT
Adipose tissue was originally classified as an energy reservoir where excess energy was
stored in the form of triacylglycerols. It is now clear that it also secretes leptin and adiponectin,
along with IL-6, TNF-and many other cytokines, and insulin resistance is associated with
macrophage infiltration. We tested the hypothesis that macrophages affect insulin resistance by
disrupting insulin-stimulated glucose transport and adipocyte differentiation. To test this
hypothesis, we co-cultured 3T3L1 adipocytes with C2D macrophage cells or primary peritoneal
mouse macrophages. We found that peritoneal macrophages significantly decreased insulin-
stimulated GLUT4 but not constitutive GLUT1 translocation to the plasma membrane, regardless
of whether the 3T3L1 cells were directly in contact with macrophages or were co-cultured in
transwell plates. The cytokines, TNF-IL-6 and IL-1all inhibited GLUT4 translocation and
transcription. However, only IL-6 was inhibitory at concentrations found in macrophage-
adipocyte co-culturesIL-6 and TNF-but not IL-1, inhibited Akt phosphorylation within 15
minutes of insulin stimulation. However, only IL-6 was inhibitory 30 minutes after stimulation.
Lastly, we found that adipocyte differentiation was inhibited by macrophages or by recombinant
TNF-IL-6 and IL-1with IL-6 having the most impact. These data support the hypothesis
that macrophages induce insulin resistance by inhibiting glucose transport in adipocytes and by
inhibiting their differentiation by secretion of proinflammatory cytokines with IL-6 being the
most effective.
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INTRODUCTION
Insulin resistance is characterized as an impairment of glucose utilization and insulin
sensitivity. There is increasing evidence of a relationship between inflammation and the
development of insulin resistance.  One hypothesis is that inflammation causes “metabolic 
syndrome”, which is defined as a combination of symptoms associated with insulin resistance
and known to precede the onset of type 2 diabetes [190, 369].
Insulin resistance not only accompanies chronic inflammation but also abnormal
mediator secretion [370]. Adipose tissue is now appreciated as an endocrine organ that secrets
hormones and cytokines including TNF-IL-1and IL-6 [371]. The cytokines are associated
with increased number of adipose tissue macrophages in obese and diabetic patients [174, 229].
Direct or indirect interactions between adipose tissue macrophages and adipocytes may impair
insulin action, affect key protein expression or activate inflammatory pathways. For example,
increased levels of TNF-IL-6, C-reactive protein (CRP) and monocyte chemoattractant
protein-1 (MCP-1; CCL-2) are elevated in obese and diabetic people [175, 372, 373]. In the
obese mouse (ob/ob), the absence of the TNF- improved insulin sensitivity and glucose
homeostasis [191]. The adoptive transfer of bone marrow cells from TNF+/+ mice into TNF-
knock-out mice reduced insulin sensitivity of the recipients [374]. Therefore, it is clear that
TNF-has an impact on insulin sensitivity. However, it is not clear if TNF- is the only
cytokine that is required to induce insulin resistance. IL-6 is overexpressed in adipose tissue of
obese and diabetes patients [375]. It reduced the adiponectin concentrations in human adipose
tissue and reduced transcription of insulin receptor substrate-1 (IRS-1) and glucose transporter 4
(GLUT-4) in 3T3L1 cells [207, 372, 376]. IL-1has also been reported to be higher in
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overweight and obese individuals. It reduced insulin receptor substrate (IRS) expression in
differentiated 3T3L1 adipocytes [377]. Moreover, individuals with a combined increase in IL-
1and IL-6 levels were at greater risk of developing type 2 diabetes than individuals with
increased IL-6 alone [222].
Collectively, these data demonstrate that TNF-α, IL1β and IL-6 play a critical role in the
onset of obesity-related insulin resistance. However, both macrophages and adipocytes produce
proinflamatory cytokines. Given that these cytokines synergize and regulate each other, there
are many unanswered questions about what happens during the adipocyte-macrophage
interaction and how insulin resistance is induced.
We hypothesized that macrophages would affect glucose uptake and the signaling that
occurs in response to insulin. To test this hypothesis, we co-cultured macrophages and
differentiated adipocytes and examined the impact of the interaction on adipocytes.
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MATERIALS AND METHODS
Antibodies and recombinant cytokines.
Mouse recombinant TNF-, IL-1 and IL-6 were purchased from R&D systems
(Minneapolis, MN). Rabbit anti-mouse GLUT4 Polyclonal antibody (Cat. ab654-250) was
obtained from Abcam (Cambridge, MA). Rabbit anti-mouse GLUT1 Polyclonal antibody (Cat.
CBL242) was obtained from BD Biosciences (San Jose, CA). Rabbit anti-Akt polyclonal
antibody (Cat.9272) and rabbit anti-phospho Akt (serine 473, Cat. 9271S) were obtained from
Cell Signaling (Beverly, MA). Allophycocyanin (APC)-conjugated goat anti-rabbit IgG (Cat. sc-
3846) was purchased from Santa Cruz Biotechnology (Santa Cruz, CA). For ELISA, anti-TNF-
antibody (capture, Cat.551225), biotinylated anti- TNF-antibody (detection, Cat.554415),
anti-IL6 antibody (capture, Cat.554400) and biotinylated anti-IL6 antibody (detection,
Cat.554402) were obtained from BD Biosciences (San Jose, CA, Cat.); anti-IL1antibody
(capture, Cat.MAB401) and biotinylated anti-IL-1antibody (detection, Cat. BAF401) were
obtained from R&D systems (Minneapolis, MN).
Cell culture.
3T3L1 adipocytes were obtained from the American Type Culture Collection (Manassas,
VA). Adipocytes were cultured and differentiated as described previously [356].
The C2D macrophage cell line was created by our group and was cultured in DMEM10 as
described previously [378]. The BHK cells were purchased from the ATCC and were cultured in
DMEM10 at 37 oC with 8% CO2..
Peritoneal macrophages were obtained from C57BL/6J mice by peritoneal lavage 4 days
after intraperitoneal injection of 1.5 ml of 4% thioglycollate. Macrophages were incubated in
ammonium chloride lysis buffer (0.15M NH4Cl, 10mM KHCO3, 0.1mM Na2EDTA, pH=7.3) for
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5 minutes on ice to lyse contaminating red blood cells. Cells were washed three times with PBS.
Indirect co-culture was performed by incubating peritoneal macrophages (1×106 cells) or C2D
macrophages (1×105 cells) in 0.4 m cell culture inserts from BD Bioscience and placing them
in 6-well plates containing 3T3L1 adipocytes differentiated at day 8 (1×106 cells) for 4 days.
Direct co-cultured was performed by directly adding peritoneal macrophages (1×106 cells) or
C2D macrophage cells (1×105 cells) into the 6-well plates containing undifferentiated 3T3L1
adipocytes (1×106 cells). Fewer C2D macrophage cells were added because they continue to
proliferate (T1/2≈ 24 hrs) [378], while peritoneal macrophages do not.
Transfection of BHK and 3T3L1 cells.
GFP tagged GLUT1and GLUT4 constructs were a gift from Dr. J. E. Pessin (SUNY
Stonybrook) and were used as previously described [379]. The eGFP-N1 empty vector plasmid
was from Clontech. Plasmids were transiently transfected into BHK cells by Transfectamine
2000 from Invitrogen (Invitrogen, Carlsbad CA) according to the manufacturer’s protocol. 
Briefly, BHK cells grown in a 12-well plate were washed with Opti-MEM (Invitrogen) when
cells were about 80% confluent. Plasmid DNA was resuspended at a concentration of 3 g per
50l opti-MEM and lipofectamine was resuspended at a concentration of 5g per 50l in Opti-
MEM. Plasmid DNA and lipofectamine were then mixed and incubated at room temperature for
20 minutes in DMEM10. One hundred l of the reaction mixture were added to cells in the 24-
mm wells of the 12-well plates. BHK cells were incubated for 24 hours at 37oC. Transfection
efficiency was determined by counting positive cells among 100 randomly selected cells using a
fluorescent microscope 24 hours after transfection. Only BHK cells with transfection efficiency
above 50% were used in our experiments. 3T3L1 adipocytes were transfected by electroporation
as described before [356].
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Immunofluorescence and Image Analysis.
Transfected and intact adipocytes were washed in phosphate buffered saline (PBS), fixed,
permeabilized and immunostained as described previously [356]. The cells were imaged using a
Zeiss LSM 510 META confocal microscope. Images were then imported to Adobe Photoshop
(Adobe Systems, Inc.) for processing.
One-step RT-PCR analysis.
Total RNA was extracted from cells by Trizma Reagent from Sigma-Aldich according to
the manufacturer’s protocol with some modification. One-step RT-PCR was performed by using
Access RT-PCR Core Reagents from Promega (Madison, WI) according to the manufacturer’s 
protocol. Primers were designed using Primer3 software (http://frodo.wi.mit.edu/) using
sequence data from NCBI sequence database. Primer sequences (forward/reverse) used were as
follows: -actin (Gene bank ID: NM_007393) 5’-tcctgtggcatccacgaaact-3’/ 5’-
gaagcatttgcggtggacgat-3’; GLUT4 (Gene bank ID: AB008453) 5’-caacagctctcaggcatcaa-3’/ 5’-
ctcaaagaaggccacaaagc-3’; IL-1Gene bank ID: NM_008361) 5’-caggcaggcagtatcactca-3’/ 
5’aggccacaggtattgtcg-3’; IL-6 (Gene bank ID: NM_031168) 5’-ttcctctctgcaagagact-3’/ 5’-
tgtatctctctgaaggact-3’; TNF-Gene bank ID:  NM_013693) 5’-gggatgagaagttcccaaatg-3’/ 5’-
ctccagctggaagactcctcccag-3’; adiponectin (Gene bank ID: NM_009605) 5’-gttgcaagctctcctgttcc-
3’/5’-tctccaggagtgccatctct-3’; GLUT1 (Gene bank ID: D10229) 5’-gctgtgcttatgggcttctc-3’/ 5’-
agaggccacaagtctgcatt-3’.  The RT -PCR products were visualized under UV light by the
FluorChem
TM
8800 Advanced Imaging System (Alpha Innotech, San Leandro, CA). The relative
density of the target band was normalized to the β-actin loading control and then expressed as a
percentage of the controls.
Flow cytometry analysis.
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For the analysis of cell surface GLUT4 and GLUT1, cells were immediately fixed in 2%
paraformaldehyde at 37oC for 15 minutes. After twice washing with PBS, cells were blocked
with goat serum for 0.5 hour and were then treated with rabbit anti-mouse GLUT4 or GLUT1
antibodies for 1 hour at room temperature. After two washes with PBS, cells were stained with
APC-conjugated goat anti-rabbit IgG for 0.5 hour. Cells were resuspended in PBS and assessed
by flow cytometry after washing with PBS twice.
For the analysis of the intracellular molecules, cells were first fixed in 2%
paraformaldehyde for 20 minutes at 37oC. Cells were then permeablized by incubating the cells
in 90% ice-cold methanol for 30 minutes. The cells were washed twice in PBS and were blocked
and probed with antibody as described above. Samples were analyzed using a FACS Caliber
analytical flow cytometer (Becton Dikson, San Jose, CA). 5,000-10,000 events measured for
each sample. Data analysis was performed with Winlist software (Verity Software House,
Topsham, ME).
Enzyme-Linked ImmunoSorbent Assay (ELISA).
TNF-, IL-1and IL-6 in cell culture supernatants were measured by ELISA [380].
Briefly, the ELISA plates were coated with capture antibodies overnight at room temperature.
After 1 hour blocking, samples were added to each well and incubated at room temperature for 2
hours. After three washes with PBS completed with 0.5% Tween-20 (PBST), biotin-conjugated
detection antibodies were added and incubated at room temperature for 2 hours. HRP-
streptavidin was then added and incubated in room temperature for 30 minutes. After three
washes, substrate was added to the wells. Within 30 minutes, the reaction was stopped by 1N
H2SO4 and absorbance was assessed using a BioRad microplate reader Model 680 (Bio-Rad
Laboratory, Inc., Hercules, CA) at 450 nm.
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Assessment of 3T3L1 adipocytes differentiation.
3T3L1 fibroblasts were induced to differentiate for 4 days as described [356]. On day
four, peritoneal macrophages or cytokines were added for 4 days. On day 8, adipocytes were
fixed with 2% paraformaldehyde at 4 oC for 15 minutes. The cells were washed twice with PBS
and were stained with Sudan IV saturated 70% isopropanol for 15 minutes. Cells were then
washed twice with 50% isopropanol. Cells were mounted on microscope slides using several
drops of glycerol and were viewed on a light microscope and photographed. To measure the
differentiation based on the amount of lipid present in the cells, absorbance was read at 500 nm
using a Packard SpectraCount spectrophotometer (Packard Instrument Company, Meriden, CT).
Statistical analysis
Data were analyzed by ANOVA. Sets with statistically significant F score were analyzed
for group-to-group variation using the least significant diference method (Fisher’s LSD). 
Differences were considered significantly different when p<0.05.
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RESULTS
Macrophage induced insulin resistance in 3T3L1 adipocytes.
To examine the impact of macrophages on insulin sensitivity of 3T3L1 adipocytes, we
first tested the hypothesis that cell-cell contact was required between macrophages and
adipocytes to affect the insulin responsiveness of 3T3L1 adipocytes. To test the hypothesis, we
examined the translocation of insulin-responsive GLUT4 from intracellular compartments to the
plasma membrane. This is a key process necessary for insulin-stimulated glucose uptake [381].
We evaluated whether the GLUT4 specific antibody for western blots would detect membrane-
located GLUT4 proteins in the plasma membrane. We expressed GLUT4-GFP in differentiated
3T3L1 cells. As described in the methods, we fixed cells with or without 0.2% Triton X-100.
We then probed the cells for GLUT4 protein with the rabbit anti-mouse GLUT4 antibody
followed by goat anti-rabbit IgG conjugated with Texas red. Permeabilized, unstimulated
adipocytes showed colocalization of GLUT4-GFP expressed intracellularly with endogenous
GLUT4 (Figure 15i), while nonpermeabilized cells expressed only GLUT4-GFP (Figure 15a).
Insulin-stimulated cells expressed GLUT4-GFP both intracellularly and on the plasma membrane
(Figure 15d). However, we only detected GLUT4 on the plasma membrane with anti-GLUT4
antibodies in nonpermeablized cells (Figure 15e). In contrast, we detected GLUT4
intracellularly and on the plasma membrane in permeabilized cells with the antibody probe
(Figure 15k).
Since the anti-GLUT4 antibody could detect both intracellular and plasma membrane
expressed GLUT4, we used it to determine if macrophages affect GLUT4 trafficking. In our first
experiment, we overexpressed GLUT4 in BHK cells. We cultured transfected BHK cells with
C2D macrophage cells for two days and we assessed GLUT4 translocation with the antibody
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Figure 15. Detection of GLUT4 in 3T3L1 adipocytes. GLUT4-GFP was expressed in
3T3L1 adipocytes (Panels a, d, g, j). Eighteen hours later, cells were incubated in serum-free
medium for 2 hours, then stimulated with (panels d, c, f, j, k, l) or without (panels a, b, c, g, h, i)
insulin, permeabilized (panels g-l), fixed (panels a-f) and immuno-stained (panels b, e, h, k) as
described in the Materials and Methods.
109
probe in cells positive for GLUT4-GFP described in our flow cytometry methods. In the absence
of insulin, BHK cells co-cultured with C2D macrophage cells expressed significantly less
membrane GLUT4 compared to BHK cells grown without C2D macrophage cells (Figure 16A).
With insulin stimulation, there was significantly more (p<0.05) translocation of GLUT4 from
intracellular storage compartments to the plasma membrane in the population of GLUT4-GFP
transfected BHK cells cultured alone than co-cultured with C2D macrophage cells (Figure 16A,
compare open bars, L to R, 1 & 3 and 2 & 4). However, membrane expressed GLUT4 levels
were much lower in cells cultured with C2D macrophage cells (Figure 16A, left 2 open bars). In
contrast, BHK cells transfected with the GFP-vector only, had no change in plasma membrane
GLUT4 expression (Figure 16A dark bars). We also examined the impact of C2D macrophage
cells on endogenous GLUT4 trafficking in differentiated 3T3L1 adipocytes to determine whether
macrophages would disrupt glucose trafficking. We co-cultured C2D macrophage cells with
3T3L1 adipocytes for 4 days by culturing them together so that they were in contact with one
another or by culturing them apart in transwell plates. In the absence of insulin, co-culture had
no impact on basal membrane GLUT4 expression (Figure 16B, open bars). However, there was
significantly less (p<0.05) membrane GLUT4 in 3T3L1 adipocytes directly co-cultured with
C2D macrophage cells compared to control 3T3L1 adipocytes after insulin stimulation (Figure
16B). An alternative analysis shows that the increase in insulin-stimulated translocation of
GLUT4 compared to basal transloaction was 2.3 fold more in adipocytes incubated alone. These
ratios were lower for adipocytes incubated with C2D macrophage cells, 1.6 and 1.5 in transwell
or direct co-culture, respectively (Figure 16B). C2D macrophage cells have an immature
phenotype and secrete small amounts of IL-6 and no TNF-or IL-1β in vitro[ 20]. Therefore; if
a combination of cytokines was necessary to alter GLUT4 metabolism, they may not be the most
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Figure 16. Macrophages inhibit insulin-stimulated translocation of GLUT4 but not
GLUT1. Cells were cultured in serum-free DMEM for 2 hours and then were stimulated with
insulin (100 nM) for 20 minutes. Cells were quickly dislodged from plates, fixed and
immunostained for flow cytometry as described in Materials and Methods. A) BHK cells were
transfected with GLUT4-GFP or GFP-N1 vector incubated with or without C2D macrophage
cells. B) 3T3L1 adipocytes were co-cultured with C2D macrophage cells directly or in transwell
plates for 4 days. The fold increase of plasma membrane GLUT4 upon insulin stimulation is
shown in the parentheses. C & D) 3T3L1 adipocytes were co-cultured with peritoneal
macrophages directly or in transwell plates for 4 days and assessed for plasma membrane
expression of GLUT4 or GLUT1. The fold increase of plasma membrane GLUT4 upon insulin
stimulation is shown in the parentheses. The data are presented as mean ± SEM (n= 3-6
independent replicates per treatment). Different letters indicate a significant difference. A p
value of < 0.05 was considered significant.
112
effective macrophages. To test this hypothesis, we co-cultured thioglycollate-elicited peritoneal
macrophages with 3T3L1 adipocytes for 4 days together in direct contact or separated in
transwell plates. The basal level of GLUT4 expressed on the adipocyte cell surface was greatly
decreased by macrophages in both culture orientations (Figure 16C). Moreover, insulin-
stimulated GLUT4 translocation was totally blocked in both experimental groups with the
insulin-stimulated increase over basal level, 1.2 and 1.0 fold for transwell and co-culture,
respectively (Figure 16C). We also measured the GLUT1 protein translocation in adipocytes in
direct or in-direct co-cultures with peritoneal macrophages and we observed no change in
GLUT1 trafficking in response to macrophages (Figure 16D).
To determine if changes in GLUT4 translocation were associated with decreased
transcription, we used RT-PCR to measure the mRNA levels of ACDC (adiponectin), GLUT 4
and GLUT1 in 3T3L1 cells cultured alone, directly co-cultured with peritoneal macrophages or
cultured in transwells. We added macrophages into the transwells at day 0, day 4 or day 8 after
inducing differentiation and co-cultured them for 4 days after which RNA was isolated. We
observed increased transcript levels of all three genes, GLUT4, GLUT1 and ACDC, in adipocytes
as they differentiated. The GLUT4 gene transcript level in adipocytes was lower after 4 days of
culture with peritoneal macrophages throughout all the differentiation process in transwell plates
(Figure 17A and 17D). However, the impact was most pronounced on cells during days 4-8 and
days 8-12 (p<0.05) of differentiation. We did not see any differences in ACDC (Figure 3A and
3B) and GLUT1 (Figure 17A and 17C) transcript levels between adipocytes alone or adipocytes
with macrophages. Therefore, the impact of macrophages was specifically on insulin-stimulated
glucose metabolism.
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Figure 17. 3T3L1 adipocyte GLUT4 transcription is inhibited by macrophages. 3T3L1
adipocytes were cultured in the bottom of transwell plates and peritoneal macrophages were
cultured in the top chamber for 4 days as described in Materials and Methods. Total RNA of
3T3L1 adipocytes was extracted and mRNA levels were analyzed by RT-PCR. Ratio of gene:
actintranscript was determined using densitometry. A) RT-PCR result of ACDC, GLUT1,
GLUT4 and-actin. A, adipocytes only, T, adipocytes co-cultured with macrophages by
transwell B) ACDC normalized toactin. C) GLUT1 normalized toactin. D) GLUT4
normalized toactin. The data are presented as mean ± SEM (n= 3 independent replicates per
treatment). Different letters indicate a significant difference. A p value of < 0.05 was
considered significant.
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Cytokine secretion in 3T3L1 adipocytes and peritoneal macrophage co-cultures.
Since GLUT4 translocation was inhibited in transwell cultures with macrophages, it
suggested that cytokines played a role in the adipocyte-macrophage interaction [222, 369]. We
assessed an array of cytokines for changes during macrophage-adipocyte co-culture including:
IFN-, IL-1α, IL-2, IL-4, IL-5, IL-10, IL-17, and GM-CSF (data not shown). However, only IL-
1, TNF-and IL-6 were altered in the co-cultures by the presence of macrophages. Therefore,
we examined the TNF-IL-1and IL-6 concentrations in supernatant from macrophage and/or
adipocyte cultures by ELISA. Both macrophages and 3T3L1 adipocytes secreted TNF-IL-
1and IL-6 (Figure 18). For this reason, we compared the cytokines in supernatants from co-
cultures to the sum of the secretion (SUM) by 3T3L1 cells and macrophages when they were
cultured alone. We found the concentrations of IL-1Figure 18Cand TNF-(Figure
18A)were significantly lower in both direct and in-direct (transwell) co-cultures. However,
there was a difference between the amount of IL-6 detected in direct co-culture and transwell
cultures. Whereas IL-6 was significantly lower compared to SUM in transwell cultures, it was
significantly higher when macrophages and adipocytes were cultured directly together (Figure
18B).
Cytokine inhibition of insulin-stimulated GLUT4 translocation.
Transwell co-culture of macrophages and adipocytes greatly inhibited GLUT4
translocation to the adipocyte plasma membrane. Since the inhibition was independent of cell-
cell contact and TNF-, IL-6 and IL-1were present in the co-cultures, we hypothesized that
GLUT4 trafficking would be affected by the proinflamatory cytokines. To test this hypothesis,
we treated fully differentiated 3T3L1 adipocytes with TNF-IL-1or IL-6 for 48 hours and
measured the plasma membrane translocation of GLUT4 by flow cytometry. We first tested the
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Figure 18. Secretion of TNF-IL-6 and IL-1in macrophage and 3T3L1 adipocytes co-
cultures. 3T3L1 adipocytes and peritoneal macrophages were incubated alone or were directly
mixed together or in transwell plates for 4 days (from day 8 to 12 in adipocyte differentiation).
Supernatants were collected and cytokine concentrations were determined by ELISA. A) TNF-
; B) IL-6 C) IL-1The data are presented as mean ± SEM (n= 3-6 independent replicates
per treatment). Different letters indicate a significant difference. A p value of < 0.05 was
considered significant.
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Figure 19. Effects of TNF-IL-6 and IL-1on insulin-stimulated GLUT4
translocation. Fully differentiated adipocytes were incubated in recombinant mouse TNF-
ng/ml)IL-6 (10 ng/ml) or IL-1ng/mlfor 2 days. Cells were serum starved for 2
hours and then were treated with insulin (100 nM) for 20 minutes. Cells were fixed and analyzed
by flow cytometry as described in the Materials and Methods. The data are presented as mean ±
SEM (n= 3-6 independent replicates per treatment). Different letters identify a significant
difference between control and treatments. A p value of < 0.05 was considered significant.
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effects of TNF-pg/ml) IL-1pg/mland IL-6 (2 ng/ml) in the concentration ranges
of what we detected in supernatants of transwell co-culture during our experiments.
Interestingly, no significant decrease of insulin-stimulated GLUT4 translocation occurred with
any of those treatments (Data not shown). There also was no effect when we mixed the three
cytokines together at those concentrations (data not shown). It is possible that cytokine
concentrations measured did not reflect the amount of cytokine that was consumed and/or
degraded during the co-culture process. Therefore, we treated 3T3L1 adipocytes with higher
concentrations of TNF-2 ng/ml)IL-1ng/mlor IL-6 (10 ng/ml) for 48 hours. Under
these conditions, the number of GLUT4 molecules translocated to the plasma membrane with or
without insulin stimulation was reduced with all three cytokines treatments (Figure 19).
TNF-IL-1and IL-6 decrease GLUT4 transcription and expression.
Since high concentrations of TNF-IL-1or IL-6 inhibited GLUT4 translocation to the
adipocyte plasma membrane, we examined the effects of TNF-IL-1and IL-6 on GLUT4
gene transcription. We treated fully differentiated adipocytes with TNF-ng/ml)IL-
1ng/mlor IL-6 (10 ng/ml) for 48 hours and subsequently measured the ACDC, GLUT1
and GLUT4 mRNA levels by semi-quantitative RT-PCR. We showed TNF-but neither IL-1
nor IL-6, significantly decreased adiponectin transcript levels (Figure 20A and 20B). No
cytokine affected GLUT1 gene transcripts (Figure 20A and 20C). However, GLUT4 transcript
levels were reduced by TNF-and IL-6, but not IL-1Figure 20A and 20D). We assessed the
action of TNF-IL-1and IL-6 on GLUT4 protein expression using flow cytometry to measure
the total GLUT4 protein in 3T3L1 adipocytes. Treatment of adipocytes with TNF-IL-1or
IL-6 all significantly decreased total GLUT4 protein level (Figure 21A), but not GLUT1 proteins
(Figure 21B).
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Figure 20. Effects of TNF-IL-6 and IL-1on GLUT4 gene transcription. Fully
differentiated 3T3L1 adipocytes were incubated in recombinant mouse TNF-ng/ml)IL-6
(10 ng/ml) or IL-1ng/mlfor 2 days. Total RNA was extracted and transcript levels were
analyzed by RT-PCR. Ratio of gene:actin expression was determined by densitometry. A)
RT-PCR result of ACDC, GLUT4, GLUT1 and-actin. B) ACDC normalized toactin. C)
GLUT1 normalized toactin. D) GLUT4 normalized toactin. The data are presented as
mean ± SEM (n= 3 independent replicates per treatment). Different letters indicate a significant
difference. A p value of < 0.05 was considered significant.
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Figure 21. Effects of TNF-IL-6 and IL-1on GLUT4 protein expression. Fully
differentiated adipocytes were incubated in recombinant mouse TNF-ng/ml) IL-6
(10ng/ml) or IL-1ng/mlfor 2 days. Cells were fixed and immuno-stained for GLUT1 and
GLUT4 expression using flow cytometry as described in Materials and Methods. The data are
presented as mean ± SEM (n= 3-6 independent replicates per treatment). Different letters
indicate a significant difference. A p value of < 0.05 was considered significant.
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TNF-, IL-6, and IL-1affect Akt phosphorylation differently.
GLUT4 translocation is triggered by insulin because PI3K activation leads to
phosphorylation of the Akt protein within 15 minutes after insulin treatment [47]. Therefore, we
evaluated the impact of TNF-IL-1and IL-6 on Akt phosphorylation using flow cytometry.
Total cellular Akt protein levels were not altered by any of the treatments (Figure 22A).
However, when we measured the phosphorylation of p473-Akt at 0, 5, 10, 15 and 30 minutes
after insulin stimulation, we observed peak phosphorylation at 15 minutes and by 30 minutes
phosphorylation was diminishing (Figure 22B). The time-dependent phosphorylation pattern of
adipocytes treated with IL-was the same as the control (Figure 22B). In contrast, Akt
phosphorylation remained at baseline levels for 30 minutes observation in adipocytes treated
with IL-6 (Figure 22B) with almost 100% inhibition. However, TNF-did not completely block
insulin signaling. It delayed the phosphorylation of Akt for approximately 10 minutes.
o confirm that IL-6 and TNF-inhibited the phosphorylation of Akt 15 minutes after
insulin stimulation; we treated cells with different concentrations of IL-6 or TNF-for 48 hours.
We then stimulated the cells with insulin and measured phosphorylated Akt after 15 minutes.
There was a dose dependent inhibition of Akt phosphorylation by IL-6 or TNF-(Figure 22C).
TNF-IL-6 and IL-1inhibit 3T3L1 differentiation.
We observed that GLUT4 transcription increased as 3T3L1 adipocytes became more
differentiated (Figure 3). Co-culturing 3T3L1 with peritoneal macrophages led to significant
inhibition of GLUT4 translocation (Figure 19). It was reported that macrophage infiltration
inhibited adipocyte differentiation [382]. Therefore, the impact macrophages have on GLUT4
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Figure 22. TNF-IL-6 and IL-1affect Akt phosphorylation differently. Fully
differentiated adipocytes were incubated with recombinant mouse TNF-IL-6 or IL-1for 2 days. Cells
were serum starved for 2 hours, stimulated with insulin (100nM) for 20 minutes, fixed and assessed for
Akt and p-Akt by flow cytometry as described in Materials and Methods. A) Total Akt protein levels
were detected after treatment with cytokines. Normalized to control set to 1. B) p-Akt was detected at 0,
5, 10, 15 or 30 minutes after insulin stimulation. C) Fully differentiated adipocytes were incubated in
DMEM10 containing TNF-IL-6 or IL-1for 2 days. p-Akt was detected at 15 minutes after insulin
stimulation. The data are presented as mean ± SEM (n= 3-6 independent replicates per treatment). An
asterisk identifies a significant difference between control (no cytokines treatment) and treatments each
time point. A p value of < 0.05 was considered significant.
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Figure 23. TNF-IL-6 and IL-1on 3T3L1 adipocyte differentiation. 3T3L1 cells were
differentiated for 4 days with peritoneal macrophages in direct co-culture or in transwells. Cells
were fixed and stained with Sudan IV dye as described in Materials and Methods. A) Cells were
imaged at 200X magnification on a light microscope B) Lipid concentration was determined by
measuring absorbance at 550 nm. Different letters indicate a significant difference. C) 3T3L1
cells were differentiated for 4 days and treated with TNF-IL-6 or IL-1for additional 4 days.
(For TNF-, high: 2 ng/ml, medium: 1 ng/ml, low: 0.5 ng/ml; for IL1-, high: 20 ng/ml,
medium: 10 ng/ml, low: 1 ng/ml; for IL-6, high: 10 ng/ml, medium: 5 ng/ml, low: 2 ng/ml). At
day 8, cells were fixed and stained by Sudan IV as described in Materials and Methods.
Differentiation was determined by measuring absorbance at 550 nm. The data are presented as
mean ± SEM (n= 3-6 independent replicates per treatment). An asterisk identifies a significant
difference between control and treatments of each time point. A p value of < 0.05 was
considered significant.
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trafficking and Akt phophorylation would be compounded if macrophages also inhibited
adipocyte differentiation. To test this possibility, we assessed adipocyte differentiation using
Sudan IV staining to detect increasing intracellular lipid as adipocytes differentiated. We
observed less Sudan IV staining in 3T3L1 cells co-cultured with peritoneal macrophages
compared to controls regardless of whether the macrophages and adipocytes were separated in
transwells or were mixed together (Figure 23A). We found a macrophage number-dependent
inhibition of 3T3L1 adipocyte differentiation (Figure 23B). We also assessed the effects of
TNF-IL-6 and IL-1on 3T3L1 differentiation. Adipocytes were incubated with varying
concentrations of cytokines ranging from 0.5-2 ng/ml of TNF-, 1–20 ng/ml of IL1-and 1-10
ng/ml of IL-6 for 4 days and were then assessed for differentiation using Sudan red. Ten ng/ml
of IL-6 had the most pronounced inhibition on differentiation, causing a 24% decrease in lipid
accumulation. Lower concentrations of IL-6 had a more modest inhibitory effect. Only 20
ng/ml of IL-1was significantly inhibitory, reducing lipid accumulation on average of 17%
(p<0.05). Two concentrations of TNF-were inhibitory (p<0.05), but they only inhibited
differentiation at most by 10% (2 ng/ml). These data support the hypothesis that TNF-IL-6
and IL-1affect glucose transport by partially inhibiting 3T3L1 adipocyte differentiation.
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DISCUSSION
According to the World Health Organization, more than 1 billion adults are overweight or
clinically obese worldwide [383]. Obesity is now known as an inflammatory disease with
pathologies similar to type 2 diabetes [384]. It is also associated with increased risk of diabetes
mellitus and decreased glucose sensitivity [369]. We studied how macrophages affect adipocyte
GLUT4 in this investigation and provide the most comprehensive analysis of this process to date.
We demonstrated that macrophages inhibited insulin-stimulated GLUT4 translocation in
adipocytes by a contact-independent process. This is consistent with data showing that
macrophage-conditioned medium blocked insulin-stimulated GLUT4-eGFP translocation and
that TNF-decreased 3T3L1 adipocyte GLUT4 protein levels [190]. The inhibition of GLUT4
could be partially due to decreased transcription since we found lower GLUT4 transcript levels in
3T3L1 adipocytes in adipocyte-macrophages transwell co-cultures (Figure 17D). Unlike
Lumeng et al, we have found a significant inhibition of GLUT4 translocation both in the basal
state (ie. No insulin) and upon insulin stimulation. Part of the discrepancy may be because they
over-expressed GLUT4 in 3T3L1 cells, which may have affected the natural regulation of the
protein.
We found that C2D macrophage cells did not inhibit GLUT4 translocation as effectively
as peritoneal macrophages. C2D macrophage cells maintained in vitro have an immature
macrophage phenotype, expressing Ly-6C [26], a marker for monocytes and immature
macrophages and do not make TNF-and IL-1[162]t appears their effectiveness is limited
to the impact of their secretion of IL-6. Leumeng et al. also found that unstimulated macrophage
medium did not inhibit GLUT4 translocation [190]. Therefore, these data are consistent with the
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hypothesis that macrophages induce insulin resistance by secreting proinflamatory cytokines and
that contact is not necessary (Figure 16).
Although peritoneal macrophages effectively inhibited GLUT4 translocation, they did not
inhibit GLUT1 transport. Moreover, we did not observe any changes in GLUT1 protein level
when adipocytes were incubated with proinflamatory cytokines. This contrasts observations
where adipocyte basal glucose uptake was increased by macrophages [190]. GLUT1 regulates
basal glucose metabolism and it is constitutively localized at the plasma membrane [385].
Therefore, macrophages only inhibit insulin-regulated glucose uptake which requires active
mobilization of the molecule [44].
The inhibition of GLUT4 trafficking by macrophage cytokines and observations that
macrophages secrete TNF- in response to adipocytes exemplifies the paracrine interaction
between the two cell types [386]. Lumeng et al. reported moderate but significantly enhanced
TNF secretion in macrophage-adipocyte co-cultures compared to what was secreted by
macrophages alone [190]. Adipocytes also secret TNF-IL-6 and IL-
1Thereforeconclusions based on macrophage secretion alone may not be valid. Indeed,
except for IL-6 when macrophages and adipocytes were directly co-cultured, the amount of
secreted proinflammatory cytokines was significantly less than the sum of what macrophages
and adipocytes made on their own (Figure 18). Our data suggest that the cytokines were
metabolized, downregulated or were degraded. ranscription ofTNF-and IL-1are regulated
through NF-B pathway [387]. Therefore, it is not surprising that they paralleled each other. It
is possible that cytokine concentrations were lower in co-cultures because adipocytes secreted
adiponectin, which suppressed TNF-and IL-6 production [127]. However, the concentration of
adiponectin detected in our co-cultures was much lower than the reported in vitro inhibitory
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concentration (1.2 mg/ml vs. 30 mg/ml). Therefore, it is unlikely that it inhibited those
cytokines. Since we also did not find decreased macrophage TNF-IL-6 and IL-
1transcription when adipocytes and macrophages were co-cultured (Data not shown), the
proinflammatory cytokines were most likely consumed or degraded. Moreover, except for IL-6
we cannot conclude that macrophages secreted more of these cytokines in response to the
adipocytes.
Although TNF-, IL-6 and IL-1contributed to insulin resistance by inhibiting the
expression of the GLUT4 receptor on 3T3L1 adipocytes (Figure 19), the cellular mechanisms
involved are still being defined. One mechanism may be that cytokines directly inhibit protein
synthesis [190]. Stephen and Pekela found that as little as 5nM of TNF-was able to inhibit
GLUT4 and C/EBP transcription [388] and altered the mRNA half life [389], which could lead to
the protein decrease. However, Niu et al. have suggested that GLUT4 transport is independent
of its activation in the plasma membrane and proinflammatory cytokines inhibit p38 MAPK
from activating the molecule at the plasma membrane [390]. Alternatively, TNF-activates
sphingomyelinase. This enzyme releases ceramide, inhibits the GLUT4 promoter [391],
depresses GLUT4 transcription [389], and which could ultimately affect glucose transport.
Another mechanism involves protein kinase B (also called Akt). Medina et al. reported that a 6
hr TNF- treatment caused Akt degradation in adipocytes [192]. Together with our
demonstration that TNF- and IL-6 decreased GLUT4 translocation and inhibited
phosphorylation of Akt suggests that Akt signal transduction is important to GLUT4 synthesis
and transcription directly or through other critical signaling molecules like PI3-kinase. Indeed,
Sun et al. demonstrated that the expression of silent mating type information regulation 2
homolog 1 (SIRT1) reversed insulin resistance and the absence of SIRT1 in muscle cells
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inhibited Akt phophorylation [392]. Interestingly, treatment of adipocytes with TNF-reduced
ACDC transcription and may partially explain how TNF-induced insulin resistance [97]. Our
data also support that argument. Lastly, TNF-induces the secretion of other cytokines by
adipocytes including IL-6, macrophage chemotactic protein-1 (MCP-1; CCL2), and even TNF-
[393] which can alter GLUT4 trafficking. Therefore, it appears that the development of
insulin resistance may be exacerbated by increased macrophage activation by the production of
multiple cytokines, some of which come from adipocytes themselves impacting multiple
signaling mechanisms.
Although our data are consistent with observations that IL-6 can promote insulin
resistance [206, 207], it contrasts the observation that IL-6 enhances glucose transport in 3T3L1
adipocytes [376]. Carey et al. showed treatment of IL-6 for 120 minutes increased fatty acid
oxidation, basal and insulin-stimulated glucose uptake, and translocation of GLUT4 to the
plasma membrane in L6 myotubes [287]. Their observation along with ours suggests that short
treatments of IL-6 have opposite effects from longer treatments (2 days). Alternatively, the
concentrations of IL-6 may be critical to the outcome. Additional side-by-side comparisons will
be necessary to resolve this discrepancy. Nevertheless, we found that Akt phosphorylation was
effectively inhibited by IL-6. Since Akt signaling is critical to GLUT4 translocation to the
plasma membrane [394], our observations are internally consistent and are supported by
observations that IL-6 inhibits IRS-1 expression which is also important for Akt phosphorylation
and signaling [207].
IL-1β also inhibited insulin-induced GLUT4 translocation. However, whereas TNF-
and IL-6 treatments were effective at cytokine concentrations in ranges close to those found in
macrophage-adipocyte co-cultures (e.g. IL-6, 8 ng/ml detected compared to 10 ng/ml that was
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needed to activate; TNF-, 250 pg/ml detected compared to 2 ng/ml that was needed to activate),
we had to use extremely high concentrations (20 ng/ml needed to activate compared to 10 pg/ml
in co-cultures) of recombinant IL-1β to see an efect. Jager et al. [226] also found that 20 ng/ml
of IL-1β inhibited insulin-stimulated GLUT4 but not GLUT1 translocation in adipocytes.
Therefore, it is clear that high concentrations of IL-1β can be inhibitory.  These data are also 
consistent with observations that treating adipocytes for a long time, e.g. 6-10 days, inhibit signal
transduction important to glucose transport (IRS-1, Akt and Erk 1 / 2) in both human and mouse
adipocytes [377]. Interestingly, although we saw that high concentrations of IL-1β could afect 
GLUT4 translocation, we did not see an effect on Akt phosphorylation. Therefore, IL-1β may 
inhibit insulin-stimulated glucose transport by nonspecific mechanisms compared to either TNFα 
or IL-6, which inhibited Akt phosphorylation (Figure 22B). Therefore, IL-1β may function most 
effectively because it synergizes with IL-6 and TNFα not because it works by itself.
Macrophages not only inhibited GLUT4, they also inhibited the differentiation of
adipocytes by secreting IL-1IL-and TNF-Figure. t is now recognized that the
stromal-vascular compartment of adipose tissue contains various precursor and stems cells,
which populate different cell lineages in vivo and in vitro [227]. Among the stromal cells, there
are preadipocytes that differentiate into adipocytes [227]. Weisberg et al. [174] and Xu et al.
[229] reported that inflammatory macrophages accumulated around small adipocytes, possibly to
promote cell apoptosis. Constant et al. reported that macrophage-conditioned medium inhibited
the differentiation of 3T3L1 and human abdominal preadipocytes [395]. IL-1and TNF-
inhibited adipogenesis directly [396, 397]. Therefore, we have confirmed those data. This
inhibition probably was caused by suppression of PPAR-and NF-B [398]. However, we did
not test that hypothesis directly.
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In summary, our data suggest that macrophages induce insulin resistance in adipocytes by
secreting a proinflamatory cocktail that inhibits insulin action, disrupts glucose uptake, and
inhibits adipocyte differentiation. Whereas others have suggested that TNF-plays a leading
role in this process [190, 396], our data suggest that IL-6 is the most potent of the individual
proinflammatory cytokines. C2D macrophage cells only make IL-6 in vitro but could still inhibit
GLUT4 translocation (Figure 16). IL-6 was the only cytokine to be increased in macrophage-
adipocyte co-cultures (Figure 18) and to completely inhibit Akt phosphorylation (Figure 22). It
also had the most significant impact on adipocyte differentiation (Figure 23).  This isn’t to say 
that IL-1and TNF- don’t affect adipocytes.  Indeed, al these proinflammatory cytokines 
impaired adipocyte function in ways that contributed to the development of insulin resistance.
We suggest that IL-1and TNF-acted in synergy with IL-6. Thus, insulin resistance will be
difficult to regulate because of the multifactorial impact and complex nature of the adipocyte-
macrophage interaction.
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CHAPTER 5
PHENOTYPIC CONVERTION OF C2D MACROPHAGE
CELLS IN
BROWN AND WHITE ADIPOSE TISSUE
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ABSTRACT
Macrophage populations exhibit a wide range of functional phenotypes depending on
environmental stimuli. C2D macrophage cells reside early in the macrophage lineage in vitro,
but differentiate to a more mature pro-inflammatory phenotype after adoptive transfer to and
isolation from the peritoneal cavity. These C2D macrophage cells expressed higher transcript
levels of pro-inflammatory cytokine genes after co-culture with 3T3L1 adipocytes in vitro for 2
days. After intraperitoneal injection, C2D macrophage cells migrated into both white adipose
tissue (WAT) and brown adipose tissue (BAT). C2D macrophage cells isolated from WAT
expressed high level of Ly-6C, CD11b, Mac-2 and F4/80, while C2D macrophage cells isolated
from BAT expressed very low levels of those molecules. Although TNF-, IL-6 and IL-1, and
Fizz-1 transcript levels significantly increased in C2D macrophage cells isolated from WAT
compared to C2D macrophage cells in vitro, only the transcript levels of IL-1and Fizz-1 were
elevated in C2D macrophage cells isolated from BAT. These data suggest that C2D macrophage
cells exhibit distinct functions and phenotypes in BAT and WAT and that the phenotype switch
occurs in less than 2 days.
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INTRODUCTION
Macrophages are present in every tissue in the body. Macrophages contribute
significantly to innate defense against microorganisms and the responsiveness of the adaptive
immune system because of their heterogeneous capabilities. Heterogeneity can be generated
through differentiation-related mechanisms, activation by foreign bodies by endogenous stimuli
[399, 400]. After monocytes/macrophage migration into a tissue the environment significantly
influences the function of macrophages such that macrophages residing in different tissues
display distinct functional patterns [401, 402]. White adipose tissue (WAT) and brown adipose
tissue (BAT) have distinct physiological functions. WAT is an energy storage organ as well as an
endocrine organ [75, 76]. In contrast, BAT functions as an energy-dissipating organ through
adaptive-thermogenesis [403]. Adipocytes of WAT contain a single large lipid droplet, while
adipocytes of BAT have multiple lipid droplets of varying size and contain many mitochondria
packed with cristae [74]. While WAT is distributed into multiple subcutaneous and visceral
deposits [404], BAT is primarily localized around bodily organs [405]. BAT is highly
vascularized for high blood flow to meet the requirements of the brain, spinal cord, heart, lungs
and kidneys during cold stress [79].
In the last few years, there has been increased study on the role of macrophages in WAT.
Proinflammatory cytokines such as TNF-, IL-6 and IL-1are thought to contribute to insulin
resistance induction and are closely related to increased immigration of inflammatory
macrophages in obese and diabetes patients [76, 131, 206, 226, 406, 407]. In contrast, resident
macrophages, activated under the control of PPAR-γ in white adipose tissue, enhance insulin 
sensitivity in adipocytes, and have an alternative macrophage phenotype [182]. Despite of
increased study of macrophages in WAT, the macrophages in BAT are poorly understood.
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Macrophages express polarized functional properties during inflammation and many of
these activities appear to the antagonistic: proinflammatory versus anti-inflamatory,
immunogenic versus tolerogenic, and tissue-destruction versus tissue-angiogenesis [402].
Based on these properties, macrophages are classified as either classically (M1) or
alternatively (M2) activated macrophages [179]. M1 macrophages express proinflammatory
cytokines, such as TNF-, IL-6 and IL-1. M2 cells are characterized as anti-inflammatory
macrophages during type I inflammatory responses to promote angiogenesis and wound healing
[408]. To study M2 macrophages, Ghassabeh et al have define M2 macrophages by their
expression of Fizz1 (Found in inflammatory zone 1; reistin like alpha), Arginase-1 and YM-1
(also called T-lymphocyte-derived eosinophil chemotactic factor (ECF-L) of M2 [409].
In a previous study, we have found that macrophages induced insulin resistance in
adipocytes by altering GLUT4 gene transcription, GLUT4 protein expression and translocation
and inhibited preadipocytes differentiation. Our working hypothesis is that there is a synergistic
interaction between adipocytes and macrophages. Given that macrophages adapt to
microenvironmental signals and little is known about BAT-macrophage interactions, we assessed
the immediate impact of BAT and WAT on macrophages with a special emphasis on the
immediate response of macrophages when they enter WAT and BAT in vivo.
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MATERIALS AND METHODS
Mouse strains.
C57BL/6J (B6, MHCII+/+, Tlr4Lps-n) mice were originally obtained from the Jackson
Laboratory (Bar Harbor, ME). All mice were bred in the rodent facility of the Division of
Biology at Kansas State University. All animal experiments were approved by the Institutional
Animal Care and Use Committee.
Antibodies and Reagents.
Antibodies and corresponding isotypes are listed on table 1. Collagense (Type II), insulin
from bovine pancreas, 3-Isobutyl-1-methylxanthine (IBMX), and dexamethasone were obtained
from Sigma-Aldrich Co. (St. Louis, MO). Carboxyfluorescein diacetate, succinmidyl ester was
purchased from Molecular probes (CFDA-SE, Molecular Probes, Eugene, OR)
Cell lines and cell culture.
The C2D macrophage cell line was created as described by our group [378]. These cells
were derived from C2D murine bone marrow and selected in the presence of CSF-1. These
cells have the MHCII-/- and Tlr4Lps-n genotype and are histocompatible with mice of the H-2b
haplotype. C2D cells were grown in Dulbecco’s Modified Eagle’s Mediumwith 4% serum
(DMEM4) supplemented with 0.3% Glutamax and 10% Opti-MEM in 150-mm tissue culture
plates.
3T3L1 adipocytes were obtained from the American Type Culture Collection (Manassas,
VA). Adipocytes were cultured and differentiated as described previously [356]. Briefly, 3T3L1
cell differentiation was induced by culturing cells in DMEM with 10 % calf serum (DMEM10)
containing 1 dexamethasone, 1.7 M insulin and 0.5 mM IBMX for 4 days. On the fourth
day, the 3T3L1 cells were cultured in DMEM10 with 1.7M insulin. On day 8, 3T3L1 cells were
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maintained in DMEM10. Preadipocytes without differentiation and adipocytes differentiated for
6-8 days were used in the experiments.
3T3L1 cells (1×106 cells) were directly co-cultured with 1×105 C2D cells grown
exclusively in vitro or 1×106 cells adoptive transferred C2D macrophage cells reisolated from the
peritoneal cavity.
Adoptive transfer of labeled cells.
C2D cells were suspended in sterile, pre-warmed (37oC) Phosphate Buffered Saline
(PBS; 137 mM NaCl, 10 mM Phosphate, 2.7 mM KCl, pH 7.4) at a concentration of 1.5 x 106
cells per ml, further stained with CFDA-SE according to the manufacturer’s protocol. Briefly, 
C2D cells were incubated with 22 M of CFDA-SE solution at 37 oC for 15 minutes. After
centrifugation at 370 x g for 10 minutes, cell pellets were suspended in pre-warmed PBS and
incubated in 37oC for an additional 20 minutes. Cells were then washed twice in PBS, and
suspended at a concentration of 3 x 107 cells/ml in PBS. One and one-half ml of the cell
suspension of CFDA-SE labeled C2D or normal C2D cells was injected intraperitoneally (i.p.)
per mouse.
Peritoneal cells extraction and fat tissues isolation
C2D macrophage cells were obtained from C57BL/6J mice by peritoneal lavage 36 hours
after intraperitoneal injection of 4 x 107 of C2D macrophage cells labeled with CFDA-SE. The
peritoneal exudates were incubated in ammonium chloride lysis buffer (0.15M NH4Cl, 10mM
KHCO3, 0.1mM Na2EDTA, pH=7.3) for 5 minutes on ice to burst red blood cells. One-half of
the cells were treated with 1 mg/ml collagenase type II at 37oC with shaking (60 rpm) for 40
minutes. Control or collagenase treated cells were washed three times with PBS and 3 x 106 cells
were plated into 15 cm cell culture plates and incubated in DMEM4 for 16 hours.
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Isolation of adipocytes and CFDA-SE labeled C2D macrophage cells was performed as
previously described [357, 410]. Adipocytes were isolated from B6 mice epididymal fat pads and
perispleen adipose tissues by collagenase digestion [411]. The fat pads were minced in pre-
warmed (37oC) Krebs-Ringer phosphate (KRP) buffer (12.5 mM HEPES, 120 mM NaCl, 6 mM
KCl, 1.2 mM MgSO4, 1 mM CaCl2, 0.6 mM Na2HPO4, 0.4 mM Na2PO4, 2.5 mM D-glucose, and 2
% bovine serum albumin, pH 7.4) and incubated with Type II collagenase (1mg/ml) for 40 min at
37°C with constant shaking at 60 rpm. Cells were centrifuged at 370 x g for 1 minute. The
adipocytes isolated from epididymal fat pads were separated into 2 major fractions. The floating
upper layer was primarily white adipocytes and the pelleted fraction was a mixture of stromal-
vascular fraction (SVF) cells containing macrophages. Both cell fractions were collected and
washed twice with KRP buffer. The adipocytes isolated from perispleen adipose were collected
from the cell pellets and washed twice with KRP buffer.
A mixture of white adipocytes (upper layer) and SVF cells was co-incubated at 37°C in
DMEM10, pH 7.4, for 16 hours at a concentration of 1 x 105 cells/ml in the 15-cm culture plate.
The adipocytes remained dispersed in the medium and the SVF cells attached to the 15-cm
culture plate. Brown adipocytes from perispleen adipose tissue (3 x 106) were cultured at 37°C in
DMEM10 in a 15 cm culture plate for 16 hours.
Flow cytometry analysis.
C2D macrophage cells isolated from peritoneal cavity, WAT and BAT were detached
with 0.02% EDTA and resuspended in DMEM4. Cells were transferred to wells of 96-well,
round-bottom plates and they were blocked with PBS-goat serum (50%-50%; 50 μl) at 4 oC for
0.5 hour. Subsequently, macrophage cell surface proteins were marked by direct or indirect
labeling. Antibodies and isotypes concentrations are shown in Table 1. For direct labeling,
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Table 1. Antibodies used for flow cytometry analysis
Conjugate Type Company Cat #
CD11c (Integrin
M, Mac-1)
APC DA eBioscience 17-0114-82
IgG APC ISO eBioscience 17-4888-82
F4/80 APC DA eBioscience 17-4801-82
IgG2a APC ISO eBioscience 17-4321-81
CD11b APC DA eBioscience 17-0112-82
IgG2b APC ISO eBioscience 17-4031-82
Mac 2 (galectin-3) ALEXA
Fluor 647
DA eBioscience 51-5301-82
IgG2a ALEXA
Fluor 647
ISO eBioscience 51-4321-80
c-fms-(CD115) Biotin PA eBioscience 13-1152-82
IgG2a Biotin ISO eBioscience 13-4321-82
Streptavidin APC SA eBioscience 17-4317-82
Ly-6C (ER-MP20) Biotin PA BD
Pharmingen
557359
IgM Biotin ISO BD
Pharmingen
559941
Streptavidin APC SA eBioscience 17-4317-82
APC: Allophycocyanin
DA: Direct antibody, PA: Primary antibody, SA: Secondary antibody, and
ISO: Isotype
eBioscience Inc, San Diego, CA
BD Pharmingen, San Jose, CA
blocked cels were incubated with the specific antibody or isotype diluted in Hank’s Buffered 
Salt Solution (HBSS; 0.137 M NaCl, 5.4 mM KCl, 0.25 mM Na2HPO4, 0.44 mM KH2PO4, 1.3
mM CaCl2, 1.0 mM MgSO4, 4.2 mM NaHCO3) for 1 hour in the dark at 4oC. After two washes
with HBSS, cells were fixed in 1% formalin. For indirect labeling, blocked cells were incubated
for 1 hour with primary antibody or isotype antibody diluted in HBSS for a total volume of 50
μl. Incubation continued in the dark for 1 hour at 4oC. Thereafter, cells were washed twice with
HBSS. Secondary antibodies diluted in HBSS for a 50 μl final volume were added to the cells
and incubation proceeded for 40 min in the dark at 4oC. Cells were washed twice with HBSS and
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they were fixed in 1% formalin. Labeled cell surface proteins were assessed by flow cytometry.
Only CFDA-SE-positive cells were scored for the presence of absence of the selected markers.
FACS analysis
Cells from peritoneal lavages, BAT and SVF cells from WAT were sorted by FACS
analysis as described previously [410]. Cell sorting was based on C2D macrophage cell CFDA-
SE fluorescence, with the lowest 10 % of the positive cells not selected. Briefly, cell sorting was
performed with a FACSVantage SE cell sorter (Becton Dickson. Rockville, MD) using specimen
optimization and calibration techniques according to the manufacture’s recommendations. Cels 
were sorted at a rate of 15,000 cells per second and approximately 1 x 106 positive cells per
group were collected on ice for RT-PCR analysis.
One-step RT-PCR analysis.
Total RNA was extracted from cells by Tri-Reagent (Molecular Research Center Inc)
according to the manufacturer’s protocol with some modification. One-step RT-PCR was
Table 2. Primers for RT-PCR
Forward (5’ to 3’) Reverse (5’ to 3’)
TNF- NM_013693 gggatgagaagttcccaaatg ctccagctggaagactcctcccag
IL-6 NM_031168 Ttcctctctgcaagagact tgtatctctctgaaggact
IL-1 NM_008361 caggcaggcagtatcactca aggccacaggtattttgtcg
Arg-1 NM_007482 acctggcctttgttgatgtcccta aaggtctcttccatcaccttgcca
Ym-1 M94584 ttccaaggctgctactcacttcca agaccacggcacctcctaaattgt
Fizz-1 NM_023881 tccagctgatggtcccagtgaata aagctgggttctccacctcttcat
-actin NM_007393 tcctgtggcatccacgaaact gaagcatttgcggtggacgat
performed using the Access RT-PCR Core Reagents from Promega according to the
manufacturer’s protocol. Primers were designed using Primer3 software
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(http://frodo.wi.mit.edu/) using sequence data from NCBI sequence database. Primer sequences
(forward/reverse) are shown in Table 2. The RT-PCR products were visualized under UV light
by the use of a FluorChem
TM
8800 Advanced Imaging System (Alpha Innotech, San Leandro,
CA). The relative density of the target band was normalized to the β-actin loading control and
then expressed as a percentage of the controls.
Immunofluorescence and Image Analysis.
Epididymal fat pads and perispleen adipose tissue were washed in Krebs-Ringer phosphate
(KRP) buffer. Fat tissue was fixed, dehydrated, embedded and processed to slice. The cells were
imaged using a Zeiss LSM 510 META confocal microscope. Images were then imported to
Adobe Photoshop (Adobe Systems, Inc.) for processing.
Statistical analysis
Data were analyzed by ANOVA. Sets with statistically significant F score were analyzed
for group-to-group variation using the least significant diference method (Fisher’s LSD). 
Differences were considered significantly different when p<0.05.
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RESULTS
Phenotype modification of peritoneal C2D macrophage cells co-cultured with 3T3L1
adipocytes in vitro
To examine the impact of adipocytes on macrophages, we evaluated the phenotypic
alteration of macrophages or C2D macrophage cells co-cultured with pre-adipocytes or
adipocytes. We measured the expression of cell surface makers, Ly-6C, Mac-2 and CD11b
using flow cytometry (Figure 24). C2D macrophage cells express Mac-2 and Ly-6C, but no
CD11b, indicative of an immature macrophage phenotype [410]. These cells are excellent
measures of changes in macrophage phenotype because they are well defined in vitro and
provide a common starting point from which to gauge change in response to adipocytes in vitro
and in vivo. We observed no change in any of the three cell surface markers on C2D macrophage
cells co-culcured with pre-adipocytes (Figure 24A) compared to C2D macrophage cells cultured
alone. However, we observed significant (p<0.05) decrease of Ly-6C on C2D macrophage cells
co-cultured with adipocytes (Figure24A).
The peritoneal cavity microenvironment induces significant change in C2D macrophage
cells changing them into cells having a functional, pro-inflammatory phenotype [410, 412],
which is accompanied by an increase in CD11b. We hypothesized that contact with adipocytes
would cause C2D macrophage cells isolated from peritoneal cavity after adoptive transfer to alter
their phenotypes. To test this hypothesis, we co-cultured peritoneal C2D macrophage cells with
adipocytes or pre-adipocytes and measured the expression of macrophage markers. Adipocytes
induced significantly more Mac-2 expression on C2D macrophage isolated from peritoneal
cavity compared to C2D macrophage cells incubated in vitro alone or with pre-adipocytes
(Figure 1B). We observed a small but significant decrease of CD11b and Mac-2 in macrophages
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Figure 24. Phenotype changes of C2D macrophage cells co-cultured with adipocytes
or pre-adipocytes in vitro. C2D macrophage cells were labeled with CFDA-SE or C2D
macrophage cells labeled with CFDA-SE and isolated from peritoneal cavity were cultured alone
or co-cultured with 3T3L1 adipocytes or pre-adipocytes as described in the methods and
materials. The cell mixture wasdispersed with 0.025% EDTA and was resuspended in HBSS
buffer. Cells were immunostained for flow cytometry as described in Materials and Methods. A)
C2D macrophage cells grown in vitro were cultured alone, co-cultured with adipocytes or with
pre-adipocytes. B) C2D macrophage cells isolated from the peritoneal cavity were cultured
alone, co-cultured with adipocytes or with pre-adipocytes. The data present mean ± SEM (n= 3
independent replicates per treatment). An asterisk (“*”) identifies a significant diference of
macrophages between control C2D macrophage cells incubated alone and treatments for each
surface marker.A pound (“#”) identifies significant diference of macrophages between co-
culture with pre-adipocytes and co-culture with adipocytes. A p value of < 0.05 was considered
significant.
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co-cultured with pre-adipocytes (Figure 24B). These data confirm that adipocytes alter the C2D
macrophage cell phenotype.
Gene transcript modification in peritoneal C2D macrophage cells co-cultured with
3T3L1 adipocytes in vitro
The increased expression of Mac-2 on C2D macrophage cells co-cultured with
adipocytes suggested that the cells were more differentiated [412, 413]. Therefore, we
hypothesized that the change would affect their cytokine profile. To test this hypothesis, C2D
macrophage cells labeled with CFDA-SE were purified by fluorescence-activated cell sorting
after being cultured with adipocytes or pre-adipocytes for two days. Cytokine gene transcripts
were detected by RT-PCR (Figure 25). C2D macrophage cells cultured alone in vitro express no
TNF-and expressed very low levels of IL-and low levels of IL-6 transcripts (Figure 25). In
co-culture with adipocytes, C2D macrophage cells had higher levels of IL-6 Figure 25A, lane
C+A and Figure 25B), but no alteration in TNF-Figure 25A, lane C+A and Figure 25C) or IL-
1Figure 25A, lane C+A and Figure 25D). No change was found in cytokine transcription
when C2D macrophage cells were co-cultured with pre-adipocytes (Figure 25A, lane C+P).
We hypothesized that peritoneal cavity-isolated C2D macrophage cells would be more
responsive to adipocytes. Therefore, we co-cultured peritoneal C2D macrophage cells with
3T3L1 adipocytes or pre-adipocytes and measured cytokine gene transcript levels. There were
significantly enhanced levels of TNF-IL-1and IL-6 (Figure 25A, lane M), in these C2D
macrophage cells. We detected a significant increase in IL-6 and TNF-transcript level by C2D
macrophage cells co-cultured with adipocytes (Figure 2A, lane M+A, Figure 25B and 25C), but
not in C2D macrophage cells co-cultured with pre-adipocytes (Figure 25A, lane M+P). We did
not find any change in the expression IL-1in C2D macrophage cells co-cultured with either
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Figure 25. Transcription of proinflammatory cytokine genes in C2D macrophage
cells co-cultured with adipocytes or pre-adipocytes in vitro. C2D macrophage cells were
labeled with CFDA-SE or C2D macrophage cells labeled with CFDA-SE and isolated from
peritoneal cavity were cultured alone or co-cultured with 3T3L1 adipocytes or pre-adipocytes as
described in the methods and materials. Cell mixtures were dispersed with 0.025% EDTA and
were resuspended in HBSS buffer. CFDA positive C2D cells were sorted by FACS as described
in methods. Gene transcripts were measured by semi-quantitative RT-PCR as described in
methods. A) C, C2D macrophage cells; M, C2D macrophage cells isolated from peritoneal
cavity; C+A, C2D macrophage cells sorted from co-cultures with 3T3L1 adipocytes; C+P, C2D
macrophage cells sorted from co-cultures with 3T3L1 pre-adipocytes; M+A, C2D macrophage
cells isolated from peritoneal cavity were sorted from co-cultures with 3T3L1 adipocytes; M+P,
C2D macrophage cells isolated from peritoneal cavity were sorted from co-cultures with 3T3L1
pre-adipocytes. B) IL-6 normalized to-actin. C) TNF-normalized to-actin. D) IL-1
normalized to-actin. The data are presented as mean ± SEM (n= 3-4 independent replicates
per treatment). Different letters indicate a significant difference. A p value of < 0.05 was
considered significant.
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adipocytes (Figure 25A, lane M+A and Figure 25D) or pre-adipocytes (Figure 25A, lane M+P
and Figure 25D).
Morphorlogical changes of mordification of C2D macrophage cells in response to
adipocytes in vitro and in vivo
Since we observed a phenotype difference in C2D macrophage cells co-cultured with
adipocytes we assessed if there were concurrent changes in cell morphology. Peritoneal cavity-
isolated C2D macrophage cells are round after cell isolation (Figure 26B, panel a and d),
compared to their larger stretched morphology when grown in vitro (Figure 26A, panel a and d).
When those C2D macrophages were cultured with preadipocytes, the cells stretched out (Figure
26A and 26B, panels b and e). In contrast, when in vitro grown or peritoneal cavity-isolated C2D
macrophage cells were co-cultured with adipocytes, we found that the cells maintained a mostly,
smaller, round morphology (Figure 26A and 26B, panels e and f), suggesting that 3T3L1
adipocytes inhibit normal adherence and stretching by the C2D macrophage cells.
The morphological and functional differences between BAT and WAT have been widely
noted, although they both belong to adipose tissue [74]. Macrophages isolated from WAT have
been characterized as a classically activated macrophages [131, 229]. Macrophages from BAT
are not well understood. We previously found that C2D macrophage cells stained with CFDA-
SE could be isolated from perinodal WAT [410]. Therefore, we assessed C2D macrophage cell
migration into WAT and BAT, with more cells being identified in WAT (Figure 26C, panels a
and c).
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Figure 26. Change in C2D macrophage cell morphology during co-cultured with
adipocytes or pre-adipocytes in vitro and C2D macrophage cells infiltration into BAT or
WAT in vivo. A and B) C2D macrophage cells were labeled with CFDA-SE or C2D
macrophage cells labeled with CFDA-SE and isolated from peritoneal cavity were cultured alone
or co-cultured with 3T3L1 adipocytes or pre-adipocytes as described in the methods and
materials. Panels a, b and c; CFDA-labeled C2D macrophage cells viewed on the fluorescent
microscope (Magnification x 200). Panels d, e and f are phase contrast images of cells in a, b and
c. C) WAT and BAT were collected from mice adoptive transferred with C2D macrophage cells
labeled with CFDA-SE two days after adoptive transfer. WAT and BAT were processed to slice
as described in Materials and Methods. Panels a and c images from the confocal microscop (x
100). Panels b and d are phase contrast images of the same fields.
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Phenotype of C2D macrophage cells 36 hours after trafficking into WAT and BAT
The identification of C2D macrophage cells in both WAT and BAT provided a unique
opportunity to determine the impact of these distinct adipose tissues on recently immigrating
macrophages. We hypothesized that macrophages develop different phenotypic heterogeneity in
response to different environmental stimuli from WAT or BAT. We previously demonstrated
that C2D macrophage cells acquired proinflammatory phenotypes when adoptively transferred
into the peritoneal cavity [410, 412]. The isolation of C2D macrophage cells from BAT and
WAT required collagenase digestion of tissue to recover the CFDA-SE labeled cells. We found
about a 70% loss of all cell surface markers (Ly-6C, Mac-2, CD11b and F4/80) with collagenase
treatment (data not shown). Therefore, in order to phenotype the recovered C2D macrophage
cells from BAT and WAT, we allowed the cells to recover in vitro at 37oC in DMEM10.
Recovery of cell surface molecules occurred within 16 hours of culture. Therefore, we cultured
macrophages isolated from the peritoneal cavity, BAT and WAT in DMEM10 for 16 hours at
37oC and treated with antibodies specific for Ly-6C, Mac-2, CD11b and F4/80. We observed a
high expression of Ly-6C (33% expression) on WAT isolated CFDA-SE labeled C2D
macrophage cells, while there was almost no expression of Ly-6C (0.4%) on BAT isolated
CFDA-SE labeled C2D macrophage cells (Figure 27A, white bar). A moderately but
significantly higher level of Mac-2 was found in WAT CFDA-SE labeled macrophage cells
compared to BAT labeled CFDA-SE macrophage cells (Figure 27A, black bar). We observed
over 30% expression of F4/80 on WAT isoloated CFDA-SE labeled macrophage cells, but
almost no expression on C2D macrophage cells from BAT (Figure 27A, striped bar). Surface
CD11b expression was also significantly higher on C2D macrophage cells isolated from WAT
compared to those isolated from BAT (Figure 27A, dotted bar).
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Figure 27. Phenotype changes in Peritoneal C2D macrophage cells isolated from
WAT or BAT in vivo after i.p. adoptive transfer. WAT and BAT were collected from mice
adoptively transferred with C2D macrophage cells labeled with CFDA-SE two days after i.p.
injection of cells. C2D macrophage cells were isolated from BAT and WAT by collagenase
treatment as described in Materials and Methods. Cells were re-plated on dishes and incubated in
DMEM10 at 37oC for 16 hours to allow cell surface molecule regenerated. Cells were dispersed
and immunostained for detecting Ly-6C, Mac-2, CD11b and F4/80 by flow cytometry as
described in Materials and Methods. A) Surface markers expression was assessed on CFDA-SE-
positive cells isolated from BAT or WAT-SVF. B) Surface markers expression was assessed on
CFDA-SE-positive cells, panel A, or CFDA-SE-negative cells, panel B, in SVF isolated from
WAT. The data are presented as mean ± SEM (n= 3-6 independent replicates per treatment). An
asterisk (“*”) identifies a significant differencebetween macrophages different treatment groups
for each surface marker. A p value of < 0.05 was considered significant.
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Odegaard et al. reported that resident macrophages in WAT displayed an alternatively
activated phenotype [182]. We hypothesized that recently immigrating C2D macrophage cells
would also adopt an M2-phenotype in the WAT. We found significantly more F4/80 on recent
recently immigrated C2D macrophage cells compared to resident macrophages (Figure 27B,
stripped bar). However, there were no differences in Ly-6C, Mac-2 and CD11b between
immigrating C2D macrophage cells and resident cells, however (Figure 27B).
Functional modification of C2D macrophage cells migrating into WAT and BAT
Since CFDA-SE labeled C2D macrophage cells had higher expression of several
machineries of mature macrophages, we hypothesized that the cells would also have different
cytokine profiles. To test this hypothesis, we used fluorescence-activated cell sorting of CFDA-
SE labeled C2D macrophage cells isolated from peritoneal cavity, WAT and BAT 36 hours after
adoptive transfer the cells into mice. We assessed the transcript levels of TNF-IL-6, IL-1,
Arg-1, Ym-1 and Fizz-1 using semi-quantitative RT-PCR to determine if the macrophages
exhibited an M1 or M2 profiles (Figure 28, Table 3). There were significantly increased TNF-
transcript levels in C2D macrophage cells isolated from peritoneal cavity and WAT (Figure
28A and Figure 28B), with 42 fold increase in C2D macrophage cells isolated from peritoneal
cavity and 107 fold increase in C2D macrophage cells isolated from WAT compared to C2D
macrophage cells maintained in vitro (Table 3). In contrast, there was little TNF-expression in
C2D macrophage cells sorted from BAT. IL-6 transcript levels also increased 2 fold in C2D
macrophage cells isolated from peritoneal cavity and by 10 fold in C2D macrophage cells
isolated from WAT, while decreasing in cells isolated from BAT (Figure 28A and 28B, Table 3).
We observed significantly higher level of IL-1transcript levels in C2D macrophage cells
isolated from the peritoneal and WAT compared to those isolated from BAT, although transcript
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Figure 28. Gene transcript modification in Peritoneal C2D macrophage cells
infiltrated into WAT or BAT in vivo. WAT and BAT were collected from mice adoptively
transferred with C2D macrophage cells labeled with CFDA-SE two days after i.p. injection of
cells. C2D macrophage cells were isolated from BAT and WAT by collagenase treatment as
described in Materials and Methods. C2D macrophage cells isolated from WAT or BAT were
sorted by FACS as described in methods. Gene transcripts were measured by one-step RT-PCR
as described in methods. A) RT-PCR result of TNF-IL-6, IL-1, Arg-1, Ym-1 and Fizz-1 B)
gene transcript levels of TNF-, IL-6 and IL-1normalized to-actin; C) gene transcript levels
of Arg-1, Ym-1 and Fizz-1normalized to-actin. C2D, C2D macrophage cells in vitro; PEC-
C2D, C2D macrophage cells isolated from peritoneal cavity; MBAT, C2D macrophage cells
isolated from BAT; MWAT, C2D macrophage cells isolated from WAT. The data are presented
as mean ± SEM (n= 3-4 independent replicates per treatment). Different letters indicate a
significant difference. A p value of < 0.05 was considered significant.
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Table 3. Comparison of M1 and M2 macrophage markers in C2D macrophage cells after
isolation from C57BL/6J mouse tissue
Fold increase in gene transcripts compare to C2D macrophage cells grown in vitro
Transcript PEC5 MBAT5 MWAT5
TNF- 42 ± 121,2 1±0 108 ± 20
IL-6 2 ± 0 1 ± 0 10 ± 1
IL-1 20 ± 4 31 ± 4 41 ± 7
Arg-1 8 ± 1 <1 ± 03 1 ± 0
Ym-1 2 ± 0 1 ± 0 <1 ±0
Fizz-14 119 ± 24 3 ± 0 94 ± 38
1. Fold increase calculated as (transcript of genes in vivo/-actin) ÷ (transcript of
gene in vitro/-actin).
2. Number represents mean ± SEM of 2-3 independent samples of 3 mice pooled per
sample.
3. Transcript upregulated <1 fold in independent replicated are expressed in the
fashion to reflect a decrease in transcription compared to C2D macrophage cells
cultured in vitro.
4. The absence of transcript in vitro is expressed as 0.01 for calculations of fold
increase for this analysis.
5. PEC: C2D macrophage cells isolated from peritoneal cavity; MBAT: C2D
macrophage cells isolated from BAT; C2D macrophage cells isolated from WAT
levels were increased in C2D macrophage cells in all three microenviroments compared to C2D
macrophage cells maintained in vitro.
Since we observed distinct proinflammatory cytokine expression profiles by C2D
macrophage cells isolated from WAT and BAT, we hypothesized that C2D macrophage cells
isolated from BAT would display an alternative activated (M2) phenotype. To test this
hypothesis, we measured the gene transcript levels of Arg-1, Ym-1 and Fizz-1 using semi-
quantitative RT-PCR. There was significantly increased expression of all three gene transcripts
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in C2D macrophage cells isolated from the peritoneal cavity (Figure 28C, black bars). C2D
macrophage cells isolated from BAT had significantly lower transcript levels compared to C2D
macrophage cells from the peritoneal cavity. Arg-1 and Ym-1 were also lower in C2D
macrophage cells isolated from WAT compared to those isolated from the peritoneal cavity.
However, Fizz-1 transcript levels were significantly elevated compared to C2D macrophage cells
maintained in vitro or isolated from BAT.
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DISCUSSION
Macrophages are remarkable for their ubiquitous distribution and their capability to
display a wide range of functions and phenotypes dependent on their microenviroments [399,
414, 415]. We used the C2D macrophage cell line [378] to explore adipose tissue
microenvironments. In previous work, C2D macrophage cells switched their phenotype from a
primarily Th2 profile when grown in vitro to a Th1 profile after in vivo intraperitoneal culture
[410]. In the current study, we discovered additional cellular changes as the C2D macrophage
cells migrated from the peritoneum into white and brown adipose tissue.
Brown and white adipocytes have distinct morphologies and functions [416]. White
adipocytes store energy and brown adipocytes dissipate energy through their numerous
mitochondria [416]. Although several studies have reported the functional phenotype of
macrophages immigrating into WAT [417-419], little is known about macrophages in BAT. Our
unique model system allowed us to trace the in vivo migration of C2D macrophage cells into
adipose tissue and to recover them to define the changes induced by these two distinct sites. This
system is also unique because it alowed us to monitor the “before” in vivo phenotype to the
“after” in vivo phenotype using cells that were derived from the same defined population that has
not been under the prolonged influence of the recipient host. Therefore, we are confident that the
changes in the macrophages were due to their immediate exposure to the BAT or WAT
environments as opposed to the cumulative exposures encountered by host resident macrophages
over a period of time.
C2D macrophage cells isolated from BAT expressed very little Ly-6C, Mac-2, CD11b
and F4/80 compared to C2D macrophage cells isolated from the peritoneal cavity [412] or from
WAT. This phenotypic difference accompanied the expression of low transcript numbers for IL-
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6, TNFαand Fizz-1 in C2D macrophage cells isolated from the BAT. These mRNA levels were
high in C2D macrophage cells sorted from the peritoneum or the WAT (Figure 28). Odegaard et
al.demonstrated that resident macrophages in WAT expressed an M2 phenotype with elevated
Arg-1 and Ym-1 [182]. In contrast, inflammatory macrophages detected in WAT had M1
phenotypes in obese and diabetic states [131, 149, 229]. Therefore, the C2D macrophage cells in
WAT better resemble macrophages bearing an M1 phenotype. In contrast, BAT suppressed the
development or maintenance of a proinflammatory macrophage phenotype without inducing
what is considered an anti-inflammatory (M2) phenotype. Fizz-1, also known as resistin-like
molecule alpha, was also up-regulated in Th2 environments [420]. This also supports the
hypothesis that that WAT, but not BAT, is a proinflammatory environment whereas BAT is not.
It is possible that longer exposure of the C2D macrophage cells to BAT is necessary for the
upregulation of Arg-1 and Ym-1. Alternatively, macrophages in BAT may acquire a unique
phenotype not defined by classic M1 and M2 markers. Studies isolating C2D macrophage cells
from BAT after longer periods of time will be necessary to answer this question.
Chronic excessive caloric intake leads to macrophage infiltration [76, 421]. Those
macrophages contributed to the elevated level of proinflammatory cytokines in those chronic
conditions [131, 149, 173, 183, 229, 422]. However, those studies were performed on people or
animals that were obese [174] or were in diabetic states [229] and do not provide clues about the
contribution of normal adipocytes to macrophage change in vivo. We provide direct evidence
that macrophage changes in WAT, or lack of changes, in BAT, occur in response to normal
adipocytes in vivo.
Adipocytes are derived from multipotent mesenchymal stem cells that pass through two
phases of adipogenesis as they mature into adipocytes [416]. The first phase involves the
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transition of stem cells to pre-adipocytes and the second phase involves the conversion from pre-
adipocytes into adipocytes [416]. Previous studies have found that co-culture of macrophages
with pre-adipocytes inhibited adipocytes differentiation [382]. However, the impact of this
interaction on macrophages is not well understood. We found that C2D macrophage cells
downregulated many mature macrophage markers when co-cultured with pre-adipocytes in vitro.
Therefore, not only is adipogenesis inhibited by the presence of macrophages [382],
macrophages are also affected by the interaction. C2D macrophage cell IL-6 gene transcription
and protein secretion were increased by co-culture with adipocytes (Figure 25). This is
consistent with our previous report that IL-6 inhibited 3T3L1 adipocyte differentiation at
concentrations generated during their co-culture. Although these data suggest that the initiation
of the macrophage changes begins even before the lipid accumulation in the adipocytes, there
were still important differences in the macrophage responses to preadipocytes and adipocytes.
Whereas preadipocytes allowed C2D macrophage cells to spread, regardless of their source
(Figure 26), adipocytes inhibited macrophage speading. Increased spreading is associated with
macrophage differentiation [423], therefore, this may reflect selective differentiation into
proinflammatory phenotype. Indeed, macrophages differentiated in substrates that cause similar
phenotypes are capable of secreting both TNF-α and IL-6 [424].
The C2D macrophage cells isolated from the peritoneum expressed a relatively
differentiated macrophage phenotype [413, 425] when co-cultured with adipocytes in vitro
(Figuer 25A and 25B). This was similar to the phenotype of the C2D macrophage cells isolated
from the WAT. Both macrophage populations demonstrated the same expression patterns of
CD11b, Mac-2 and F4/80 as mature resident macrophages (Figure 27B). Therefore, C2D
macrophage cells rapidly adapted the same phenotype as resident adipose macrophages. It also
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validates that the C2D macrophage cells are serving as reliable indicators of the tissue
environment.
In summary, the WAT microenvironment alters the capabilities of C2D macrophage
cells, causing them to express primarily a functional pro-inflammatory phenotype. However, the
BAT environment keeps C2D macrophage cells quiescent. To our knowledge, this is the first
study to directly compare the macrophages response to different adipose tissues in the absence of
complicating chronic diseases or altered genetic states. The evidence that infiltrating
macrophages display a pro-inflammatory phenotype even in normal mice suggests that the
“inflammatory fire”[426] begins relatively quickly in permissive environments. WAT appears
to be one of those environments however, BAT does not. Determining the properties of BAT
that make it refractory may give us clues on how to extinguish the inflammatory fire.
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CHAPTER 6
FUTURE PROSPECTIVE
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My studies have demonstrated that adiponectin and leptin are secreted through distinct
intracellular trafficking pathways. Adiponectin, in the steady state, is localized in trans Golgi
Network (TGN). Adiponectin exits from TGN, dependent on GGA1- coated vesicles.
Adiponectin trafficking also requires Rab11 and Rab5 proteins, thus implicating endosome
compartments are required. In contrast, trafficking of leptin to the plasma membrane does not
require endosomal compartments, although leptin also passes through the TGN. Leptin secretion
occurs through a constitutively pathway dependent on PKD1.
Future studies will need to identify other protein and components that participate in the
generation and trafficking of adiponectin and leptin-containing vesicles. For example, our
preliminary data showed overexpression of constitutively active forms of Arf1, Arf3 or Arf5 all
inhibited adiponectin secretion. However, Arf proteins seem to have overlapping functions [243,
244]. Thus, double interfering or triple knock down of Arf proteins will need to determine
specific isoforms in adiponectin trafficking. Also, recent studies have shown that replacing the
hypervariable domain of Rab5a with that of Rab1a, Rab2a, Rab7 and Rab27a had no effect on its
function and localization on early endosome [261]. These kinds of experiments indicate other
Rab proteins might also participates in the secretion of adiponectin. Bose et al. reported v-
SNARE Vti1a regulated adiponectin secretion [427]. Which t-SNARE proteins are required for
adiponectin secretion and in which steps they are involved during trafficking and secretion also
need further clarification. Potential t-SNARE proteins can be screened by yeast two hybrid
studies and their functions can be explored. For leptin, it will be important to determine if the
PKD1 dependent constitutively secretory pathway is the only secretory route. Actually, the
knock down of PKD1 only inhibited leptin secretion by 15%, which suggests other protein or
pathway may also exist. Indeed, the intracellular compartmentalization of leptin in adipocytes
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has remained controversial [357]. Although our study demonstrated that leptin mostly localized
in the ER, there is some questions on whether leptin distributes in other small intracellular
vesiculars. Furthermore, the mechanisms by which insulin stimulates adiponectin or leptin
secretion are still poorly understood.
Obesity and diabetes are now regarded as inflammatory diseases. Understanding the
interaction between macrophages and adipocytes will help define the underlying mechanisms
leading to the onset of those diseases. I demonstrated that macrophages induced insulin
resistance in 3T3L1 adipocytes by secreting TNF-, IL-1and IL-6. IL-6 might be most
important cytokine during the induction of insulin resistance by altering GLUT4. I also studied
the action of adipocytes on macrophages. I demonstrated that C2D macrophage cells increased
their IL-6 transcript levels co-culture with adipocytes in vitro. In vivo, C2D macrophage cells
infiltrated into WAT display primarily functional pro-inflammatory phenotypes, however, BAT
environment keeps C2D macrophage cells quiescent.
Future study will need to test the interaction of macrophages and adipocytes in vivo.
Those studies will require a focus on the role of IL-6 in the onset of diabetes in vivo. Charriere
et al. showed that preadipocytes have the potential to be efficiently and rapidly converted into
mature macrophages in a macrophage environment [178]. The cytokine profile of that
macrophage population and whether this population is involved in causing diabetes is still
unknown. Moreover, whether the secretion of hormones like adiponectin, leptin, resistin, etc., by
adipocytes is altered in the presence of these macrophage cells also needs to be studied. Studies
are proposed to explore C2D macrophage cells infiltrated into WAT after adoptive transfer in
diabetic mice or mice on a high fat diet and it will also lead to insights on how that tissue
changes the functional phenotype of these macrophages as the chronic disease progress. These
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studies will shed light on the cellular and molecular basis of obesity and diabetes as an
inflammatory disease and whether macrophages are the cause or the effect of the disease.
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